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20 AML:  Acute  myeloid  leukaemia 
ARDS:  Acute  respiratory  distress  syndrome 
BMT:  Bone  marrow  transplantation 
CRP:  C-reactive  protein 
CSF:  Cerebrospinal  fluid 
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ITU:  Intensive  therapy  unit 
MIC:  Minimum  inhibitory  concentration 
MUD:  Matched  unrelated  donor 
NHL:  Non-Hodgkin's  lymphoma 
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21 SUMMARY 
The  earliest  reports  of  viridans  streptococcal  bacteraemia  in  immunocompromised 
patients  with  malignant  disease  appeared  in  1978,  and  throughout  the  following 
decade,  several  centres  reported  increased  incidence  of  this  infection.  The  clinical 
course  of  this  infection  was  variable,  but  included  a  severe  form  with  septic  shock 
and/or  acute  respiratory  distress.  The  development  of  such  acute  symptoms  seemed 
inconsistent  with  the  limited  pathogenic  properties  of  these  oral  commensals. 
Amongst  the  paediatric  haematology/oncology  patients  attending  the  Royal  Hospital 
for  Sick  Children,  Glasgow,  episodes  of  viridans  streptococcal  bacteraemia 
increased  from  12%  of  all  microbiologically  documented  bacteraemias  (r.  e.  10/81)  in 
1993  to  22%  (18/83)  in  1994.  During  the  first  year  of  this  project  (which  started  in 
December  1994),  ITU  support  was  required  following  the  development  of  viridans 
streptococcal  bacteraemia  on  6  occasions,  and  of  these,  there  were  two  fatalities. 
The  overall  aim  of  this  study  was  to  improve  the  management  of  this  infection  and  to 
explore  preventative  startegies.  Three  different  approaches  were  adopted: 
(1)  An  extensive  epidemiological  analysis  was  undertaken  -  to  include  all  episodes 
of  viridans  streptococcal  bacteraemia  from  December  1994  to  December  2000. 
(2)  Phenotypic,  followed  by  genotypic  analyses  of  isolates  of  viridans  streptococci 
from  mouth  swabs  and  blood  cultures  were  carried  out  to  determine  whether 
the  mouth  was  in  fact  the  source  of  organisms  responsible  for  this  infection. 
(3)  Extensive  antibiotic  susceptibility  studies  were  performed  on  all  isolates  of 
viridans  streptococci  from  blood  culture. 
In  total,  69  episodes  of  viridans  streptococcal  bacteraemia  occurred  in  54  children. 
The  infection  was  more  often  associated  with  patients  with  haematological 
22 malignancy  (particularly  AML),  than  those  with  solid  tumours,  and  in  the  majority 
(84%)  of  episodes,  the  patients  suffered  from  chemotherapy-induced  mucositis  or 
other  forms  of  oral  compromise.  Forty-eight  episodes  of  infection  (70%  of  total) 
responded  well  to  antimicrobial  therapy  with  no  evidence  of  additional  clinical 
complications.  However,  in  21  cases  (30%  of  total),  pulmonary  complications 
developed,  with  8  of  these  requiring  mechanical  ventilation  and  supplemental 
oxygen.  Five  of  these  8  cases  also  developed  septic  shock. 
S.  oralis  was  the  species  most  commonly  isolated  from  blood  culture  (63%  of  total 
isolates  of  viridans  streptococci),  and  S.  mitis  represented  25%  of  total  isolates. 
Polymicrobial  bloodstream  infection  occurred  in  23%  of  episodes. 
In  agreement  with  the  findings  of  earlier  workers,  the  incidence  of  viridans 
streptococcal  bacteraemia  was  highest  amongst  those  patients  who  had  recently 
received  chemotherapeutic  regimens  containing  high-doses  of  the  antimetabolite, 
cytosine  arabinoside,  in  particular,  the  CLASP  regimen  (cytosine  arabinoside  3g/m2 
twice  daily  with  sequential  asparaginase).  Therapy  with  high-dose  cytosine 
arabinoside  is  associated  with  profound  neutropenia  and  severe  mucositis. 
Pulmonary  toxicity,  also  associated  with  the  use  of  this  agent,  had  previously  been 
proposed  by  others  as  a  factor  related  to  the  development  of  the  acute  respiratory 
distress  syndrome  (ARDS)  in  patients  with  viridans  streptococcal  bacteraemia. 
However  the  present  study  demonstrated  additional  contributory  factors. 
Concomitant  infection  with  respiratory  viruses  or  Pneumocystis  carinii  was 
associated  with  6  episodes  of  viridans  streptococcal  bacteraemia  and  5  of  these 
exhibited  respiratory  complications  with  3  progressing  to  ARDS. 
In  phase  2  of  the  study,  phenotypic  analysis  using  a  commercial  identification  system 
(BioMerieux  Rapid  ID  32  Strep)  plus  antibiograms,  followed  by  genotypic  analysis 
23 using  the  technique  of  pulsed-field  gel  electrophoresis,  demonstrated  that  in  two 
selected  cases,  viridans  streptococci  from  the  oral  cavity  were  indistinguishable  from 
those  isolated  from  blood  cultures.  Both  mucositis  and  gingivitis  were  shown  to  be 
probable  portals  of  entry.  The  same  techniques  were  also  used  to  demonstrate  that 
isolates  of  Streptococcus  oralis  with  Staphylococcus  epidermidis  causing  poly- 
microbial  bacteraemia,  originated  in  the  oral  cavity  of  a  patient  with  severe  mucositis. 
Genotypic  methods  also  demonstrated  that  one  strain  of  S.  oralis  which  persistently 
colonized  the  mouth  of  one  of  the  above  patients,  and  which  had  caused 
bacteraemia,  was  also  capable,  within  a  short  time  interval,  of  colonizing  the 
patient's  toothbrush.  This  demonstrated  that  a  tool  used  for  mouth  care  could 
potentially  become  a  reservoir  of  organisms  capable  of  causing  bacteraemia  and 
underscored  the  importance  of  regular  replacement  of  toothbrushes  used  by 
neutropenic  patients. 
Early  results  from  the  antimicrobial  susceptibility  study  revealed  a  high  rate  of 
resistance  to  certain  ß  -lactam  antibiotics  amongst  viridans  streptococci  isolated  from 
blood  culture.  Of  particular  concern  was  resistance  to  the  third  generation 
cephalosporin,  ceftazidime,  which  in  combination  with  amikacin  comprised  first  line 
empirical  antibiotic  therapy  for  episodes  of  febrile  neutropenia  at  the  beginning  of  this 
study.  Although  all  isolates  were  sensitive  to  vancomycin,  this  agent's  potential  for 
causing  nephrotoxicity  rendered  it  unsuitable  for  first  line  empirical  therapy.  Early 
results  of  this  study  showed  that,  against  viridans  streptococci,  piperacillin/ 
tazobactam  demonstrated  superior  in  vitro  activity  to  that  of  ceftazidime.  The  author 
and  ward  staff  had  experience  of  the  former's  good  activity  against  Gram-negative 
organisms  and  good  safety  profile  from  participation  in  IATCG/EORTC  Trial  IX  during 
1991-92,  therefore,  after  discussion,  in  summer  1996,  piperacillin/tazobactam 
replaced  ceftazidime  as  the  ß  -lactam  component  of  first  line  empirical  therapy.  This 
24 intervention  later  provided  the  opportunity  to  conduct  a  retrospective  sequential 
study  to  compare  antimicrobial  susceptibility  of  viridans  streptococci  from  blood 
cultures  prior  to  this  change  with  those  following  it. 
While  ceftazidime  was  used  as  empirical  therapy,  the  geometric  mean  MIC  of  this 
agent  against  viridans  streptococci  from  blood  cultures  (31  isolates,  throughout  19 
months  (period  1))  was  9.6  mg/L  compared  with  3.3  mg/L  for  isolates  cultured  from 
blood  after  empirical  therapy  was  changed  to  piperacillin/tazobactam  (45  isolates 
over  a  period  of  54  months  (period  2))  (P  <  0.05).  Of  note,  the  geometric  mean  MICs 
for  other  ß  -lactam  antibiotics  tested  (piperacillin/tazobactam,  cefaclor,  penicillin, 
cefpirome  and  meropenem)  against  these  isolates  also  decreased  from  period  1  to 
period  2  (from  2.8  -  fold  for  piperacillin/tazobactam  to  1.4  -  fold  for  meropenem) 
Prior  treatment  with  first  line  empirical  antibiotics  was  associated  with  93%  of 
episodes  of  viridans  streptococcal  bacteraemia  during  the  first  interval  of  time, 
compared  with  85%  during  the  second  (P  >  0.25).  The  majority  of  patients  who 
developed  viridans  streptococcal  bacteraemia  were  receiving  cotrimoxazole 
prophylaxis  at  the  time  (93%  of  episodes  during  period  1  and  88%  during  period  2), 
with  resistance  rates  of  74%  and  73%  respectively  -  therefore  this  was  a  constant 
factor  throughout.  No  other  form  of  antibiotic  prophylaxis  was  used.  Comparing  the 
patients  with  viridans  streptococcal  bacteraemia  during  period  1  with  those  of  period 
2,  there  were  no  statistically  significant  differences  between  the  proportion  with 
haematological  malignancy  versus  solid  tumours,  the  presence  of  mucosal  lesions  or 
the  presence  of  neutropenia  or  between  the  number  of  episodes  associated  with 
treatment  with  high  or  intermediate-high  dose  cytosine  arabinoside  or  allogeneic 
bone  marrow  transplantation,  i.  e.  the  therapies  most  associated  with  mucositis.  The 
mouth  care  protocol  remained  essentially  unchanged  throughout  the  two  time 
intervals. 
25 During  period  1,  viridans  streptococcal  bacteraemia  was  associated  with  4.6%  of  all 
febrile  episodes  compared  with  2.2%  during  period  2  (P  <  0.005).  This  corresponded 
to  17%  of  all  microbiologically  documented  episodes  during  period  1  compared  with 
8%  during  period  2  (P  <  0.001). 
While  there  was  little  variation  in  the  actual  chemotherapy  regimens  used  throughout 
the  two  study  periods,  the  proportions  of  the  various  regimens  used  inevitably 
differed.  It  was  not  possible  to  obtain  information  on  every  course  of  chemotherapy 
administered  throughout  the  entire  study  period.  However,  it  was  possible  to  perform 
an  analysis  of  the  total  number  of  patients  in  the  haematology/oncology  unit  who 
received  CLASP  chemotherapy  and  the  development  of  viridans  streptococcal 
bacteraemia  during  period  1  compared  with  period  2.  All  of  these  patients  had 
previously  received  multiple  courses  of  empirical  antibiotic  therapy.  During  period  1, 
eleven  courses  of  CLASP  were  administered  and  7  episodes  of  viridans 
streptococcal  bacteraemia  occurred,  compared  with  23  courses  of  CLASP  and  4 
episodes  of  viridans  streptococcal  bacteraemia  during  period  2  (P  <  0.01).  Therefore, 
in  spite  of  the  continued  use  of  intensive  chemotherapeutic  regimens,  fewer  cases  of 
viridans  streptococcal  bacteraemia  occurred  after  the  change  in  empirical  therapy. 
Loss  of  mucosal  integrity  would  generally  be  required  to  provide  a  portal  of  entry. 
However,  amongst  patients  who  have  previously  received  empirical  therapy,  viridans 
streptococcal  bacteraemia  may  be  less  likely  to  occur  if  the  agent  used  has  a  low 
propensity  to  select  for  overgrowth  of  resistant  strains. 
The  final  part  of  the  antimicrobial  susceptibility  study  revealed  that  three  newer 
antibiotics  -  cefpirome,  quinupristin/dalfopristin  and  linezolid  exhibited  significant  in 
vitro  activity  against  isolates  of  viridans  streptococci,  demonstrating  that  even  within 
the  time  span  of  this  study,  the  potential  range  of  antibacterial  agents  against 
multiply-resistant  Gram-positive  bacteria  had  increased. 
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1.1  Microbiology 
Viridans  streptococci,  members  of  the  genus  Streptococcus,  are  spherical  or  ovoid 
bacteria,  <2pm  in  diameter,  arranged  in  chains  or  pairs.  They  are  Gram-positive, 
facultatively  anaerobic,  non-motile  and  catalase-negative. 
The  term  viridans  is  derived  from  the  Latin  word  viridis:  green.  Many  viridans 
streptococci  produce  a  greenish  discolouration  (a  -haemolysis)  when  cultured  on  blood 
agar  due  to  the  partial  clearing  of  erythrocytes.  However,  some  strains  produce 
complete  (ß)  haemolysis  while  others  may  be  non  -  (ö)  haemolytic. 
Viridans  streptococci  are  fastidious  with  respect  to  their  growth  requirements; 
enriched  agars  and  broths  are  recommended  for  optimal  recovery  from  primary 
cultures.  The  presence  of  carbon  dioxide  generally  enhances  growth  while  some 
strains  require  anaerobic  conditions.  Appearance  of  the  colonies  varies  depending  on 
the  composition  of  the  medium  and  the  atmosphere  of  incubation. 
Viridans  streptococci  are  distinct  from  the  pyogenic  group  of  streptococci  and  can 
generally  be  distinguished  from  Streptococcus  pneumoniae,  (which  also  produces  a- 
haemolysis  on  blood  agar)  by  resistance  to  optochin  and  lack  of  bile  solubility.  Some 
isolates  of  viridans  streptococci  react  with  Lancefield  grouping  antisera,  but  the 
species  do  not  correspond  to  specific  serogroups  and  many  isolates  are  non- 
groupable  (Whitey  &  Beighton,  1998).  In  addition  to  the  traditional  antigenic, 
biochemical  and  physiological  tests  used  to  identify  different  species  of  streptococci  in 
the  past,  more  modern  schemes  utilizing  molecular  biological  techniques  are  now 
available  to  increase  accuracy  in  this  field. 
29 Viridans  streptococci  can  be  isolated  from  all  sites  of  the  mouth  and  comprise  a  major 
part  of  the  resident  microflora.  As  a  result,  the  term  `viridans  streptococci'  has  often 
been  used  interchangeably  with  that  of  `oral  streptococci'.  However,  in  common  with 
the  former  term,  `oral  streptococci'  is  not  a  completely  accurate  description  of  these 
organisms  as  they  may  also  be  isolated,  to  a  lesser  extent,  from  other  sites,  such  as 
the  upper  respiratory  tract  and  gastrointestinal  and  genitourinary  tracts  and  are 
sometimes  isolated  from  the  skin. 
1.2  Classification  and  identification  of  viridans  streptococci 
Microbial  classification  is  a  dynamic  area  with  existing  species  being  re-classified  due 
to  the  application  of  more  sophisticated  techniques  and  more  stringent  tests,  together 
with  the  recognition  of  genuinely  newly-discovered  species.  Taxonomy  and 
identification  are  important  in  making  associations  between  particular  species  and 
specific  patterns  of  disease. 
1.2.1  Taxonomic  history  of  viridans  streptococci 
Classification  systems  for  the  genus  Streptococcus,  which  included  streptococci  from 
saliva  and  the  throat,  have  been  proposed  since  the  early  twentieth  century  (Gordon, 
1905).  However  it  was  not  until  the  1960s  and  1970s  that  significant  advances  in  this 
field  were  achieved.  Around  this  time,  Colman  and  Williams,  using  chemotaxonomic 
and  genetic  approaches,  together  with  biochemical  characterization,  established  the 
basis  for  the  classification  and  identification  schemes  subsequently  adopted  by  many 
laboratories  in  the  U.  K.  and  the  rest  of  Europe.  This  system  recognized  five  species 
of  viridans  streptococci  (Streptococcus  mutans,  Streptococcus  mil/eri,  Streptococcus 
sanguis,  Streptococcus  salivarius  and  Streptococcus  mitior)  (Colman  &  Williams, 
1972).  In  the  1970s  in  the  USA,  the  system  of  Facklam  (1977)  was  more  widely  used. 
This  system  assigned  strains  classified  by  Colman  and  Williams  as  S.  sanguis  to  S. 
30 sanguis  biotype  I  and  S.  mitior  to  S.  sanguis  biotype  II  or  S.  mitis.  It  also  divided 
strains  of  S.  milleri  into  S.  anginosus-constellatus  and  S.  MG-intermedius.  Inevitably, 
these  differences  in  classification  and  nomenclature  resulted  in  considerable 
confusion  in  the  literature  (Facklam,  1984).  In  the  1980s,  by  which  time  molecular 
biological  techniques  were  becoming  established  in  the  field  of  bacterial  taxonomy, 
Kilian  and  co-workers  devised  an  identification  system  based  on  phenotypic  tests 
which  correlated  with  the  advances  in  genotypic  identification  (Kilian,  Mikkelsen  & 
Henrichsen,  1989).  This  scheme  utilized  chromogenic  substrates  for  the  detection  of 
glycosidic  hydrolases,  peptidases,  phosphatases,  esterases  and  lipases,  together  with 
tests  for  the  detection  of  IgA  protease  and  neuraminidase  activity,  as  well  as 
conventional  tests  for  carbohydrate  fermentation.  These  authors  proposed  a  scheme 
for  the  identification  of  S.  gordonii,  S.  mitis,  S.  oralis,  S.  sanguis,  S.  salivarius,  S. 
mutans,  and  S  anginosus  (=  `S.  milleri  group).  However  several  of  the  more  recently 
described  species  -  S.  vestibularis,  S.  parasanguis  and  the  three  distinct  species 
within  the  `S.  milleri  group'  (S.  anginosus,  S.  constellatus  and  S.  intermedius)  were  not 
included. 
In  the  early  1990s,  Beighton  and  co-workers  in  the  U.  K.  developed  a  more 
comprehensive  system  (Beighton,  Hardie  &  Whiley,  1991).  They  collected  strains,  the 
taxonomic  position  of  which  had  been  established  by  DNA-DNA  hybridization  or  by 
SDS-PAGE  studies  (Whiley,  1987).  -  Phenotypic  tests  were  then  performed.  These 
included  the  ability  to  produce  acid  from  nine  carbohydrates,  to  hydrolyse  aesculin 
and  arginine  and  to  hydrolyse  ten  fluorogenic  (4-methylumbelliferone-linked) 
glycosidase  substrates.  This  battery  of  tests  allowed  representatives  of  all  reported 
human  viridans  streptococci  at  that  time,  to  be  distinguished.  Subsequent  to  this 
work,  molecular  taxonomic  analyses  identified  the  species  Streptococcus  crista 
(Handley  et  al.,  1991),  Streptococcus  peroris  and  Streptococcus  infantis  (Kawamura 
et  al.,  1998),  all  members  of  the  mitis  group. 
31 1.2.2  The  current  classification 
Figure  1.1  shows  a  recent  representation  of  the  genus  Streptococcus  comprising  the 
pyogenic  group,  the  bovis  group  and  the  four  species  groups  of  viridans  streptococci: 
the  mitis,  salivarius,  anginosus  and  mutans  groups  (Kawamura  et  al.,  1995). 
Figure  1.1  Phylogenetic  relationships  of  members  of  the  genus  Streptococcus  by 
rRNA  gene  sequence  analysis 
ä. 
Pyogei  is  group 
S. 
S. 
uýaktcýue:  PYa 
Py  ctiae  \&  \IIS.  ems  .£ 
ubeHs 
i3--ý 
ý.  angMos  u 
Sc 
anginosm  group 
mitirs  group 
. 
Ipneý 
oraýý 
S.  R*b 
s.  to" 
S.  s  quk 
S.  pmaww*5 
I.  silk 
S.  ac4omärm  nun 
ý  s. 
do 
aom 
S.  pIzo»  vrphus 
£ 
Source:  Kawamura  et  al.,  1995. 
N--..  S.  dt 
S.  Mail 
sdivariw 
bovis  group 
ratans  group 
salivarius  group 
(N.  B:  Three  more  species  of  viridans  streptococci  are  now  recognized  as  members  of  the  mitis 
group:  S.  crista  (Handley  et  al.,  1991),  S.  peroris  and  S.  infantis  (Kawamura  et  al.,  1998)). 
32 With  the  advent  of  molecular  biological  techniques  the  classification  of  viridans 
streptococci  has  been  improved  and  clarified.  Techniques  used  include  whole 
genomic  DNA-DNA  hybridization  (Adnan  et  al.,  1993;  Whiley  et  al.,  1990;  Whiley  & 
Beighton,  1991;  Kikuchi  et  al.,  1995,  Kawamura  et  al.,  1998),  DNA-ribosomal  RNA 
hybridization  (Rudney  &  Larson,  1993,  Rudney  &  Larson,  1994),  and  rRNA  gene 
sequencing  (Whiley  et  al.,  1990;  Bentley,  Leigh  &  Collins,  1991;  Kawamura  et  al., 
1995;  Kawamura  et  al.,  1998).  Arbitrarily  primed-PCR  protocols  have  also  been 
developed  to  facilitate  identification  of  viridans  streptococci  of  the  mitis  group  (Rudney 
&  Larson,  1999).  Methods  using  species  specific  PCR  primers  based  on  the  D- 
alanine:  D-alanine  ligase  (ddl)  gene  (Garnier  et  al.,  1997)  and  comparative  analysis  of 
the  partial  sequences  of  the  manganese  dependent  superoxide  dismutase  (SodA) 
gene  have  also  been  used  to  identify  members  of  this  group  (Poyart  et  al.,  1998, 
Kawamura  et  al.,  1999).  Recently,  DeGheldre  and  colleagues  (1999)  have  described 
rapid  identification  of  viridans  streptococci  by  PCR  analysis  of  transfer  DNA  intergenic 
spacer  length  polymorphism. 
However,  with  such  technical  advances,  certain  problems  arise;  an  organism 
described  in  earlier  reports  using  less  sophisticated  identification  schemes  may  now 
have  been  re-classified  and  re-named.  An  existing  species  name  may  no  longer 
apply  to  all  or  any  of  the  strains  of  viridans  streptococci  which  it  previously  described. 
For  example,  S.  mitis  described  in  earlier  reports  may  no  longer  be  equivalent  to  the 
isolate  designated  'S.  mitis'  using  current  identification  systems  (Table  1.1).  As  a 
result,  it  is  difficult  and  sometimes  impossible  to  retrospectively  draw  conclusions 
regarding  the  association  of  certain  species  of  viridans  streptococci  with  particular 
disease  presentations. 
33 Table  1.1  Present,  compared  with  previous  nomenclature  of  selected  species  of 
1.2.3 
viridans  streptococci  belonging  to  the  mitis  group 
Present  nomenclature  Previous  nomenclature 
S.  sanguis 
S.  gordonii  S.  sanguis  I 
S.  oralis 
S.  mitis  S.  sanguis  II/S.  mitior  /  S.  mitis 
Commercial  systems  for  identifying  viridans  streptococci 
Conventional  identification  of  viridans  streptococci  may  be  a  lengthy  process, 
requiring  special  biochemical  tests  and  sera  not  generally  used  in  the  clinical 
microbiology  laboratory.  Commercial  identification  kits  provide  a  convenient,  quicker 
alternative  and  also  a  standardized  means  of  testing,  whereby  the  results  from 
different  laboratories  can  be  compared.  However,  it  has  been  demonstrated  that  for 
certain  species  of  viridans  streptococci,  commercial  systems  may  not  provide  results 
of  comparable  accuracy  with  those  obtained  from  conventional  tests  or  DNA-DNA 
hybridization  (Hinnebusch,  Nikolai  &  Bruckner,  1991,  Beighton,  Carr  &  Oppenheim, 
1994)  and  as  taxonomy  of  viridans  streptococci  advances,  it  takes  considerable  time 
to  incorporate  recent  revisions  into  commercial  systems. 
Various  commercial  identification  kits  have  been  marketed  (Hinnebusch,  Nikolai  & 
Bruckner,  1991).  However  those  used  most  commonly  in  clinical  microbiology 
34 laboratories  in  the  U.  K.  have  been  the  API  20  Strep  system,  followed  more  recently  by 
the  Rapid  ID  32  Strep  method  (BioMerieux,  Basingstoke,  U.  K.  ).  The  former  system 
performs  less  satisfactorily  (West  et  a!.,  1998)  as  it  does  not  contain  certain  critical 
tests  such  as  urea  hydrolysis  and  N-acetyl-ß  -glucosaminidase. 
The  study  of  Kikuchi  and  co-workers  (1995)  assessed  the  accuracy  of  the  Rapid  ID  32 
Strep  system  in  identifying  171  isolates  of  viridans  streptococci.  Results  were 
compared  with  those  of  DNA-DNA  hybridization  and  conventional  physiological  tests. 
Eighty-seven  percent  of  strains  were  identified  correctly.  Incorrect  identification  was 
obtained  for  8%  and  no  identification  for  5%.  It  was  difficult  to  differentiate  some 
strains  of  S.  mitis  from  S.  oralis,  and  S.  parasanguis  and  S.  crista  could  not  be 
identified  because  neither  of  these  organisms  were  included  in  the  identification 
database  at  that  time.  The  conclusions  of  these  workers  were  that  this  system  could 
be  used  for  the  differentiation  of  most  species  for  which  phenotypic  characteristics 
had  been  described  if  the  database  were  revised  according  to  the  more  recently 
reported  amended  criteria,  with  the  reservation  that  a  few  species  such  as  S.  mitis 
and  S.  oralis  may  be  problematic.  Since  then,  the  APILAB  database  has  been  revised 
to  Version  2.0  (from  March,  1998)  and  now  includes  S.  parasanguis  (BioMerieux, 
1998). 
Until  recently,  published  studies  investigating  the  usefulness  of  the  Rapid  ID  32  Strep 
system  have  used  the  earlier  identification  database  (Version  1.1)  (West  et  al.  1998; 
Jensen,  Konradsen  &  Bruun,  1999),  therefore  evaluation  of  the  updated  version  has 
not  been  generally  available. 
35 1.3  Viridans  streptococci  and  the  oral  ecosystem 
1.3.1  Acquisition  of  viridans  streptococci 
The  mouth  of  the  newborn  baby  is  usually  sterile.  However  from  the  first  feeding 
onwards,  the  mouth  is  regularly  inoculated  with  micro-organisms  and  the  process  of 
acquisition  of  resident  oral  microflora  begins.  By  one  month  of  age,  virtually  all  infants 
are  colonized  with  at  least  one  species  of  viridans  streptococcus.  Colonizing  micro- 
organisms  originate  in  food,  milk  or  water  or  may  come  from  the  saliva  of  individuals 
close  to  the  baby  (Kononen,  2000).  Acquisition  of  micro-organisms  from  the  birth 
canal  itself  may  also  occur  (Carlsson  &  Gothefors,  1975). 
The  role  of  saliva  in  transmission  of  micro-organisms  has  been  confirmed 
conclusively.  Bacteriocin-typing  of  strains  has  enabled  the  transfer  of  S.  mutans  from 
mother  to  child  via  saliva  to  be  followed  (Berkowitz  &  Jordan,  1975).  Similarly, 
comparisons  of  the  DNA  of  a  variety  of  oral  bacteria  indicated  that  the  same  strain 
was  found  within  mother-child  pairs  and  within  family  groups  and  that  different 
patterns  are  observed  between  such  groups  (Caufield  et  al.,  1988;  Caufield  &  Walker, 
1989;  Alaluusua  et  al.,  1993). 
From  birth,  the  human  oral  cavity  is  a  highly  selective  environment  which  can  only  be 
colonized  by  certain  micro-organisms  (Kononen,  2000).  The  predominant  `pioneer 
species'  in  the  mouth  are  streptococci.  S.  salivarius  usually  becomes  established 
within  the  first  48  hours  of  life  (McCarthy,  Snyder  &  Parker,  1965).  More  recently, 
Pearce  and  colleagues  (1995)  have  also  identified  S.  mitis  I  and  S.  oralis  as  early 
colonizers,  in  a  study  of  streptococcal  species  isolated  from  the  mouths  of  neonates  at 
different  sampling  times  -  1-3  days,  2  weeks  and  1  month  post  partum.  The  ability  of 
some  pioneer  viridans  streptococci  to  produce  immunoglobulin  Al  protease  may 
influence  their  ability  to  survive  in  this  habitat  (Cole  et  al.,  1994). 
36 With  time,  the  metabolic  activity  of  the  pioneer  community  can  modify  its  environment. 
Change  in  pH  or  redox  potential  or  provision  of  new  receptors  or  nutrients  allows 
colonization  by  new  organisms  (Marsh  &  Martin,  1992).  Once  established,  bacterial 
species  tend  to  persist  in  the  mouths  of  infants  (Carlsson  et  al,  1970;  Kononen  et  al., 
1999).  However,  at  a  clonal  level,  there  exists  a  high  degree  of  diversity  amongst 
strains  (Fitzsimmons  et  al.,  1996)  and  the  turnover  rate  of  these  may  be  higher  in 
children  than  in  adults.  Among  more  than  600  S.  mitis  biotype  I  isolates  from  two 
families,  including  two  infants,  collected  four  times  at  3-monthly  intervals,  some 
persisting  clones  were  found  in  adults  but  none  in  infants  (Hohwy,  1997).  The  results 
from  a  study  by  Kononen  and  co-workers  (1994)  demonstrated  a  similar  pattern  for 
the  oral  anaerobe,  Prevotella  melaninogenica. 
In  the  oral  cavity,  acquisition  of  viridans.  streptococci  along  with  many  other  micro- 
organisms  continues  with  age.  Species  which  prefer  to  colonize  hard  surfaces, 
appear  or  increase  in  number  once  teeth  have,  erupted.  The  oral  microflora  of 
teenagers  differs  from  that  of  most  5  year-olds.  Eighteen  to  forty  percent  of  5  year- 
olds  are  colonized  with  black-pigmented  anaerobes,  while  90%  of  teenagers  aged  13- 
16  years  harbour  these  organisms.  It  has  been  proposed  that  the  increased 
prevalence  of  this  bacterial  group  during  puberty  might  be  due  to  hormones  entering 
the  gingival  crevice  and  acting  as  a  nutrient  source  (Marsh  &  Martin,  1992).  The 
process  of  microbial  succession  continues  until  a  stable  situation  or  `climax 
community',  comprising  highly  diverse  species  of  micro-organisms  is  established. 
1.3.2  Distribution  of  viridans  streptococci 
Viridans  streptococci  have  species-specific  predilections  for  anatomic  areas  of  the 
oral  cavity  and  pharynx.  For  example,  in  the  healthy  adult  mouth,  S.  sanguis  and 
37 S.  mitis  I  are  commonly  associated  with  the  buccal  mucosa,  whereas  the  pharyngeal 
mucosa  is  more  likely  to  be  colonized  with  S.  salivarius  (Fransden,  Pedrazzoli  & 
Kilian,  1991).  On  the  teeth,  mutans  streptococci  and  members  of  the  anginosus  and 
mitis  groups  are  found  as  these  organisms  have  a  high  affinity  for  hard  surfaces.  On 
the  dorsum  of  the  tongue,  the  major  species  found  are  S.  mitis  11  and  S.  salivarius 
(Fransden,  Pedrazzoli  &  Kilian,  1991). 
In  contrast  to  the  oral  microflora  of  adults,  it  has  been  found  that  S.  sanguis  is  not 
generally  isolated  from  the  buccal  mucosa  of  neonates  and  S.  mitis  II  rarely  colonizes 
the  dorsum  of  the  tongue  (Pearce  et  al.,  1995,  Fransden,  Pedrazzoli&  Kilian,  1991). 
S.  oralis  was  commonly  recovered  from  the  oral  mucosa  of  neonates  by  Pearce  and 
co-workers  (1995),  however  it  was  found  almost  exclusively  on  the  teeth  of  adults 
(Fransden,  Pedrazzoli  &  Kilian,  1991).  In  the  adult  mouth,  on  average,  streptococci 
represent  28%  of  the  total  cultivable  microflora  from  supragingival  dental  plaque,  29% 
from  the  gingival  crevice,  45%  from  the  tongue  and  46%  from  saliva  (Marsh  &  Martin, 
1992). 
1.3.3  Microbial  diversity  in  the  oral  cavity 
In  addition  to  viridans  streptococci,  the  mouth  supports  the  growth  of  a  wide  variety  of 
other  micro-organisms.  These  include  diverse  bacterial  species  with  yeasts,  viruses 
and,  on  occasions,  protozoa.  Many  of  the  bacteria  are  fastidious  in  their  nutritional 
requirements  and  are  difficult  to  culture  and  identify  in  the  laboratory;  many  are 
obligate  anaerobes  (Table  1.2). 
38 Table  1.2  Bacterial  genera  found  in  the  oral  cavity 
Gram-positive  Gram-negative 
Cocci  Enterococcus  Moraxella 
Peptostreptococcus  Neisseria 
Streptococcus  Veillonella 
Stomatococcus 
Bacilli  Actinomyces  Actinobacillus 
Bifidobacterium  Campylobacter 
Corynebacterium  Capnocytophaga 
Eubacterium  Centipeda 
Lactobacillus  Eikenella 
Propionibacterium  Fusobacterium 
Rothia  Haemophilus 
Leptotricha 
Mitsuokella 
Porphyromonas 
Prevotella 
Selenomonas 
Simonsiella 
Treponema 
Wolinella 
Adapted  from:  Marsh  and  Martin,  1992. 
The  diverse  habitats  unique  to  the  oral  cavity  together  with  a  variety  of  nutrients  can 
support  this  mixed  population.  In  addition,  in  dental  plaque,  gradients  develop  in 
parameters  of  ecological  significance,  such  as  oxygen  tension  and  pH,  providing 
39 conditions  suitable  for  the  growth  and  survival  of  micro-organisms  with  a  wide 
spectrum  of  requirements.  The  distribution  of  micro-organisms  is  also  related  to  their 
ability  to  adhere  at  a  site,  as  well  as  to  the  need  for  their  nutritional  and  environmental 
requirements  to  be  satisfied.  Many  species  of  bacteria  have  been  shown  to  adhere  by 
specific  molecular  interactions  between  adhesins  located  on  their  cell  surface  and 
ligands  on  the  host.  These  ligands  are  derived  mainly  from  the  acquired  pellicle  and 
mucus  coat  on  enamel  and  mucosal  surfaces  respectively.  Under  the  conditions 
found  in  the  healthy  mouth,  no  one  bacterial  population  has  a  particular  advantage 
and  numerous  species  can  co-exist. 
1.3.4  Persistence  of  the  oral  microflora  and  `colonization  resistance' 
The  persistence  of  the  resident  oral  microflora  is  dependent  on  the  ability  of  these 
organisms  to  obtain  nutrients  and  multiply  in  the  mouth.  Nutrients  are  derived  mainly 
from  the  metabolism  of  endogenous  substrates  present  in  saliva  and  gingival 
crevicular  fluid.  Superimposed  on  these  components  are  exogenous  nutrients,  which 
are  supplied  intermittently  via  the  diet;  the  most  significant  of  these  are  carbohydrates 
and  casein.  The  concentration  of  nutrients  will  affect  the  growth  rate  and  physiology 
of  the  microflora,  as  will  any  changes  in  pH  resulting  from  microbial  metabolism.  The 
fluctuating  conditions  of  nutrient  supply  and  environmental  change  require  the 
microflora  to  possess  biochemical  flexibility. 
In  the  healthy  mouth,  members  of  the  resident  microflora,  including  viridans 
streptococci,  prevent  colonization  by  more  pathogenic  micro-organisms;  a 
phenomenon  called  `colonization  resistance'.  This  can  be  achieved  by  various  means 
including  competition  for  mucosal  adherence  sites  and  the  production  of  bacteriocins. 
One  such  bacteriocin  is  hydrogen  peroxide,  produced  by  certain  members  of  the  mitis 
group,  which  exerts  an  inhibitory  effect  on  the  growth  of  competing  bacteria  (Garcia- 
40 Mendoza,  1993).  The  indigenous  species  may  also  be  more  efficient  in  utilizing 
natural  substrates  in  the  mouth  so  that  invading  organisms  cannot  flourish.  The 
metabolism  of  the  resident  microflora,  producing  changes  in  pH  or  redox  potential, 
can  also  make  conditions  unsuitable  for  colonization  by  other  organisms.  Host  factors 
also  play  a  role  in  colonization  resistance.  Immune  and  innate  host  defences  also 
help  exclude  invading  organisms  (Marsh  &  Martin,  1992). 
1.3.5  Disruption  of  the  oral  ecosystem 
Colonization  resistance  may  be  impaired  by  factors  which  compromise  the  integrity  of 
the  host  defences  or  perturb  the  resident  microflora  (Bagg,  1990;  Sixou  et  al.,  1996; 
Lucas  et  al.,  1997;  Sixou  et  al.,  1998).  Classical  examples  are  the  use  of  broad- 
spectrum  antibiotics  or  cytotoxic  chemotherapy  but  other  more  subtle  mechanisms 
can  apply.  Fibronectin  has  been  shown  to  prevent  adhesion  of  Pseudomonas 
aeruginosa  to  buccal  epithelial  cells  (Woods  et  al.,  1981;  Woods  et  al.,  1983).  Levels 
of  fibronectin  in  seriously  ill  adults  and  in  infants  are  lower  than  those  in  healthy  adults 
and  may  account  for  the  higher  rates  of  colonization  by  Gram-negative  bacilli  in  these 
subjects. 
The  ecology  of  the  oral  cavity  also  varies  with  diet.  The  regular  intake  of  dietary 
carbohydrates  can  lead  to  the  enrichment  of  aciduric  and  cariogenic  organisms  such 
as  mutans  streptococci  (Grindefjord  et  at.,  1991),  while  poor  oral  intake  in  debilitated 
cancer  patients  may  also  influence  the  microbial  composition. 
The  very  diverse  resident  oral  microflora  with  its  characteristic  composition,  exists,  for 
the  most  part,  in  harmony  with  the  host.  However,  components  of  this  microflora  can 
act  as  opportunistic  pathogens  when  the  habitat  is  disturbed  or  when  micro-organisms 
are  found  at  sites  not  normally  accessible  to  them. 
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1.4.1  Introduction 
In  the  past,  the  isolation  of  viridans  streptococci  from  blood  culture  or  cerebrospinal 
fluid  has  often  been  regarded  as  contamination.  Viridans  streptococci  are  frequently 
considered  to  be  commensal  organisms  of  low  virulence.  Their  major  disease 
associations  were  formerly  limited  to  dental  caries  (Bagg  et  al.,  1999)  and 
endocarditis  (Douglas  et  al.,  1993).  Over  the  last  twenty  years  however,  these 
bacteria  have  emerged  as  significant  pathogens  in  certain  patient  populations, 
particularly  the  immunocompromised  (Cohen  et  al.,  1983;  Sotiropolous  et  al.,  1989; 
Classen  et  al.,  1990;  Guiot  et  al.,  1990;  Kern,  Kurrie  &  Schmeiser,  1990;  Villablanca  et 
al.,  1990;  Weisman  et  al.,  1990;  McWhinney  et  al.,  1991;  Burden  et  al.,  1991;  Elting, 
Bodey  &  Keefe,  1992;  Awada  et  al.,  1992;  Steiner  et  al.,  1993;  Donnelly  et  al.,  1993; 
Bochud  et  al.,  1994;  Richard  et  al.,  1995;  Wisplinghoff  et  al.,  1999;  Bilgrami  & 
Feingold,  2000;  Marron  et  al.,  2000). 
The  following  section  provides  background  information  on  the  major  disease 
associations  of  viridans  streptococci.  Infection  in  the  immunocompromised  host  will 
be  discussed  in  Chapter  3.  It  should  again  be  emphasized,  that  due  to  the  history  of 
numerous  taxonomic  changes,  it  is  often  difficult  to  definitively  associate  any  particular 
species  responsible  for  infection  in  earlier  studies  with  species  identified  using  recent 
systems. 
1.4.2  Dental  caries 
Dental  caries  is  a  plaque-associated  infection  (Bagg  et  al.,  1999).  The  development 
of  plaque  follows  a  definite  pattern  of  bacterial  colonization.  Adhesion  by  pioneer 
species  (S.  mitis,  S.  oralis,  S.  sanguis)  is  followed  by  a  gradual  increase  in  the 
42 complexity  of  the  microflora  to  a  climax  community  of  high  species  diversity,  including 
many  filamentous  and  obligately  anaerobic  bacteria.  A  variety  of  studies  have  found  a 
strong  association  between  viridans  streptococci  of  the  mutans  group  and  the 
development  of  dental  caries.  Evidence  has  also  emerged  that  microbial  succession 
may  occur  during  the  different  stages  of  lesion  development,  both  on  enamel  and  on 
root  surfaces.  Mutans  streptococci  are  associated  with  early  demineralization  while 
lactobacilli  are  implicated  more  with  lesion  progression  and  cavitation.  Two  features 
that,  if  not  unique,  are  certainly  distinctive  properties  of  cariogenic  bacteria  are  the 
ability  to  rapidly  transport  sugars,  when  in  competition  with  other  plaque  bacteria,  and 
to  convert  sugars  rapidly  to  acid,  even  under  extreme  environmental  conditions,  such 
as  at  a  low  pH.  Few  oral  bacteria  are  able  to  tolerate  acidic  conditions  for  prolonged 
periods,  but  mutans  streptococci  and  lactobacilli  are  not  only  able  to  remain  viable  at 
low  pH,  but  are  able  to  continue  to  metabolise  and  multiply  (Hamilton  &  Buckley, 
1991).  Such  conditions  would  favour  the  proliferation  of  these  organisms,  possibly  at 
the  expense  of  other  oral  bacteria  and  thus  increase  demineralization. 
1.4.3  Dental  abscesses 
A  dental  abscess  is  a  collection  of  pus  in  the  pulp  or  around  the  root  of  a  tooth,  which 
usually  results  from  necrosis  following  the  progression  of  dental  caries.  Viridans 
streptococci  are  often  recovered  from  dental  abscesses  and  are  believed  to  be 
involved  in  the  early  pathogenesis  of  this  infection.  As  the  abscess  develops  there  is 
a  progression  from  a  facultative  to  an  obligate-anaerobic  state.  The  presence  of 
different  species  of  both  facultatively  and  obligately  anaerobic  oral  bacteria  may 
enhance  abscess  formation  more  efficiently  than  would  be  possible  in  infection  by  a 
single  species  (Lewis,  MacFarlane  &  McGowan,  1990). 
43 Most  oral  abscesses  result  in  some  bacteria  accessing  the  bloodstream.  Usually  this 
bacteraemia  is  transient  as  host  defence  systems  readily  eliminate  the  organisms. 
Occasionally,  however,  septicaemia  may  develop  (Marinella,  1998)  and/or  metastatic 
abscesses  may  form  in  the  brain,  liver  or  kidneys. 
1.4.4  Endocarditis 
Bacteraemia  caused  by  viridans  streptococci  is  usually  of  little  clinical  consequence  in 
healthy  individuals.  Those  with  poor  dental  hygiene  may  even  suffer  viridans 
streptococcal  bacteraemia  as  a  result  of  innocuous  activities  such  as  chewing  or 
tooth-brushing  (Roberts  et  al.,  1997).  Further  causes  include  dental  extraction, 
periodontal  surgery,  bronchoscopy  and  certain  upper  respiratory  tract  and 
oesophageal  procedures  (Daly  et  al.,  1997;  Roberts  et  al.,  1997;  Dajani  et  al.,  1997; 
The  American  Heart  Association,  1997).  However,  as  a  sequela  of  viridans 
streptococcal  bacteraemia,  patients  with  cardiac  compromise  may  develop  infective 
endocarditis.  Conventional  microbiological  techniques  and  ribotyping  have  confirmed 
that  the  mouth  may  be  the  source  of  viridans  streptococci  causing  endocarditis  (Fiehn 
et  al.,  1995). 
In  the  pre-antibiotic  era  viridans  streptococcal  endocarditis  was  always  fatal.  Without 
adequate  therapy,  progressive  damage  to  the  heart  valves  occurred,  resulting  in 
cardiac  failure  and  death.  Today,  viridans  streptococcal  endocarditis  accounts  for 
about  40%  of  all  cases  of  infective  endocarditis  (Working  Party  of  the  BSAC,  1998) 
with  a  mortality  rate  of  15-30%.  Viridans  streptococci  of  the  mitis  group,  are  most 
commonly  involved,  representing  over  50%  of  all  isolates.  Streptococcus  mutans  and 
S.  salivarius  are  the  next  most  frequently  isolated  species.  In  patients  with  prosthetic 
cardiac  valves,  viridans  streptococci  are  a  common  cause  of  late-onset  endocarditis 
(Stanbridge  &  Isalska,  1997). 
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may  predispose  to  endocarditis.  When  blood  flow  is  slowest,  deposition  of  platelets 
and  fibrin  may  form  a  thrombotic  vegetation.  It  is  believed  that  viridans  streptococci 
present  in  the  bloodstream  due  to  the  development  of  bacteraemia,  bind  to  this 
platelet-fibrin  aggregate  (Manning  et  al.,  1994).  Further  deposition  of  platelets  and 
fibrin  together  with  bacterial  multiplication,  result  in  increase  in  the  size  of  the 
vegetation  thus  impairing  valvular  function. 
Previously,  the  major  predisposing  factor  for  the  development  of  viridans 
streptococcal  endocarditis  was  rheumatic  heart  disease,  the  incidence  of  which  has 
now  declined.  While  this  condition  must  still  be  considered  a  predisposing  factor, 
other  risk  factors  include  prosthetic  cardiac  valves,  previous  bacterial  endocarditis, 
systemic-pulmonary  shunts,  congenital  heart  disease  and  mitral  valve  prolapse  (when 
associated  with  a  systolic  murmur)  (Working  Party  of  the  BSAC,  1982  &  1990;  The 
American  Heart  Association,  1997). 
1.4.5  Meningitis 
Viridans  streptococci  are  an  infrequent  cause  of  meningitis,  representing  less  than  5% 
of  all  cases  of  bacterial  meningitis  (Cabellos  et  al.,  1999).  Isolation  of  a-haemolytic 
streptococci,  other  than  S.  pneumoniae,  from  CSF  can  also  represent  contamination. 
Careful  clinical  examination  and  precise  interpretation  of  CSF  laboratory  results  is  of 
paramount  importance.  Of  the  viridans  streptococci,  members  of  the  `mitis'  or 
`salivarius'  groups  are  most  frequently  isolated  (Cabellos  et  al.,  1999).  However 
meningitis  caused  by  S.  constellatus  has  also  been  reported  (Roca,  Romera  &  Simon, 
1998).  Viridans  streptococcal  meningitis  may  occur  in  all  age  groups  including 
neonates  of  mothers  with  genital  tract  colonization  with  these  organisms  (Hellwege  et 
al.,  1984). 
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puncture  (Schneeberger,  Janssen  &  Voss,  1996).  In  this  setting,  the  source  of  the 
infecting  organisms  may  be  the  patient's  endogenous  flora,  or  contamination  of  a 
drug,  or  may  be  due  to  poor  infection  control  by  the  physician.  Two  cases  of  vindans 
streptococcal  meningitis  have  been  described  following  percutaneous  glycerol 
rhizotomy  of  the  trigeminal  ganglion  (James,  Kibbler  &  Gillespie,  1995).  Meningitis 
has  also  been  reported  in  association  with  viridans  streptococcal  bacteraemia, 
following  upper  gastrointestinal  endoscopy  and  cauterization  for  gastric  bleeding 
(Carley,  1992),  and  is  a  very  rare  complication  of  dental  treatment  (Colville  et  al., 
1993;  Shetty,  Keyser  &  Ridgeway,  1998). 
Clinical  symptoms  include  fever,  headache,  meningeal  signs  and  confusion.  With 
antimicrobial  therapy,  mortality  rates  are  low.  The  majority  of  fatalities  occur  in 
association  with  viridans  streptococcal  bacteraemia  in  immunocompromised  patients, 
in  whom  the  symptoms  and  signs  of  meningitis  may  be  more  difficult  to  detect 
because  of  an  impaired  inflammatory  response.  Of  particular  concern  are  reports  of 
meningitis  caused  by  penicillin-resistant  viridans  streptococci  in  paediatric  neutropenic 
patients  (Balkundi  et  al.,  1997;  Tokuda  et  al.,  2000).  Viridans  streptococcal  meningitis 
has  also  been  reported  in  association  with  endocarditis  (Cabellos  et  al.,  1999). 
1.4.6  Pneumonia 
Pneumonia  associated  with  viridans  streptococci  has  been  described  in  both 
immunocompromised  and  immunocompetent  individuals  (Pratter  &  Irwin,  1980; 
Marrie,  1993).  It  must  be  stressed  however  that  viridans  streptococci  are  often 
isolated  from  cultures  of  lower  respiratory  tract  specimens  as  normal  flora 
contaminants.  Viridans  streptococci  grow  more  readily  on  culture  media  than  more 
fastidious  organisms  such  as  S.  pneumoniae  -  the  a  -haemolytic  streptococcus 
46 associated  with  classical  bacterial  pneumonia.  Viridans  streptococcal  infection  has 
become  more  commonly  associated  with  a  different  form  of  pulmonary  pathology  - 
acute  respiratory  distress  syndrome  in  haematology/oncology  patients  -  to  be 
discussed  in  Chapter  3. 
1.4.7  Infection  in  neonates 
There  are  several  reports  describing  viridans  streptococcal  infection  in  neonates,  most 
commonly  associated  with  obstetric  complications  such  as  prolonged  rupture  of 
membranes,  premature  labour  or  peri-partum  fever.  Cases  of  bacteraemia 
(Broughton,  Krafka  &  Baker,  1981;  Moomjian,  Sokal  &  Vijayan,  1984;  Spigelblatt  et 
al.,  1985)  and  meningitis  (Hellwege  et  al.,  1984)  have  been  described,  usually 
occurring  within  the  first  week  of  life.  The  mode  of  transmission  is  probably  vertical  as 
the  female  genitourinary  tract  may  be  colonized  with  viridans  streptococci.  Species 
involved  are  usually  members  of  the  mitis  group  and,  less  commonly,  S.  salivarius 
(Spigelblatt  et  al.,  1985;  West  et  at.,  1998).  The  infection  generally  responds  well  to 
antibiotic  therapy.  Rare  fatal  cases  of  viridans  streptococcal  bacteraemia  in  this 
patient  group  tend  to  be  associated  with  extreme  prematurity  (Moomjian,  Sokal  & 
Vijayan,  1984). 
1.4.8  Infections  associated  with  the  anginosus  group  of  viridans  streptococci 
The  anginosus  group  of  viridans  streptococci  is  associated  with  endogenous  pyogenic 
infections,  which  sharply  delineates  these  organisms  from  the  other  viridans 
streptococci  (Hardie  &  Whiley,  1994;  Jacobs,  1997).  Disruption  of  mucosal  surfaces 
due  to  surgical  procedures,  ulceration  and  perforation  has  been  associated  with 
infection.  Other  predisposing  factors  include  diabetes  mellitus,  malignancy  and 
immunosuppression  (Brook  &  Frazier,  1994;  Jacobs,  1997).  It  should  be  emphasized, 
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infection  by  viridans  streptococci  of  the  mitis  rather  than  the  anginosus  group. 
S.  intermedius  appears  to  associated  with  abscesses  of  the  brain  and  liver,  while  S. 
anginosus  is  more  commonly  isolated  from  gastrointestinal  and  genitourinary 
infections  (Hardie  &  Whiley,  1994;  Jacobs  et  al.,  1995;  Yamamoto  et  al.,  1999).  S. 
constellatus  is  recovered  from  a  wide  range  of  sites  including  the  thorax  (Jacobs  et 
al.,  1995).  Infection  by  viridans  streptococci  of  the  anginosus  group  may  involve 
pathogenic  synergism  with  other  bacterial  species  (Lewis,  MacFarlane  &  McGowan, 
1990;  Brook  &  Frazier,  1994;  Quinlivan  et  al.,  1996;  Nagashima,  Takao  &  Maeda, 
1999).  Bacteraemia  caused  by  anginosus  group  streptococci  is  uncommon  (Gossling, 
1988). 
1.5  Pathogenicity 
Historically,  viridans  streptococci  have  been  regarded  as  organisms  which  lack 
traditional  virulence  factors.  However  various  subtle  mechanisms  contribute  to 
pathogenicity  in  infection  by  these  organisms. 
1.5.1  Cariogenic  activity 
The  properties  that  confer  pathogenicity  to  cariogenic  bacteria  are  related  to  the  ability 
to  rapidly  catabolise  dietary  carbohydrates  to  acid,  and  for  the  organisms  to  survive 
and  proliferate  under  the  fluctuating  conditions  of  pH  in  plaque.  Mutans  streptococci 
are  both  acidogenic  and  aciduric  and  thus  can  play  an  active  role  in  demineralization 
of  enamel  (Marsh  &  Martin,  1992). 
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In  cases  of  endocarditis,  the  efficient  adherent  ability  of  some  species  of  viridans 
streptococci,  particularly  of  the  mitis  group,  allows  them  to  attach  to  vegetations 
(Manning  et  al,  1994).  Evidence  from  in  vitro  studies  suggests  that  fibronectin  may 
mediate  the  binding  of  viridans  streptococci  to  damaged  heart  valves.  The  extent  to 
which  strains  of  viridans  streptococci  can  adhere  to  fibronectin,  fibrinogen  and 
platelet-fibrin  clots  in  vitro  may  be  related  to  their  ability  to  produce  endocarditis  in 
animal  models  (Manning  et  al.,  1994).  Further  animal  studies  suggest  that  the 
production  of  dextran,  a  feature  of  several  members  of  the  'mitis'  group,  also 
correlates  with  the  ability  to  induce  endocarditis  (Douglas  et  al.,  1993). 
1.5.3  Virulence  mechanisms  of  the  anginosus  group 
As  mentioned  previously,  members  of  the  anginosus  group  are  unique  amongst  the 
viridans  streptococci  in  their  association  with  purulent  infection  and  have  been  shown 
to  produce  extracellular  enzymes  which  contribute  to  pathogenicity  (Jacobs,  1997). 
The  production  of  the  hydrolytic  enzymes,  hyaluronidase  and  chondroitin  sulphate 
depolymerase  may  facilitate  the  spread  of  these  organisms  through  host  tissues 
(Homer  et  al.,  1993).  Anginosus  group  streptococci  also  produce  ribonuclease  and 
deoxyribonuclease,  enzymes  which  may  facilitate  liquefaction  of  pus  (Homer  et  al., 
1993). 
1.5.4  Glycolytic  and  proteolytic  activity 
It  has  been  shown  that  the  rate  of  growth  of  certain  species  of  viridans  streptococci  on 
the  teeth  of  primates  is  generally  unaffected  by  the  availability  of  the  host  diet 
(Beighton  &  Hayday,  1986).  S.  oralis  and  S.  mitis  persist  in  the  mouths  of  neutropenic 
patients  with  cancer  in  spite  of  reduced  or  negligible  food  intake.  By  virtue  of  their 
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viridans  streptococci  to  degrade  glycoproteins  in  vitro  (Homer,  Whiley  &  Beighton, 
1990;  Rafay,  Homer  &  Beighton,  1996).  Such  enzymatic  activity  may also  allow  these 
species  to  obtain  nutrients  from  host-derived  salivary  glycoproteins  in  vivo  and  may  be 
related  to  their  persistence  in  the  mouths  of  patients  with  cancer.  This  finding  may,  in 
turn,  be  associated  with  the  predominance  of  these  particular  species  in  viridans 
streptococcal  bacteraemia  in  this  patient  group  (Beighton,  Carr  &  Oppenheim,  1994). 
1.5.5  Induction  of  cytokines 
It  has  been  demonstrated  that  cell  wall  products  of  viridans  streptococci,  such  as 
lipoteichoic  acid,  can  induce  the  proinflammatory  mediators,  nitric  oxide  and  tumour 
necrosis  factor  (English  et  al.,  1996).  In  addition,  a  number  of  investigators  have 
shown  that  extracellular  fractions  of  viridans  streptococci  can  induce  cytokine 
production  (Soto  et  al.,  1998,  Matsushita  et  al.,  1995;  Takada  et  al.,  1993).  Engel  and 
co-workers  (1996)  showed  that  interleukin-6  levels  in  blood  of  two  neutropenic 
patients  with  severe  viridans  streptococcal  sepsis,  were  much  higher  than  those  of 
control  patients  with  uncomplicated  bacteraemia  caused  by  Gram-positive  organisms. 
A  potential  association  of  cytokine  induction  by  viridans  streptococci  with  development 
of  severe  sepsis,  exclusively  in  neutropenic  patients  with  cancer,  will  be  discussed 
further  in  Chapter  3. 
1.6  Antibiotic  susceptibility 
Reduced  susceptibility  of  viridans  streptococci  to  penicillin  was  first  described  in  1949 
(Krumwiede).  However  around  that  time  little  clinical  significance  was  attached  to  this 
or  other  early  reports.  Resistance  to  penicillin  amongst  viridans  streptococci, 
particularly  of  the  mitis  group,  is  now  common  in  many  hospitalized  patients,  with 
resistance  rates  exceeding  50%  in  some  reports  (Tuohy  &  Washington,  1997). 
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individuals  (Guiot,  Corel  &  Vossen,  1994).  Resistance  to  penicillin  in  these  organisms 
is  due  to  the  development  of  altered  forms  of  penicillin  binding  proteins  which  have 
reduced  affinity  for  the  antibiotic.  These  high-molecular  weight  proteins  are  encoded 
by  `mosaic'  genes  that  are  produced  by  genetic  recombination  events  between 
different  strains  or  species  of  oral  streptococci  (Chalkley  et  al.,  1991).  Several 
streptococcal  species,  including  S.  oralis,  S.  mitis,  S.  sanguis  and  S.  pneumoniae  are 
naturally  transformable,  and  can  easily  transfer  antibiotic  resistance  markers  into 
closely  related  species  (Potgieter  &  Chalkley,  1995). 
Resistance  to  penicillin  in  viridans  streptococci  is  also  associated  with  resistance  or 
decreased  susceptibility  to  other  ß-lactam  antibiotics,  including  cephalosporins 
(McWhinney  et  al.,  1993;  Alcaide  et  al.,  1995;  Doern  et  al.,  1996;  Pfaller  &  Jones, 
1997;  Pfaller,  Marshall  &  Jones,  1997;  Marron  et  al.,  2001;  Kennedy  et  al.,  2001). 
The  prevalence  of  resistance  of  viridans  streptococci  to  erythromycin  and  other 
macrolide  antibiotics  has  also  increased  (Maskell  et  al.,  1990).  Resistance  to 
macrolides  in  viridans  streptococci  is  associated  with  the  presence  of  an  rRNA 
methylase  gene,  ermB,  which  confers  resistance  to  macrolides,  lincosamides  and 
streptogramin  B  antibiotics  (Clermont  &  Horaud,  1990).  A  different  mechanism, 
conferring  resistance  to  macrolides  but  not  to  lincosamides  and  streptogramin  B,  has 
more  recently  been  described  (Luna  et  al.,  1999;  Arpin  et  al.,  1999).  The  gene 
responsible,  mef,  codes  for  a  membrane  bound  efflux  protein.  Resistance  to 
tetracycline  in  viridans  streptococci  is  encoded  by  the  tetM  gene  which  is  often  found 
linked  with  ermB  (Poutanen  et  al.,  1999).  Resistance  to  chloramphenicol  and 
kanamycin  is  encoded  by  the  cat  and  aphA  genes  respectively.  Several  studies  have 
described  resistance  to  two  or  more  different  classes  of  antibiotic  amongst  viridans 
streptococci  (Pfaller  et  al.,  1997). 
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teicoplanin  has  remained  high  (Potgieter  et  al.,  1992;  McWhinney  et  al.,  1993;  Tuohy 
&  Washington,  1997;  Teng  et  al.,  1998;  Marron  et  al.,  2001;  Kennedy  et  al.,  2001). 
However,  the  potential  for  nephrotoxicity  associated  with  the  use  of  vancomycin, 
results  in  this  agent  commonly  being  reserved  until  microbial  documentation  of 
infection  is  available. 
During  the  early  years  of  the  present  study,  there  existed  some  concern  that  the 
observed  increase  in  resistance  of  viridans  streptococci  to  ß  -lactam  antibiotics  such 
as  penicillin,  cefaclor  and  ceftazidime  might  escalate  and  possibly  spread  to  include 
the  more  modern  ß  -lactam  agents  such  as  ceftriaxone  and  the  carbapenems. 
Around  this  time,  two  new  anti-Gram-positive  drugs,  the  streptogramin  antibiotic, 
quinupristin/dalfopristin  and  the  oxazolidinone,  linezolid  were  being  evaluated  in 
clinical  trials.  The  in  vitro  activity  of  these  agents  was  also  being  determined  - 
however  predominantly  against  established  Gram-positive  pathogens  (Pepper  & 
Bouanchaud,  1996),  rather  than  against  opportunistic  pathogens  such  as  viridans 
streptococci. 
Information  was  required  on  the  susceptibility  of  viridans  streptococci  to  the  more 
modern  ß  -lactam  antibiotics,  such  as  the  carbapenems  and  the  fourth  generation 
cephalosporins  and  to  the  new  agents,  quinupristin/dalfopristin  and  linezolid. 
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2.1  Introduction 
In  the  United  Kingdom  one  in  every  10,000  children  under  the  age  of  15  years 
develops  cancer  each  year.  Childhood  malignancies  differ  markedly  from  those  in 
adults,  in  type,  site  and  incidence.  Enormous  progress  has  been  made  in  the 
treatment  of  childhood  cancer,  with  more  than  60%  of  children  now  being  cured  -a 
much  higher  rate  than  that  for  adults.  Because  paediatric  neoplasms  are 
characterized  by  a  high  growth  fraction  with  a  propensity  for  frequent,  early 
micrometastases,  chemotherapy  has  become  the  cornerstone  of  treatment. 
With  the  wider  use  of  chemotherapy,  more  intensive  treatment  schedules  have  been 
developed,  with  or  without  bone  marrow  transplantation.  Accordingly,  infection  has 
become  an  expected  sequela  of  the  therapy  of  paediatric  malignancy.  The  patients 
described  in  the  present  study  were  receiving  therapy  for  a  wide  range  of 
malignancies.  The  following  section  provides  a  short  description  of  the  major  types  of 
childhood  cancer. 
2.2  Childhood  cancer 
Leukaemias  comprise  approximately  one  third  of  all  paediatric  malignancies  with 
approximately  400  new  cases  occurring  every  year  in  the  United  Kingdom  (Figure 
2.1).  Around  85%  of  these  cases  are  acute  lymphoblastic  leukaemia  (ALL).  Acute 
myeloid  leukaemia  (AML)  accounts  for  10-15%  of  childhood  leukaemia  but  is  the 
commonest  leukaemia  of  adulthood  (Liesner  &  Goldstone,  1997).  Chronic  myeloid 
leukaemia  (CML)  occurs  occasionally  in  young  adults  and  is  even  less  common  in 
children. 
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Tumours  of  the  central  nervous  system  constitute  the  largest  group  of  solid 
neoplasms  in  children  (Figure  2.1).  The  overall  distribution  of  childhood  brain  tumours 
according  to  their  histologic  appearance  differs  markedly  from  the  pattern  seen  in 
adults  as  do  the  sites  in  which  they  arise.  The  predominant  brain  tumours  in  children 
are  primitive  neuroectodermal  tumour  (medulloblastoma)  and  astrocytoma. 
Lymphomas  are  malignant  tumours  of  the  lymph  nodes  and  are  the  third  most 
common  group  of  cancers  in  children  and  adolescents  (Sandlund,  Downing  &  Crist, 
1996).  There  are  two  groups  of  lymphomas:  Hodgkin's  and  non-Hodgkin's 
lymphomas  (NHL).  The  presence  of  large  binucleate  cells  (Reed-Sternberg  cells)  in 
the  cancerous  lymph  nodes  distinguishes  the  former  from  the  latter. 
Incidence  and  mortality  rates  of  specific  paediatric  malignancies  vary  with  age.  Acute 
lymphoblastic  leukaemia  is  commonest  in  the  age  range  2-10  years  with  a  peak  at  3-4 
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0  100  200  300  400  500 years  (Liesner  &  Goldstone,  1997).  The  majority  of  cases  of  neuroblastoma,  Wilms' 
tumour  (or  'nephroblastoma')  and  retinoblastoma  occur  within  the  population  under  5 
years  of  age  (Crist,  2000).  Many  of  the  tumours  that  occur  in  this  age  group  are 
embryonal  in  nature.  Hodgkin's  and  non-Hodgkin's  lymphoma  and  testis  and  bone 
tumours  occur  more  frequently  in  children  over  10  years  of  age  (Pratt,  1985).  Some 
malignancies,  such  as  acute  lymphoblastic  leukaemia  and  neuroblastoma  occur 
slightly  more  frequently  in  boys  than  in  girls  (Crist  &  Smithson,  2000;  McManus  & 
Gilchrist,  2000). 
2.3  Predisposition  to  infection 
Development  of  sepsis  in  patients  with  cancer  is  influenced  by  both  the  type  and 
extent  of  host  predisposition  to  infection  and  by  the  individual's  exposure  to  potentially 
pathogenic  organisms.  Predisposing  factors  include  the  malignancy  itself,  specific 
therapy  directed  against  it,  and  supportive  care. 
2.3.1  Immunosuppression  in  malignancy  and  predisposition  to  infection 
An  intact  and  functioning  immune  system,  along  with  physical  barriers  is  necessary  for 
protection  against  infecting  micro-organisms.  Immunosuppression  in  patients  with 
cancer  takes  many  forms  and  although  one  aspect  may  predominate,  others  may  also 
be  involved  at  more  subtle  levels.  This  section  will  describe  the  major  causes  of 
immune  system  dysfunction  in  patients  with  malignant  disease. 
2.3.1.1  Immunosuppression  associated  with  malignancy 
Granulocytopenia  associated  with  tumour  alone  occurs  most  often  with 
haematological  malignancies  intrinsic  to  marrow.  However  lymphomas,  neuro- 
blastoma,  malignant  melanoma  and  certain  carcinomas  may  also  manifest 
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replacement  with  tumour.  Defects  in  cell  mediated  immunity  are  recognized  in 
patients  with  advanced  Hodgkin's  disease  and  to  a  lesser  extent  other  lymphomas 
and  acute  and  chronic  Ieukaemias  (Feld  &  Sutcliffe,  1987;  Schimpff,  1995). 
2.3.1.2  Immunosuppression  associated  with  anti-cancer  therapy 
The  tumoricidal  effect  of  most  anti-cancer  drugs  depends  on  their  ability  to  kill  dividing 
cells.  This  action  inevitably  damages  normal  cell  populations  in  the  skin,  mucosal 
surfaces,  gonads  and  bone  marrow,  resulting  clinically  in  alopecia,  mucositis,  nausea, 
diarrhoea,  infertility  and  myelosuppression. 
Myelosuppression  is  the  most  serious  complication  of  anti-cancer  therapy.  Anaemia 
and  thrombocytopenia  can  usually  be  corrected  with  transfusion,  but  the  problems 
associated  with  neutropenia  can  still  be  formidable.  It  is  generally  recognized  that  in 
cancer  patients  the  risk  of  infection  is  highest  during  episodes  of  neutropenia  following 
intensive  chemotherapy  for  acute  leukaemia  or  following  allogeneic  bone  marrow 
transplantation.  Other  patients  at  high  risk  include  those  receiving  intensive 
chemotherapy  for  relapsed  lymphoma,  because  they  frequently  have  severely 
compromised  bone  marrow  reserve  and  other  defects  in  immune  function.  Commonly 
used  chemotherapeutic  agents  with  dose  limiting  haematologic  toxicity  are  listed  in 
Table  2.1. 
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Neutropenia  Mucositis 
Antimetabolites 
Methotrexate  (high-dose)  +++*  +++* 
Cytosine  arabinoside  (high-dose)  +++  +++ 
Fludarabine  +/++  +/- 
6-mercaptopurine  +++  +/- 
Alkylating  agents 
Cyclophosphamide  +++  - 
Mciphalan  (high-dose)  +++  +++ 
Anti  tumour  antibiotics 
Doxorubicin  +++  +++ 
Daunorubicin  +++  +++ 
Mitozantrone  +++  +++ 
Vinca  alkaloids  &  Etoposide 
Vincristine  -  - 
Vinblastine  ++  + 
Etoposide  ++  ++ 
Platinum  analogues 
Carboplatin  ++  - 
Cisplatin  +  - 
Sources:  Perren,  1992;  McGeer  &  Feld,  1994 
(*  +++,  ++,  +,  -,  etc:  Interpretative  severity  guides) 
After  administration  of  chemotherapy,  the  neutrophil  count  nadir  typically  occurs  1-2 
weeks  later,  although  this  can  vary  to  some  extent,  depending  on  the  particular  agents 
used.  Both  the  depth  and  duration  of  neutropenia  are  related  to  the  development  of 
infection  (Bodey  et  al.,  1966;  Brown,  1984). 
The  frequency  of  infection  begins  to  rise  as  the  neutrophil  count  drops  below  0.5  x 
109/L.  The  absolute  level  of  neutropenia  is  a  useful  index  of  infection  risk,  however 
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much  more  likely  to  be  associated  with  an  increased  risk  of  infection  than  is  the  slow 
decline  observed  with  syndromes  such  as  cyclic  neutropenia. 
In  addition  to  well-defined  quantitative  defects,  qualitative  abnormalities  in  neutrophil 
function  can  occur  in  leukaemia  and  lymphoma  patients,  including  defects  in 
chemotaxis,  phagocytosis,  and  bactericidal  activity  (Curnette  &  Boxer,  1985). 
Corticosteroids,  for  example,  can  decrease  phagocytosis  and  migration,  and  a 
number  of  antineoplastic  agents,  including  vinca  alkaloids,  asparaginase,  6- 
mercaptopurine,  methotrexate  and  anthracyclines  can  significantly  decrease 
phagocytic  and  bactericidal  activity  (Pickering,  Ericsson  &  Kohl,  1978). 
Corticosteroids  can  also  alter  macrophage  function,  diminishing  host  defence  against 
fungi  and  other  pathogens  including  mycobacteria,  Listeria  and  Brucella  as  well  as 
protozoans  and  viruses  (Schaffner,  Douglas  &  Braude,  1982). 
The  introduction  of  halogenated  purine  analogues,  such  as  fludarabine,  to  certain 
drug  regimens  has  added  a  new  dimension  to  the  infection  risk  associated  with 
chemotherapy.  These  compounds  do  produce  neutropenia,  but  they  are  more 
specifically  lymphocytotoxic.  There  are  reports  of  the  use  of  these  agents  and  the 
development  of  infections  usually  associated  with  defects  in  cell-mediated  immunity 
e.  g.  P.  carinii  pneumonia  and  herpes  virus  infections  (Schilling  &  Vadhan-Raj,  1990; 
Spielberger,  1993). 
Radiation  therapy,  used  alone,  is  generally  associated  with  the  least  predisposition  to 
infection.  Radiation  fields  which  include  large  volumes  of  bone  marrow  (for  instance 
total  craniospinal  irradiation)  are  associated  with  some  degree  of  reversible 
neutropenia;  however  the  nadir  neutrophil  count  is  generally  above  1.0  X  109/L,  and 
defined  infections  and  febrile  neutropenia  are  rare.  Extended  field  radiation  therapy, 
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lymphopenia  and  alterations  in  T  lymphocyte  subsets  (Job  et  al.,  1984). 
2.3.1.3  Immunosuppression  associated  with  bone  marrow  transplantation 
Risks  of  infection  for  bone  marrow  transplant  (BMT)  patients  include  the  underlying 
disease  and  its  remission  status  at  the  time  of  transplant,  the  ablative  radiotherapy 
and/or  chemotherapy  used  to  prepare  the  recipient  for  transplantation,  the  prior 
infections  of  the  donor,  graft-versus-host  disease  (GVHD)  and  the  immuno- 
suppressive  therapy  used  for  prevention  or  treatment  of  it.  Patients  who  receive 
syngeneic  or  autologous  BMT  have  fewer  infectious  complications  than  recipients  of 
allogeneic  transplants  (Hunter,  Haynes  &  Russell,  1995). 
During  the  period  before  engraftment,  patients  undergoing  any  form  of  BMT  are  at  risk 
of  developing  bacterial  or  fungal  infections.  This  period  usually  lasts  for  the  first  21  to 
28  days  after  BMT,  however  the  risk  continues  if  complications  such  as  acute  GVHD 
occur.  Acute  GVHD  may  induce  ulceration  of  the  gastrointestinal  tract  and 
abnormalities  of  granulocyte  function  (Meyers,  Flournoy  &  Thomas,  1986),  however 
treatment  of  acute  GVHD  also  enhances  the  risk  of  infection. 
As  the  neutrophil  count  recovers,  the  pattern  of  infection  changes,  particularly  for 
allogeneic  transplant  recipients,  who  remain  profoundly  immunosuppressed.  Cellular 
immunity  is  particularly  compromised  and  patients  may  develop  life-threatening  viral 
infections  (Griffiths,  1995).  Major  pathogens  after  the  initial  period  of  engraftment 
include  cytomegalovirus  (CMV),  adenovirus  and  fungi  (including  P.  carinii). 
The  late  phase  of  infection  risk  post  BMT  begins  approximately  three  months  after 
transplantation,  around  the  time  when  chronic  GVHD  may  develop.  Sinopulmonary 
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caused  by  CMV  and  P.  carinii  may  develop.  Months,  or  even  years  after  engraftment, 
encapsulated  organisms  such  as  S.  pneumoniae  may  cause  severe  respiratory 
infections  and  bacteraemia  attributable  to  the  inability  to  make  opsonizing  antibody 
(Meyers,  Flournoy  &  Thomas,  1986). 
2.3.2  Splenectomy  and  predisposition  to  infection 
Patients  who  have  undergone  splenectomy  have  a  life-long  increased  risk  of  sepsis 
due  to  S.  pneumoniae,  Haemophilus  influenzae  and  Neisseria  meningitidis.  This 
occurs  because  the  spleen  is  of  critical  importance  in  clearing  non-opsonized 
pathogens  from  the  bloodstream  early  in  infection  (Bohnsack  &  Brown,  1986).  Adults 
are  at  lower  risk  than  children  because  they  often  have  antibodies  which  can  at  least 
partially  recognize  pathogens. 
2.3.3  Malnutrition  and  predisposition  to  infection 
The  effects  of  malnutrition  on  the  immune  system  are  complex  and  widespread; 
neutrophil  migration,  phagocytosis  and  bactericidal  activity  are  all  reduced,  delayed 
type  hypersensitivity  is  impaired,  antibody  responses  to  specific  antigens  are  reduced, 
and  cytokine  secretion  is  abnormal  (Chandra,  1983).  Altered  nutrition  also  contributes 
to  the  loss  of  integrity  of  the  integument  and  mucosa.  However  it  is  difficult  to 
estimate  the  size  of  these  effects  in  predisposing  to  infection  because  malnutrition 
does  not  occur  in  isolation. 
2.3.4  Disruption  of  physical  defence  barriers  and  predisposition  to  infection 
Integumentary  and  mucosal  physical  defence  barriers  can  be  altered  by  tumour  (e.  g. 
obstruction  of  drainage).  Chemotherapy  may  produce  oral  or  gastrointestinal 
mucositis  (Table  2.1),  which  provides  a  nidus  for  colonization  and  a  portal  for  systemic 
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implanted  intravenous  catheters  such  as  Hickman  lines  offers  sites  for  local  as  well  as 
systemic  infection  (Elliot  &  Tebbs,  1998;  Raad,  2000). 
2.3.5  Disturbance  of  normal  microbial  flora  and  predisposition  to  infection 
Administration  of  antimicrobial  agents  may  alter  natural  colonization  resistance  which, 
may  in  turn,  predispose  to  infection  by  exogenous  pathogens.  Repeated  courses  of 
empirical  therapy  or  prophylaxis  with  antimicrobial  agents  may  be  associated  with 
resistance  amongst  endogenous  organisms  (Carratala  et  al.,  1995,  Spanik  et  al., 
1997,  Kennedy  et  al.,  2001). 
2.4  Infection  in  patients  with  malignancy 
Infection  is  an  expected  sequela  of  the  therapy  of  many  forms  of  cancer.  Although  the 
fundamental  principle  of  treatment  of  infection  is  to  treat  only  sites  that  have  been 
microbiologically  defined,  the  standard  practice  for  febrile  neutropenic  patients  is  to 
use  broad  spectrum  antibiotics  empirically  (Kibbler,  1995).  This  approach  originated 
in  the  late  1960s  and  early  1970s  and  was  based  on  the  observations  of  Schimpff, 
Bodey  and  others  who  demonstrated  that  empirical  therapy  could  reduce  the  early 
morbidity  and  mortality  associated  with  undiagnosed  and  untreated  infections 
(Schimpff  et  al.,  1971;  Bodey  et  al.,  1972). 
Neutropenia  not  only  increases  the  likelihood  of  infection  developing  -  it  also 
influences  the  severity  of  infection  and  the  rapidity  of  its  progression  if  left  untreated 
(Schimpff  et  al.,  1971).  In  the  late  1960s  and  early  1970s  Gram-negative  infections 
predominated  and  suitable  antibiotics  available  for  therapy  were  more  limited  than 
today.  The  literature  of  that  period  shows  that  infectious  complications  were  an 
overwhelming  problem  for  the  haematologist/oncologist  (Hersh  et  al.,  1965).  The 
mortality  from  Gram-negative  sepsis  was  reported  to  be  70-80%  and  reached  100%  in 
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changed  significantly  with  the  availability  of  a  wider  range  of  potent  antibiotics  and  the 
recognition  that  they  should  be  started  as  soon  as  the  neutropenic  patient  becomes 
febrile  (Schimpff,  1986). 
However,  while  the  principles  of  empirical  therapy  have  remained  central  to  treatment 
of  the  febrile  neutropenic  patient,  management  of  infection  remains  a  dynamic  field, 
as  the  challenges  encountered  continue  to  change  as  a  function  of  the  cancer  treated, 
the  antineoplastic  regimens  used,  the  hospital  environment  and  the  medical  devices 
used.  New  and/or  resistant  pathogens  have  emerged.  In  particular,  with  the 
increasing  use  of  bone  marrow  transplantation,  many  and  varied  factors  interact  to 
cause  serious  risk  of  infection,  which  may  require  several  modifications  in 
antimicrobial  regimens,  together  with  adjunctive  cytokine  therapy,  to  maximize  patient 
outcome. 
2.4.1  Micro-organisms  associated  with  infection  in  patients  with  malignancy 
Within  the  last  25  years  there  has  been  a  major  shift  in  the  pattern  of  infection  in 
febrile  neutropenia.  The  studies  of  the  International  Antimicrobial  Therapy 
Cooperative  Group  (IATCG)  of  the  European  Organization  for  Research  and 
Treatment  of  Cancer  (EORTC)  demonstrated  that  in  the  mid-late  1970s,  around  70% 
of  cases  of  single-organism  bacteraemia  were  caused  by  Gram-negative  bacilli, 
predominantly  Escherichia  coli,  Klebsiella  pneumoniae  and  Pseudomonas  aeruginosa 
(EORTC  Antimicrobial  Therapy  Project  Group,  1978).  Throughout  the  1980s,  the 
proportion  of  infections  caused  by  Gram-negative  bacteria  declined  while  Gram- 
positive  pathogens  started  to  become  more  prominent.  By  the  1990s,  a  reversal  of 
proportions  relative  to  1970s  figures,  had  become  established,  with  Gram-positive 
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(Cometta,  et  al.,  1995;  Cometta  et  al.,  1996). 
Table  2.2  The  changing  pattern  of  bacteraemia  -  EORTC  trials  1973  -  94 
Trial 
No. 
Dates  Total  No.  of  cases 
of  single-organism 
bacteraemia 
No.  of  cases  (%) 
of  Gram-positive 
bacteraemia 
No.  of  cases(%)  of 
Gram-negative 
bacteraemia 
1  1973-6  145  42(29)  103  (71) 
II  1977-80  111  37(33)  74(67) 
III  1980-3  141  58(41)  83(59) 
IV  1986-7  219  90  (41)  129  (59) 
VIII  1988-90  151  104  (69)  47  (31) 
IX  1991-2  161  108  (67)  53(33) 
XI  1993-4  199  138  (69)  61  (31) 
Sources:  EORTC  Antimicrobial  Therapy  Project  Group,  1978;  EORTC  Antimicrobial  Therapy 
Group,  1983;  Klatersky  et  al.,  1986;  EORTC  International  Antimicrobial  Therapy  Cooperative 
Group,  1987;  EORTC  International  Antimicrobial  Therapy  Cooperative  Group,  1993;  Cometta 
et  al.,  1995;  Cometta  et  al.,  1996. 
Bacteria  have  remained  the  most  common  pathogens  in  neutropenic  patients, 
accounting  for  approximately  90%  of  the  culture-documented  infections  (Pizzo,  1989). 
Although  bacteria  tend  to  be  the  initial  cause  of  infection,  fungi,  such  as  Candida  and 
Aspergillus  spp.  can  emerge  as  important  pathogens  in  patients  who  have  protracted 
periods  of  neutropenia.  In  some  cases,  particularly  post  BMT,  viruses  such  as  herpes 
simplex  virus  (HSV),  cytomegalovirus  (CMV),  adenovirus  and  varicella  zoster  virus 
(VZV)  may  cause  serious  infectious  complications.  Pathogens  associated  with 
infection  in  immunocompromised  patients  vary,  to  some  extent,  from  centre  to  centre, 
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therapeutic  antibacterials,  use  of  central  lines,  and  the  patient's  environment. 
Of  the  organisms  responsible  for  bacteraemia,  Gram-negative  bacilli  remain  a  major 
threat  in  view  of  their  pathogenicity.  E.  coli  is  generally  the  most  frequently  isolated 
member  of  the  Enterobacteriaceae,  and  although  Pseudomonas  aeruginosa  is 
isolated  less  frequently  than  in  the  1970s,  it  can  still  produce  very  rapidly  progressing 
sepsis  with  significant  morbidity  and  mortality.  Other  Gram-negatives  associated  with 
bacteraemia  include  Klebsiella  pneumoniae,  Enterobacter  cloacae  and  Serratia  spp. 
Selective  antibiotic  pressure  and  the  use  of  indwelling  IV  catheters  may  be 
contributory  factors  associated  with  the  emergence  of  Gram-negative  `environmental' 
organisms,  such  as  Stenotrophomonas  maltophilia,  as  causes  of  bacteraemia 
(Spencer,  1995). 
The  frequency  of  anaerobic  infections  in  neutropenic  patients  has  remained  relatively 
stable  throughout  the  years,  accounting  for  3-5%  of  isolated  organisms  (Brown  et  a/., 
1989).  The  most  commonly  isolated  anaerobes  are  Clostridium  and  Bacteroides  spp. 
As  mentioned  in  the  preceding  section,  Gram-positive  bacteria  are  now  the 
commonest  cause  of  bacteraemia  in  adult  and  paediatric  neutropenic  patients,  and 
there  is  evidence  that  the  shift  to  Gram-positives  may  have  been  more  marked  in  the 
latter  patient  group  (Langley  &  Gold,  1988;  Viscoli,  1988).  The  reason  for  the 
prominence  of  Gram-positives  is  probably  multifactorial,  and  includes  the  use  of 
antibiotics  targeted  predominantly  against  Gram-negative  bacteria,  the  use  of 
antimicrobial  prophylaxis,  the  use  of  indwelling  venous  access  devices  and  therapy 
with  more  intensive  chemotherapy  causing  severe  mucositis  (Schimpff,  Scott  &  Wade, 
1994;  Rupp  &  Archer,  1994;  Oppenheim,  1998). 
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mainly  Staphylococcus  epidermidis.  It  is  generally  accepted  that  the  skin  is  an 
important  source  of  these  organisms  and  that  the  use  of  indwelling  central  venous 
catheters  provides  a  surface  to  which  bacteria  can  adhere,  form  a  biofilm  and  persist 
(Pfaller  &  Herwaldt,  1988).  However,  certain  centres  noticed  an  increase  in 
coagulase  -  negative  staphylococcal  bacteraemias  a  few  years  before  the  introduction 
of  these  catheters  (Schimpff,  Scott  &  Wade,  1994).  Changing  antibiotic  prophylaxis 
and  therapy  may  have  been  contributory,  exerting  selection  pressure,  resulting  in 
colonization  of  the  oral  cavity  and  gastrointestinal  tract  with  these  organisms.  In  1993, 
using  molecular  biological  techniques,  Wade  demonstrated  that  strains  of  S. 
epidermidis  found  in  blood  cultures  of  a  patient  with  leukaemia  matched  strains  found 
in  the  alimentary  tract. 
The  relative  frequency  of  Staphylococcus  aureus  bacteraemia  in  neutropenic  patients 
has  decreased.  However  while  coagulase-negative  staphylococcal  bacteraemia  is 
usually  a  somewhat  indolent  infection,  that  associated  with  S.  aureus  can  be  life- 
threatening. 
Over  the  last  2  decades,  Enterococcus  spp.  (including  glycopeptide-resistant 
isolates),  Corynebacterium  spp.,  Bacillus  spp.  and  Rhodococcus  spp.  have  been 
reported  as  causes  of  bacteraemia  in  neutropenic  patients.  However,  of  greatest 
clinical  significance,  throughout  the  1980s  and  1990s  in  some  centres,  and  from  the 
early  1990s  in  others,  was  the  emergence  of  viridans  streptococci  as  important 
pathogens  (Cohen  et  al.,  1983;  Henslee  et  al.,  1984;  Groot-Loonen  et  al.,  1987; 
Menichetti  et  al.,  1987;  Dybedal  &  Lamvik,  1989;  Sotiropoulos  et  a!.,  1989;  Classen  et 
al.,  1990;  Villablanca  et  a!.,  1990;  Guiot  et  al.,  1990;  Kern,  Kurrie  &  Schmeiser,  1990; 
McWhinney  et  al.,  1991;  Burden  et  al.,  1991;  Elting,  Bodey  &  Keefe,  1992;  Awada  et 
al.,  1992;  Steiner  et  a!.,  1993;  Bochud  et  al.,  1994;  Richard  et  a!.,  1995).  The  course 
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severe  form  with  acute  respiratory  distress  and  septic  shock  (Cohen  et  a/.,  1983; 
Groot-Loonen  et  al.,  1987;  Menichetti  et  al.,  1987;  Dybedahl  &  Lamvik,  1989;  Guiot  et 
al.,  1990;  Kern,  Kurrle  &  Schmeiser,  1990;  Steiner  et  al.,  1993;  Bochud,  Calandra  & 
Francioli,  1994).  Amongst  paediatric  patients,  reported  manifestations  of  the  severe 
form  included  pulmonary  or  cardiac  failure,  shock,  encephalopathy,  pneumonia  and 
renal  involvement  (Leblanc  et  al.,  1989;  Sotiropoulos  et  al.,  1989).  The  median  fatality 
rate  was  around  10%  (Bochud,  Calandra  &  Francioli,  1994).  The  epidemiology, 
aetiology,  pathogenesis  and  management  of  viridans  streptococcal  bacteraemia  will 
be  discussed  further  in  Chapter  3. 
2.4.2  Management  of  infection 
Although  many  febrile  neutropenic  patients  do  not  initially  have  a  proven  site  of 
infection,  the  prompt  use  of  empirical  antimicrobial  therapy  is  crucial  to  a  successful 
outcome.  Selection  of  first  line  empirical  therapy  should  be  based  on  the  local  pattern 
of  clinical  isolates  and  their  antimicrobial  susceptibilities.  The  individual  patient's 
infection  history,  results  of  surveillance  cultures,  and  the  presence  of  indwelling 
catheters,  etc.  should  also  be  considered.  First  line  empirical  antibiotic  therapy  for 
episodes  of  febrile  neutropenia  usually  comprises  combination  therapy  of  aß  -lactam 
plus  an  aminoglycoside,  or  monotherapy  with  a  very  broad-spectrum  ß  -lactam  agent 
e.  g.  a  carbapenem.  A  benefit  of  using  synergistic  combination  therapy  has  been 
confirmed  in  the  group  of  Ieukaemic  patients  with  Gram-negative  bacteraemia  and 
severe  protracted  neutropenia  (EORTC  International  Antimicrobial  Therapy 
Cooperative  Group,  1987).  Other  studies  of  empirical  therapy,  such  as  EORTC  Trial 
XI,  comparing  meropenem  monotherapy  with  combination  therapy  of  amikacin  plus 
67 ceftazidime  suggested  that  each  approach  was  equivalent  in  efficacy  (Cometta  et  al., 
1996). 
The  question  of  whether  the  predominant  Gram-positive  organisms  should  be  fully 
covered  by  empirical  therapy  remains  controversial.  Most  studies  of  the  introduction 
of  first-line  Gram-positive  cover  used  the  glycopeptide  antibiotics,  vancomycin  or 
teicoplanin,  as  these  antibiotics  historically  have  been  the  most  effective  of  all  against 
a  wide  range  of  Gram-positive  pathogens  (Karp  et  al.,  1986;  Shenep  et  al.,  1988; 
EORTC  International  Antimicrobial  Therapy  Cooperative  Group,  1991).  However, 
some  authors  argue  that  infections  caused  by  coagulase-negative  staphylococci  are 
quite  indolent  and  carry  a  very  low  mortality  rate,  therefore  it  would  be  appropriate  to 
wait  for  microbiological  documentation  before  adding  or  substituting  vancomycin 
(Rubin  et  al.,  1988).  The  potential  for  nephrotoxicity  with  vancomycin,  particularly  in 
combination  with  aminoglycosides  (Kibbler  et  al.,  1989;  Wood,  1996),  and  the 
development  of  glycopeptide  resistance  amongst  Enterococcus  spp.  and  reduced 
susceptibility  amongst  some  strains  of  S.  aureus  (Witte,  1999),  also  lend  support  to 
the  option  of  withholding  glycopeptide  therapy  until  the  infection  is  microbiologically 
documented. 
Algorithms  are  traditionally  used  to  guide  the  antimicrobial  therapy  of  febrile 
neutropenia  (Figure  2.2).  If  the  infecting  organism  can  be  cultured,  therapy  can  be 
modified  to  suit,  if  necessary.  However  in  cases  of  fever  unresponsive  to  first-line 
empirical  therapy,  alternative  or  additional  antibiotic  cover  is  generally  considered.  If 
neutropenia  is  prolonged,  the  development  of  fungal  infection  becomes  more  likely. 
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The  recombinant  haemopoietic  growth  factors,  granulocyte  colony-stimulating  factor 
(G-CSF)  and  granulocyte  macrophage  colony-stimulating  factor  (GM-CSF)  offer  the 
potential  of  decreasing  the  duration  of  neutropenia  after  chemotherapy  or  bone 
marrow  transplantation.  In  cases  of  neutropenic  sepsis,  as  an  adjunct  to  antibiotics, 
their  use  has  been  shown  to  augment  the  host  response.  However  the  majority  of 
studies  indicate  that  there  is  no  significant  reduction  in  mortality  or  decrease  in 
duration  of  hospitalization  (American  Society  of  Clinical  Oncology,  1994). 
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69 2.4.3  Preventative  strategies 
Shortly  after  their  introduction  in  the  early-mid  1980s,  the  fluoroquinolone  antibiotics 
were  considered  useful  agents  for  antibacterial  prophylaxis  of  infection  in  neutropenic 
patients.  These  antibiotics  had  increased  activity  against  Gram-negative  bacilli, 
particularly  P.  aeruginosa,  compared  with  cotrimoxazole,  which  had  been  used 
prophylactically  in  some  units  prior  to  this  time.  In  addition,  unlike  cotrimoxazole  they 
were  not  myelosuppresive  and  did  not  appear  to  induce  hypersensitivity. 
Chemoprophylaxis  with  quinolones  has  proved  to  be  efficacious  in  preventing  Gram- 
negative  bacteraemia  in  several  studies  (Lew  et  al.,  1991;  Patrick,  1997;  Engels,  Lau 
&  Baraza,  1998),  and  their  use  in  the  setting  of  neutropenia  has  become  widely 
accepted  in  many  centres.  Due  to  possible  drug-induced  arthropathy,  fluoro- 
quinolones  have  not  been  widely  used  in  children  (Schluter,  1987). 
A  major  concern  associated  with  the  use  of  antimicrobial  prophylaxis  however  is  the 
development  of  resistance.  Prophylaxis  with  both  quinolones  and  cotrimoxazole  has 
been  reported  as  one  of  the  risk  factors  for  viridans  streptococcal  bacteraemia 
(Classen  et  al.,  1990;  Kern,  Kurrle  &  Schmeiser,  1990;  Elting,  Bodey  &  Keefe,  1992)  - 
a  topic  which  will  be  discussed  further  in  Chapter  3.  In  addition,  reports  of  increasing 
resistance  of  Gram-negative  bacilli  to  these  agents  (Carratala  et  al.,  1995;  Spanik  et 
al.,  1996)  may  necessitate  a  general  re-assessment  of  the  prophylaxis  of  bacterial 
infections  in  neutropenic  patients  (Kerr,  1999). 
Other  preventative  approaches  include  the  use  of  high-efficiency  particulate  air 
(HEPA)  filtration  systems,  good  hospital  hygiene,  dietary  advice,  mouth  care  protocols 
and  meticulous  care  of  intravenous  catheters. 
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3.1  Historical  perspective 
In  1978,  two  groups  in  the  United  States  produced  the  first  reports  of  viridans 
streptococci  as  pathogens  in  immunocompromised  patients  with  cancer.  The 
publication  of  Hoecker  and  colleagues  (1978)  described  6  children  with  malignant 
disease  in  whom  S.  salivarius  bacteraemia  was  diagnosed.  Their  ages  ranged  from  6- 
14  years.  Information  on  their  specific  underlying  neoplastic  diseases  was  not 
provided.  The  portal  of  entry  in  all  patients  but  one  was  thought  to  be  the  mouth, 
pharynx  or  respiratory  tract.  Three  patients,  who  were  profoundly  neutropenic,  died  in 
spite  of  antibiotic  treatment  with  intravenous  penicillin.  The  authors  stated  that 
"penicillin  G  is  the  antibiotic  of  choice  in  treating  infections  due  to  S.  salivarius"  and 
added  that  "these  organisms  are  sensitive  to  the  majority  of  antibiotics  except 
aminoglycosides  and  tetracycline  occasionally". 
The  study  of  Pizzo  and  co-workers  (Pizzo,  Ladisch  &  Witebsky,  1978),  of  29  episodes 
of  viridans  streptococcal  bacteraemia  in  27  patients,  suggested  that  these  organisms 
may  cause  clinically  significant  systemic  infection  in  cancer  patients,  even  in  the 
absence  of  recent  dental  treatment.  The  median  age  of  the  patients  was  16  years 
(range  2-57  years).  Underlying  diseases  included  leukaemia  (18),  lymphoma  (7),  and 
solid  tumours  (2).  Twenty-six  of  the  episodes  (90%)  occurred  when  the  patient's 
malignancy  was  in  relapse,  and  75%  occurred  during  episodes  of  neutropenia.  Six  of 
the  patients  had  clinically  apparent  mucositis  and  two  had  a  tooth  extraction 
immediately  prior  to  the  onset  of  chills  and  fever. 
72 Viridans  streptococci  were  the  only  organisms  isolated  in  17  of  the  episodes  (59%), 
whereas  they  were  isolated  as  part  of  polymicrobial  sepsis  in  twelve.  The  penicillin 
minimum  inhibitory  concentrations  (MICs)  were,  <  0.8  mg/L  for  27  isolates  (93%),  1.6 
mg/L  for  one  and  3mg/L  for  the  remaining  strain.  The  authors  proposed  that  it  was 
probable  that  chemotherapy-induced  oral  mucositis  provided  a  portal  of  entry  into  the 
bloodstream  and  that  neutropenia  allowed  viridans  streptococci  to  persist.  They 
concluded  that  the  isolation  of  viridans  streptococci  from  the  blood  of  patients  with 
cancer  should  not  automatically  be  dismissed  as  contamination. 
In  the  1980s,  reports  from  other  centres  followed.  In  the  U.  K.,  the  article  by  Cohen 
and  colleagues,  published  in  1983,  evoked  considerable  interest,  and  prompted 
groups  elsewhere  in  Europe  as  well  as  in  North  America,  to  describe  their  recent 
clinical  experience  of  viridans  streptococcal  sepsis  in  cancer  patients  (Henslee  et  al., 
1984;  Ringden  et  al.,  1984;  Bostrom  &  Weisdorf,  1984;  Mascret  et  al.,  1984). 
Substantial  morbidity  and  mortality,  associated  with  a  severe  form  of  viridans 
streptococcal  bacteraemia  became  documented,  with  complications  such  as  septic 
shock  and  acute  respiratory  distress  syndrome  (Cohen  et  al.,  1983;  Henslee  et  al., 
1984;  Groot-Loonen  et  al.,  1987;  Dybedal  &  Lamvik,  1989;  Sotiropoulos  et  al.,  1989; 
Leblanc  et  al.,  1989).  In  certain  cases,  in  spite  of  the  use  of  appropriate  antibiotics, 
clinical  response  required  the  recovery  of  neutrophil  counts  (Cohen  et  al.,  1983).  High 
mortality  rates  were  associated  with  the  severe  form  of  viridans  streptococcal  sepsis. 
During  the  1980s,  in  addition  to  reports  involving  patients  receiving  conventional 
chemotherapy,  several  articles  described  viridans  streptococcal  bacteraemia  in  bone 
marrow  transplant  patients  (Henslee  et  al.,  1984;  Ringden  et  al.,  1984;  Bostrom  & 
Weisdorf,  1984).  Around  this  time,  as  referred  to  in  the  previous  chapter,  the  trials  of 
the  IATCG  of  the  EORTC  demonstrated  a  shift  towards  a  predominance  of  Gram- 
positive  organisms  causing  bacteraemia  in  febrile  neutropenia,  with  the  main 
organisms  responsible,  being  coagulase-negative  staphylococci,  Staphylococcus 
73 aureus  and  viridans  streptococci  (EORTC  IATCG,  1990).  Other  groups  documented 
a  similar  pattern  (Pizzo  et  al.,  1986;  Del  Favero  et  al.,  1988;  Shenep  et  al.,  1988; 
Viscoli  et  al.,  1988).  Identification  schemes  used  at  that  time,  suggested  that  S.  mitis 
and  S.  sanguis  were  the  most  common  species  of  viridans  streptococci  causing 
bacteraemia  (Cohen  et  al.,  1983;  Henslee  et  al.,  1984;  Leblanc  et  al.,  1989; 
Sotiropoulos  et  al.,  1989). 
In  the  late  1980s,  the  association  between  chemotherapy  with  high-dose  cytosine 
arabinoside  and  viridans  streptococcal  bacteraemia  was  proposed  (Kern,  Kurrle  & 
Vanek,  1987;  Weisman  et  al.,  1989;  Dybedal  &  Lamvik,  1989;  Sotiropoulos  et  al., 
1989).  Several  groups  described  viridans  streptococcal  infection  in  paediatric 
patients  (Henslee  et  al.,  1984;  Mascret  et  al.,  1984;  Leblanc  et  al.,  1989;  Sotiropoulos 
et  al.,  1989)  and  one  study  suggested  that  this  infection  was  more  common  in  children 
than  in  adults  (Mascret  et  al.,  1984). 
During  the  following  decade,  further  studies  describing  viridans  streptococcal 
bacteraemia  in  paediatric  immunocompromised  patients  were  published.  Weisman 
and  colleagues  (1990)  described  a  predominance  of  Gram-positive  bacteria 
(coagulase-negative  staphylococci:  35.8%  and  viridans  streptococci:  28.4%)  from  109 
consecutive  episodes  of  microbiologically  documented  bloodstream  infection  in 
paediatric  patients.  Underlying  diseases  were  predominantly  leukaemias  with  a 
smaller  proportion  of  solid  tumours.  Various  chemotherapeutic  regimens  were  used. 
A  significantly  higher  incidence  of  viridans  streptococcal  bacteraemia  was  found 
among  those  patients  who  had  received  high-dose  cytosine  arabinoside. 
The  study  of  Villablanca  and  co-workers  (1990),  of  a  total  of  832  paediatric  and  adult 
BMT  (autologous:  214,  allogeneic:  618)  patients,  demonstrated  that  age  less  than  18 
years  was  a  significant  risk  factor  for  viridans  streptococcal  infection.  Valteau  and 
74 colleagues  (1991)  described  33  episodes  of  viridans  streptococcal  bacteraemia  of  a 
total  of  91  cases  of  bloodstream  infection  in  paediatric  patients  post  autologous  BMT. 
No  prophylactic  antibacterial  treatment  was  given.  The  high  rate  of  infection  by 
viridans  streptococci  and  the  poor  outcome  for  patients  with  prolonged  and  profound 
neutropenia  led  this  group  to  modify  their  choice  of  first-line  empirical  antibiotic 
therapy  from  cefotaxime  plus  an  aminoglycoside  to  ceftazidime  plus  teicoplanin.  The 
antibiotic  sensitivity  pattern  of  the  viridans  streptococci  isolated,  showed  that  three  of 
34  (9%)  were  resistant  to  penicillin  and  41%  were  intermediately  susceptible.  These 
investigators  suggested  that  "the  previous  use  of  antibiotics,  even  though  different 
from  penicillin,  might  increase  the  rate  of  the  resistant  strains". 
Similar  clinical  experiences  resulted  in  other  groups  reviewing  empirical  therapy 
(Rossetti  et  al.,  1995),  or  employing  or  considering  prophylaxis  against  viridans 
streptococcal  infection  (Guiot  et  al.,  1990;  Broun  et  al.,  1994;  Rolston  et  al.,  1995). 
Children  were  shown  to  be  at  higher  risk  of  developing  viridans  streptococcal  shock 
syndrome  than  adults  (Steiner  et  al.,  1993;  Martino  et  al.,  1995). 
During  the  early  1990s,  several  papers  discussed  risk  factors  for  viridans 
streptococcal  bacteraemia  (Villablanca  et  al.,  1990;  Kern,  Kurrle  &  Schmeiser,  1990; 
Elting,  Bodey  &  Keefe,  1992;  Steiner  et  al.,  1993;  Bochud  et  al.,  1994;  Donnelly  et  al., 
1995;  Engelhard  et  al.,  1995;  Richard  et  al.,  1995)  and  some  case  control  studies 
were  published  (Kern,  Kurrle  &  Schmeiser,  1990;  Elting,  Bodey  &  Keefe,  1992; 
Bochud  et  al.,  1994;  Richard  et  al.,  1995).  Several  authors  associated  the 
prophylactic  use  of  certain  antimicrobial  agents,  to  be  discussed  in  Section  3.2,  with 
the  development  of  viridans  streptococcal  bacteraemia  (Classen  et  al.,  1990;  Kern, 
Kurrle  &  Schmeiser,  1990;  Elting,  Bodey  &  Keefe,  1992). 
75 The  majority  of  papers  published  at  the  beginning  of  the  1990s,  again  suggested  that 
S.  mitis  and  S.  sanguis  were  the  predominant  species  causing  viridans  streptococcal 
bacteraemia  (Guiot  et  al.,  1990;  McWhinney  et  al.,  1991;  Classen  et  al.,  1990;  Burden 
et  al.,  1991;  Awada  et  al.,  1992;  Elting,  Bodey  &  Keefe,  1992;  Steiner  et  al.,  1993; 
Bochud  et  al.,  1994).  However,  two  groups  of  investigators  found  a  different  pattern. 
McWhinney  and  colleagues  identified  47  sequential  blood  culture  isolates  of  viridans 
streptococci  from  febrile  neutropenic  patients  (McWhinney  et  al.,  1993)  according  to 
the  scheme  described  by  Beighton  and  co-workers  (Beighton,  Hardie  &  Whiley,  1991) 
and  also  using  the  commercial  system,  API  20  Strep  (BioMerieux).  The  former 
system,  which  accommodated  the  recent  taxonomic  changes  of  that  time,  identified 
39  isolates  of  S.  oralis,  5  of  S.  mitis  and  1  of  S.  parasanguis.  Two  isolates  could  not 
be  identified  to  species  level.  In  contrast,  the  results  obtained  using  the  older  and 
more  limited  commercial  system  followed  the  pattern  described  earlier,  with  S.  mitis 
and  S.  sanguis  predominating.  One  year  later,  the  report  by  Beighton  and  colleagues, 
utilizing  the  same  two  identification  schemes,  also  demonstrated  that  the  more 
modern  and  comprehensive  system  identified  S.  oralis  as  the  predominant  strain 
associated  with  bacteraemia  in  a  group  of  neutropenic  patients  with  cancer  (Beighton, 
Carr  &  Oppenheim,  1994). 
3.2  Established  Risk  Factors 
As  mentioned  earlier,  a  number  of  case  control  studies  have  been  performed 
(Villablanca  et  al.,  1990;  Kern,  Kurrle  &  Schmeiser,  1990;  Elting,  Bodey  &  Keefe, 
1992;  Bochud  et  al.,  1994;  Richard  et  al.,  1995).  However,  risk  factors  vary  to  some 
extent  from  study  to  study,  because  different  control  populations  were  used  and,  in 
some  cases,  different  potential  predisposing  factors  were  considered. 
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predisposes  to  viridans  streptococcal  infection  (Elting,  Bodey  &  Keefe,  1992).  Many 
investigators  proposed  that  chemotherapy-induced  oral  mucositis,  was  frequently 
involved  (Cohen  et  al.,  1983;  Sotiropoulos  et  al.,  1989;  Classen  et  al.,  1990;  Kern, 
Kurrle  &  Schmeiser,  1990;  Burden  et  al.,  1991)  and  this  has  been  shown  to  be  a 
significant  predisposing  factor  in  two  case  control  studies  (Elting,  Bodey  &  Keefe, 
1992;  Bochud  et  al.,  1994).  However  at  the  commencement  of  the  present  study, 
there  existed  no  definitive  proof  that  the  oral  cavity  could  be  the  source  of  viridans 
streptococci  causing  bacteraemia.  Ringden  and  colleagues  suggested  that  oral 
ulceration  caused  by  Herpes  simplex  virus  could  also  provide  a  portal  of  entry 
(Ringden  et  al.,  1984).  However  other  investigators  found  no  association  with  oral 
herpes  infection  (Bostrom  &  Weisdorf,  1984). 
The  use  of  high-doses  of  cytosine  arabinoside,  as  therapy  for  various  forms  of 
leukaemia  has  been  shown  to  be  a  significant  risk  factor  for  the  development  of 
viridans  streptococcal  bacteraemia  (Bochud  et  al.,  1994;  Richard  et  al.,  1995).  Used 
in  high-doses,  this  agent  produces  profound  neutropenia  and  severe  mucositis.  It  has 
been  hypothesized  that  oral  and  gastrointestinal  mucositis  produced  by  this  agent 
provides  a  portal  of  entry  for  bacteria  into  the  bloodstream  and  that  neutropenia  allows 
the  persistence  of  the  organisms. 
Administration  of  high  doses  of  this  agent  has  also  been  associated  with 
accompanying  respiratory  complications  (Sotiropoulos  et  al.,  1989;  Dybedal  &  Lamvik, 
1989;  Kern,  Kurrie  &  Schmeiser,  1990;  Guiot  et  al.,  1990;  Bochud  et  al.,  1994).  In 
addition  to  its  toxic  effects  on  the  marrow  and  mucosa,  high-dose  cytosine 
arabinoside  produces  significant  pulmonary  toxicity.  It  has  been  proposed  that 
immune-mediated  effects,  resulting  from  viridans  streptococcal  bacteraemia,  have  a 
role  in  the  development  of  the  acute  respiratory  distress  syndrome  (ARDS)  in  patients 
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arabinoside  (Guiot  et  al.,  1990;  Bochud,  Calandra  &  Francioli,  1994;  Bochud,  Cometta 
&  Francioli,  1997).  This  topic  will  be  discussed  further  in  Section  3.6. 
The  development  of  viridans  streptococcal  bacteraemia  has  also  been  associated  with 
the  use  of  antimicrobial  prophylaxis  with  the  quinolone  antibiotics  (Kern,  Kurrle  & 
Schmeiser,  1990;  Classen  et  al.,  1990)  and  with  cotrimoxazole  (Elting,  Bodey  & 
Keefe,  1992).  Both  the  earlier  quinolone  antibiotics  and  cotrimoxazole  have  poor 
activity  against  viridans  streptococci  and  could  thus  select  for  resistant  populations 
(Lew  et  al.,  1995).  The  study  of  Donnelly  and  co-workers  (1995)  added  a  further 
dimension  to  this  topic,  by  demonstrating  that  two  different  cytostatic  regimens  -  one 
containing  idarubicin  and  the  other  high-dose  cytosine  arabinoside,  had  a  much 
greater  influence  on  the  development  of  viridans  streptococcal  bacteraemia  than  did 
prophylactic  antibiotics. 
The  use  of  antacids  and  H2-antagonists  in  the  treatment  of  gastritis,  has  also  been 
associated  with  viridans  streptococcal  bacteraemia  in  immunocompromised  patients 
(Elting,  Bodey  &  Keefe,  1992).  The  resulting  increase  in  gastric  pH  may  favour  the 
multiplication  of  these  organisms. 
3.3  Clinical  features 
Pyrexia  is  generally  the  first  clinical  feature  of  viridans  streptococcal  bacteraemia. 
Bloodstream  infection  occurs  early  in  the  course  of  neutropenia.  The  more  common 
and  less  severe  form  of  viridans  streptococcal  bacteraemia  responds  to  appropriate 
antibiotic  therapy,  with  resolution  of  symptoms.  As  discussed  previously,  a  small  sub- 
set  of  patients  progresses  to  fulminant  sepsis  associated  with  prolonged  fever  and 
severe  respiratory  distress  (Guiot  et  al.,  1990;  McWhinney  et  al.,  1991;  Bochud  et  al., 
78 1994).  In  some  cases  septic  shock  accompanies  this  form  (Henslee  et  al.,  1984; 
Kern,  Kurrle  &  Schmeiser,  1990;  Elting,  Bodey  &  Keefe,  1992;  Bochud  et  al.,  1994), 
with  increased  morbidity  and  mortality  (Bochud,  Calandra  &  Francioli,  1994). 
Endocarditis  is  not  a  common  complication  of  viridans  streptoccoccal  bacteraemia  in 
neutropenic  patients,  although  some  cases  have  been  reported  (Elting,  Bodey  & 
Keefe,  1992;  Bochud  et  al.,  1994). 
3.4  Management  of  viridans  streptococcal  bacteraemia 
Empirical  antibiotic  therapy  for  episodes  of  febrile  neutropenia  should  ideally  have 
activity  against  Gram-negative  pathogens  and  against  potentially  life-threatening 
Gram-positive  organisms.  Today,  first-line  empirical  therapy  usually  consists  of  the 
combination  of  an  aminoglycoside  antibiotic  plus  either  a  ureidopenicillin  (+/-  a  13- 
lactamase  inhibitor)  or  a  third  generation  cephalosporin,  or  monotherapy  using  a  very 
broad-spectrum  ß-Iactam  agent,  such  as  a  carbapenem. 
Historically,  viridans  streptococci  were  considered  to  be  uniformly  sensitive  to 
penicillin,  however,  as  discussed  in  chapter  1,  this  is  no  longer  the  case  (Mogi  et  al., 
1997;  Ghaffar  et  al.,  1999).  One  report  comparing  penicillin-resistant  viridans 
streptococcal  colonization  in  both  healthy  children  who  had  not  recently  received 
antibiotics,  those  with  malignant  haematological  disorders  and  adult  leukaemia 
patients,  found  that  both  paediatric  groups  had  a  significantly  higher  prevalence  than 
adults  with  leukaemia  (Guiot,  Corel  &  Vossen,  1994). 
If  viridans  streptococci  are  regarded  as  organisms  with  potentially  reduced 
susceptibility  or  resistance  to  penicillin  (Carratala  &  Gudiol,  1995),  the  choice  of  ß- 
lactam  agent  for  empirical  therapy  of  febrile  neutropenia  must  be  made  with  care  - 
particularly  in  settings  where  viridans  streptococcal  bacteraemia  is  likely.  Some 
79 centres  have  reported  high  resistance  rates  to  ceftazidime,  a  third  generation 
cephalosporin  commonly  used  as  empirical  therapy,  necessitating  review  of 
therapeutic  options  (Carratala  &  Gudiol,  1995).  Carefully  conducted  studies  are 
required  to  establish  whether  the  use  of  certain  ß-Iactam  agents  is  associated  with 
selection  of  antibiotic-resistant  strains  of  viridans  streptococci. 
Previously,  at  institutions  where  infection  by  ß-Iactam-resistant  viridans  streptococci 
had  become  a  clinical  problem,  vancomycin  has  been  considered  as  an  option  as  part 
of  initial  empirical  therapy  (McWhinney  et  al.,  1993;  Carratala  &  Gudiol,  1995). 
However  this  practice  may  encourage  development  of  glycopeptide  resistance  and 
vancomycin  is  potentially  nephrotoxic  -  as  discussed  in  Chapter  2  (Section  2.4.2).  A 
more  extensive  range  of  antibiotics  specifically  directed  against  Gram-positive 
bacteria  would  be  useful.  The  present  study  assessed  two  such  novel  agents 
(Chapter  6). 
If  viridans  streptococci  are  isolated  from  blood  culture,  antimicrobial  susceptibility 
testing  should  be  performed  to  guide  therapy.  If  the  organism  is  resistant  to  first-line 
therapy  and/or  clinical  response  is  sub-optimal,  change  of  therapy  or  addition  of  a 
glycopeptide  antibiotic  is  recommended.  However,  it  should  be  noted  that  in  the 
severe  form  of  viridans  streptococcal  bacteraemia,  even  with  appropriate  antimicrobial 
therapy,  total  resolution  of  symptoms  may  not  be  achieved  until  neutrophil  recovery 
(Cohen,  1983).  If  viridans  streptococcal  shock  syndrome  develops,  ITU  support  may 
be  required,  with  inotropic  support  for  severe  hypotension  along  with  vasodilators  to 
improve  peripheral  perfusion,  and  ventilation  for  respiratory  complications. 
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Various  antibiotics  have  been  used  as  prophylaxis  against  viridans  streptococcal 
bacteraemia  in  neutropenic  patients.  While  the  use  of  penicillin  in  this  setting  has 
been  shown  to  reduce  the  incidence  of  viridans  streptococcal  bacteraemia,  it  also 
became  associated  with  the  emergence  of  some  strains  with  reduced  susceptibility  or 
resistance  to  this  antibiotic  (Broun  et  al.,  1994;  Bochud  et  al.,  1994;  Krcmery  &  Trupl, 
1995).  The  study  of  Bilgrami  and  colleagues  (1998)  demonstrated  that  the 
prophylactic  use  of  ampicillin  resulted  in  selection  for  organisms  that  were  resistant  to 
ß-lactam  antibiotics  and  failed  to  reduce  the  incidence  of  viridans  streptococcal 
sepsis.  Vancomycin  has  been  used  successfully  as  prophylaxis  (Broun  et  al.,  1994; 
Rolston,  Elting  &  Bodey,  1995;  Arns  da  Cunha  et  al.,  1998),  however  again  there  is 
concern  that  such  use  of  vancomycin  may  accelerate  the  emergence  of  glycopeptide- 
resistant  bacteria. 
As  oral  compromise  may  be  associated  with  viridans  streptococcal  bacteraemia,  the 
establishment  and  maintenance  of  good  oral  hygiene  both  before  and  during  the 
period  of  neutropenia  may  be  beneficial.  The  oral  care  protocol  should  ideally  suit  the 
needs  of  the  individual  patient,  depending  on  the  findings  of  pre-treatment  oral 
assessment,  and  the  type  and  duration  of  chemotherapy  to  be  used  (Gibson,  Horsford 
&  Nelson,  1997). 
3.6  Theories  on  the  pathogenesis  of  viridans  streptococcal  bacteraemia 
in  immunocompromised  patients 
The  pathogenesis  of  viridans  streptococcal  bacteraemia  in  immunocompromised 
patients  has  not,  as  yet,  been  fully  elucidated.  The  outcome  of  any  infection  is  the 
end-product  of  a  complex  set  of  interactions  between  the  host  and  the  pathogen.  In 
the  development  of  viridans  streptococcal  bacteraemia  in  cancer  patients,  medical- 
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patients,  viridans  streptococcal  bacteraemia  in  the  immunocompetent  host  is  usually 
of  little  clinical  significance. 
Viridans  streptococci  reside  in  an  ideal  habitat  for  invasion  with  resultant  bacteraemia 
in  patients  with  mucosal  damage.  Factors  such  as  adherence,  their  general  stability 
within  the  oral  ecosystem  and  their  ability  to  degrade  salivary  glycoproteins  for 
nutrition  as  discussed  in  Chapter  1,  may  result  in  their  effective  persistence  on 
mucosal  surfaces..  Damage  to  such  surfaces  could  potentially  provide  a  portal  of 
entry  into  the  bloodstream. 
Once  in  the  bloodstream  of  a  patient  with  cancer,  neutropenia  may  allow  these 
organisms  to  persist.  However  in  the  majority  of  cases,  when  appropriate  antibiotic 
therapy  is  administered,  viridans  streptococci  are  eliminated  readily,  with  resolution  of 
symptoms. 
By  what  mechanisms  then,  might  the  severe  form  of  viridans  streptococcal 
bacteraemia  develop?  Some  investigators  have  proposed  that  a  particularly  high 
bacterial  load  may  be  cleared  less  readily  from  the  bloodstream,  allowing  these 
organisms  to  elicit  the  production  of  cytokines  and  thus  increase  severity  of  clinical 
symptoms  (Donnelly  et  al.,  1995;  Bochud,  Cometta  &  Francioli,  1997).  An  overgrowth 
of  bacteria  at  source  -  in  the  oral  cavity  or  gastrointestinal  tract  may  conceivably 
develop  if  selection  pressure  is  exerted  by  prior  use  of  prophylactic  or  therapeutic 
antibiotics  with  poor  activity  against  these  organisms  (Carratala  et  al.,  1995). 
As  mentioned  earlier,  viridans  streptococci  have  generally  been  regarded  as  `low- 
grade'  pathogens,  sometimes  described  in  the  same  category  as  coagulase-negative 
staphylococci.  However  the  latter  organisms  do  not  cause  shock  and  ARDS  -  even  in 
82 immunocompromised  patients.  Nevertheless,  the  extent  of  oral  and  gastrointestinal 
colonization  by  viridans  streptococci  probably  far  exceeds  that  of  coagulase-negative 
staphylococci,  lending  support  to  the  theory  that  the  magnitude  of  the  bacterial  load 
may  be  important. 
Gram-negative  septic  shock  and  that  produced  by  the  more  potentially  pathogenic 
Gram-positive  organisms,  Staphylococcus  aureus  and  Streptococcus  pyogenes, 
involve  the  induction  of  pro-inflammatory  cytokines.  Several  studies  have  been 
performed  to  investigate  whether  viridans  streptococci  might  also  have  the  ability  to 
induce  these  agents.  It  has  been  demonstrated  that  cell  wall  components  of  viridans 
streptococci,  such  as  lipoteichoic  acid  or  peptidoglycan  can  stimulate  synthesis  of 
proinflammatory  mediators,  such  as  tumour  necrosis  factor  or  nitric  oxide  ex  vivo 
(Bhakdi  et  a!.,  1991;  Huemann  et  al.,  1994;  Standiford  et  al.,  1994;  English  et  al., 
1996).  However  the  extent  of  cytokine  induction  was  generally  found  to  be  less  than 
that  associated  with  Iipopolysaccharide  from  Gram-negative  bacteria.  Lipoteichoic 
acid  from  viridans  streptococci  has  also  been  shown  to  activate  complement  in  vitro 
(Monefeldt,  Helgeland  &  Tollefsen,  1994). 
Engel  and  colleagues  (1996)  measured  cytokine  levels  in  serum  from  neutropenic 
patients,  and  demonstrated  that,  in  both  viridans  streptococcal  shock  syndrome  and  in 
Gram-negative  bacteraemia,  IL-6  levels  increased  to  a  similarly  high  level.  In 
contrast,  using  serum  from  patients  with  uncomplicated  Gram-positive  bacteraemia, 
levels  of  IL-6  were  much  lower.  In  patients  with  viridans  streptococcal  shock,  TNF-a 
levels  were  slightly  elevated,  whereas  from  those  with  uncomplicated  Gram-positive 
bacteraemia,  TNF-a  was  undetectable.  This  study  involved  a  small  number  of 
patients,  with  only  two  per  group,  but  it  did  demonstrate  an  association  between 
viridans  streptococci  and  induction  of  cytokines  in  vivo,  a  finding  worth  investigating 
further  in  a  larger  group. 
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of  streptococcal  toxic  shock.  Superantigenic  bacterial  toxins  such  as  streptococcal 
pyrogenic  exotoxin  A  can  cause  profound  hypotension,  inflammation  and  organ  failure 
in  animal  models  (deAzavedo,  1989)  and  it  is  believed  that  strains  of  Streptococcus 
pyogenes  which  produce  this  toxin  cause  toxic  shock  syndrome  in  humans.  By 
circumventing  the  usual  rules  of  antigen  presentation,  superantigens  can  elicit 
massive  and  often  destructive  immune  responses,  involving  substantial  release  of 
pro-inflammatory  cytokines  (Kotb,  1992).  To  date  however,  although  several 
investigators  have  shown  that  extracellular  fractions  of  viridans  streptococci  can 
induce  pro-inflammatory  cytokines  (Takada  et  al.,  1993;  Soto,  Evans  &  Cohen,  1996; 
Soto  et  al.,  1998)  there  is  no  convincing  evidence  that  the  production  of 
superantigenic  toxin  is  involved  in  viridans  streptococcal  shock  syndrome  (Soto  et  al., 
1998). 
As  mentioned  previously,  ARDS  is  a  predominant  feature  of  the  severe  form  of 
viridans  streptococcal  bacteraemia.  This  respiratory  complication  is  defined  as  a  form 
of  non-cardiogenic  pulmonary  oedema  that  results  from  acute  damage  to  the  alveoli 
(Tobin,  2000).  Clinical  and  experimental  studies  have  provided  circumstantial 
evidence  of  the  occurrence  of  neutrophil-mediated  injury  in  ARDS  (Ware  &  Matthay, 
2000),  therefore  its  development  in  neutropenic  patients  (Braude  et  a/.,  1985; 
Ognibene  et  al.,  1986;  Sivan  et  al.,  1990)  is  somewhat  anomalous.  Interleukin-8  (IL- 
8)  has  an  important  association  with  neutrophil  accumulation  and  lung  damage  in  non- 
neutropenic  patients  with  ARDS  (Donnelly  et  al.,  1993),  and  isolates  of  viridans 
streptococci  have  been  shown  to  induce  this  cytokine  from  human  peripheral  blood 
mononuclear  cells  in  vitro  (Soto  et  al.,  1998),  however  the  clinical  significance  of  this 
finding  with  regards  to  neutropenic  patients  is  unclear. 
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emphasizes  the  heterogeneity  of  this  condition.  Several  investigators  have  proposed 
that  multiple  factors  may  influence  its  development  in  this  patient  group.  The 
administration  of  chemotherapeutic  agents  such  as  cytosine  arabinoside  has  been 
shown  to  increase  alveolar  capillary  permeability  resulting  in  acute  pulmonary 
oedema,  manifested  by  the  onset  of  respiratory  failure  (Haupt,  Hutchins  &  Moore, 
1981).  The  study  of  Guiot  and  co-workers  (1990)  suggested  that  streptococcal 
infection  may  also  play  a  part.  As  prophylaxis  against  streptococcal  bacteraemia, 
twenty  patients  about  to  receive  intermediate  high-dose  cytosine  arabinoside  were 
given  penicillin  G.  The  incidence  of  streptococcal  infection  following  chemotherapy 
decreased  from  0.76  per  episode  for  controls  who  did  not  receive  penicillin  G  to  0.11 
per  episode  in  the  prophylaxis  group.  Simultaneously,  a  decrease  in  the  incidence  of 
respiratory  failure  was  observed.  It  was  hypothesized  that  bacteraemia  caused  by 
streptococci  may  trigger  the  development  of  respiratory  distress  in  patients  with  pre- 
existing  damage  to  the  lungs  due  to  treatment  with  cytosine  arabinoside. 
It  has  also  been  shown  that  the  incidence  of  respiratory  complications  associated  with 
viridans  streptococcal  bacteraemia  was  higher  than  that  associated  with  bacteraemia 
caused  by  other  micro-organisms  (Weisman  et  al.,  1990).  Some  investigators  have 
suggested  that  S.  mitis  has  a  greater  predilection  to  cause  shock  and  ARDS  than 
other  species  of  viridans  streptococci  (Cohen  et  a!.,  1983;  McWhinney  et  al.,  1991; 
Steiner  et  al.,  1993;  Bochud,  Calandra  &  Francioli,  1994). 
85 3.7  Viridans  streptococcal  bacteraemia  in  paediatric  immunocompromised 
patients  attending  the  Royal  Hospital  for  Sick  Children,  Glasgow. 
3.7.1  Background  to  the  investigation 
During  1994,  the  author  noticed  that  the  number  of  cases  of  viridans  streptococcal 
bacteraemia  in  immunocompromised  patients  at  RHSC  appeared  to  be  increasing. 
Anecdotally,  some  of  these  episodes  were  associated  with  greater  morbidity  than  had 
been  observed  in  the  past.  All  episodes  did  resolve,  but  in  many  cases,  only  after  the 
addition  of  vancomycin  to  the  standard  empirical  antibiotic  therapy  at  that  time  - 
ceftazidime  plus  amikacin.  Towards  the  end  of  1994,  the  annual  prevalence  of 
viridans  streptococcal  bacteraemia  was  compared  with  that  of  the  previous  year.  In 
1993,  there  had  been  10  episodes  of  viridans  streptococcal  bacteraemia,  of  a  total  of 
81  episodes  of  culture-proven  bloodstream  infection  (i.  e.  12%),  compared  with  18 
episodes  of  a  total  of  83  (i.  e.  22%)  in  1994.  These  findings  prompted  a  literature 
search  on  viridans  streptococcal  bacteraemia  in  immunocompromised  patients  with 
cancer,  to  obtain  details  of  this  infection  in  patients  in  other  haematology/oncology 
units.  It  was  decided  that  from  December  1994  all  isolates  of  viridans  streptococci 
from  blood  culture  should  be  collected  and  stored  at  -70°C  and  the  present  study 
commenced. 
3.7.2  Aims  of  the  study 
1.  To  collect  and  identify  to  species  level,  all  significant  isolates  of  viridans 
streptococci  isolated  from  blood  culture  throughout  the  study  period  (1St  December 
1994  -  31st  December  2000),  and  to  determine  whether  particular  species  were 
associated  with  this  infection  or  severity  of  symptoms. 
86 2.  To  collect  epidemiological  information  regarding  the  frequency  of,  and  range  of 
clinical  features  associated  with  viridans  streptococcal  bacteraemia  in  paediatric 
immunocompromised  patients  with  cancer  attending  The  Royal  Hospital  for  Sick 
Children,  Glasgow  and  to  make  interim  analyses  of  data  obtained.  From 
commencement,  it  was  decided  that  the  epidemiological  study  should  take  the 
form  of  a  descriptive  report  using  the  inclusion  criteria  and  definitions  detailed  in 
Section  4.1.3. 
3.  To  record  details  of  all  co-infecting  micro-organisms  from  blood  culture  and  any 
concomitant  viral  infections,  and  to  determine  whether  or  not  mixed  infection  was 
associated  with  greater  morbidity. 
4.  To  determine  the  susceptibility  of  all  blood  culture  isolates  to  a  wide  range  of 
antibiotics,  including  those  commonly  used  in  the  empirical  therapy  of  febrile 
neutropenia. 
5.  To  investigate  factors  which  might  influence  resistance  patterns  in  viridans 
streptococci.  Based  on  the  early  results  of  antibiotic  susceptibility  testing,  first-line 
empirical  therapy  was  changed  from  ceftazidime  plus  amikacin  to  piperacillin/ 
tazobactam  plus  amikacin  in  July  1996.  This  provided  an  opportunity  to  compare, 
in  a  retrospective  sequential  study,  the  antibiotic  susceptibilities  of  viridans 
streptococci  isolated  from  blood  culture  prior  to  this  change  with  those  following  it. 
6.  To  determine  susceptibility  of  all  blood  culture  isolates  to  novel  antibiotics  which 
were  undergoing  clinical  trials  at  the  commencement  of  the  study.  This 
information  could  potentially  provide  suitable  alternative  therapies  for  the  future. 
87 7.  To  investigate,  using  phenotypic  and  genotypic  analyses,  whether  the  mouth  was 
a  potential  source  of  viridans  streptococci  causing  bacteraemia. 
8.  To  investigate  whether  tools  used  for  mouth  care  could  potentially  become  vectors 
of  viridans  streptococcal  infection. 
9.  To  improve  management  of  the  infection  and,  if  possible,  to  reduce  its  incidence. 
3.7.3  Plan  of  investigation 
1.  Throughout  the  period  of  the  study,  as  cases  of  viridans  streptococcal  bacteraemia 
occurred,  isolates  from  blood  cultures  were  subcultured,  identified  and  stored  at 
-70°C,  as  were  isolates  from  mouth  swabs. 
2.  Clinical  details  of  infection  were  recorded  from  case  notes. 
3.  Extensive  antibiotic  susceptibility  testing  was  performed  on  batches  of  stored 
organisms  at  approximately  6  monthly  intervals. 
4.  Three  cases  were  selected,  and  pulsed-field  gel  electrophoresis  (PFGE)  was 
performed  using  DNA  extracted  from  viridans  streptococci  isolated  from  blood 
culture  and  from  mouth  swabs,  to  determine  whether  the  oral  cavity  was  a 
possible  source  of  organisms  causing  bacteraemia. 
5.  Throughout  the  period  of  this  study,  at  weekly  ward  round  meetings  with  clinical 
staff  of  the  department  of  haematology/oncology,  relevant  findings  were  discussed 
and  management  of  viridans  streptococcal  bacteraemia  was  reassessed  as 
appropriate. 
88 From  the  outset  it  was  hoped  that  the  results  of  this  study  would  enhance  knowledge 
and  understanding  of  the  epidemiology,  aetiology  and  clinical  progression  of  viridans 
streptococcal  bacteraemia,  as  well  as  provide  measures  by  which  this  serious 
infection  could  be  optimally  treated  or  even  prevented.  The  following  chapters 
describe  how  these  goals  were  achieved. 
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METHODS 
90 METHODS 
4.1  Epidemiological  analysis 
4.1.1  Application  for  ethics  committee  approval 
At  the  commencement  of  this  study,  an  application  was  submitted  to  the  Ethics 
Committee  of  Yorkhilt  NHS  Trust.  Full  approval  was  granted. 
4.1.2  Construction  of  case  record  forms 
Case  record  forms  were  constructed  to  facilitate  transcription  of  patient 
demographics,  antimicrobial  therapy,  the  clinical  course  of  viridans  streptococcal 
bacteraemia  and  any  potential  predisposing  factors  (Figure  4.1). 
4.1.3  Definitions 
A  case  was  defined  as  any  paediatric  patient  with  malignant  disease,  admitted  to  the 
haematology/oncology  unit  of  RHSC  from  1St  December  1994  to  31st  December 
2000,  with  two  or  more  temporally  spaced  blood  cultures  positive  for  viridans 
streptococci  or  with  one  blood  culture  positive  for  viridans  streptococci  in  conjunction 
with  clinical  illness  compatible  with  viridans  streptococcal  bacteraemia.  Viridans 
streptococci  were  considered  to  be  probable  contaminants  and  of  no  clinical 
significance  if  isolated  from  one  blood  culture  from  patients  without  compatible 
clinical  findings,  where  recovery  occurred  without  anti-streptococcal  therapy  and 
repeat  blood  cultures  were  negative.  Polymicrobial  blood  stream  infection  was 
defined  as  the  isolation  of  additional  micro-organisms  (bacteria  or  fungi)  in  addition 
to  viridans  streptococci  from  blood  culture,  or  the  isolation  of  more  than  one  strain  or 
species  of  viridans  streptococcus  from  the  same  blood  culture  during  a  febrile 
91 Figure  4.1  Case  record  form 
VIRIDANS  STREPTOCOCCAL  INFECTION  STUDY  CASE  RECORD  FORM 
PATIENT  NAME: 
............................................ 
HOSPITAL  No: 
........................ 
SEX: 
.................... 
DATE  OF  BIRTH:  WEIGHT:  Kg  SURFACE  AREA  m2  ...........................  .................  ..................... 
DIAGNOSIS: 
....................................................................................................................................... 
ANTI  CANCER  THERAPY  (including  BMT  if  appropriate)  WITH  DATES: 
.................................. 
............................................................................................................................................................... 
DATE  OF  EPISODE  OF  BACTERAEMIA  :....................................................................................... 
HICKMAN  LINE  IN  SITU: 
RECENT  DENTAL  MANIPULATION: 
ORAL  HSV-I  INFECTION: 
OTHER  RELEVANT  INFECTION: 
ANTIMICROBIAL  PROPHYLAXIS: 
SIGNS  &  SYMPTOMS  OF  INFECTION 
MUCOSITIS: 
DIARRHOEA: 
RESPIRATORY  COMPLICATIONS: 
YES  NO  COMMENTS 
F]  F1 
0  0 
...........  I ............................... 
0  0 
......................................... 
0  0 
......................................... 
........................................  MILD  MOD  SEVERE  COMMENTS 
0  0  11 
0  11  11 
0 
0  0  0 
No.  OF  PYREXIAL  DAYS: 
.......................................................................................................... 
MOUTH  CARE: 
........................................................................................................................... 
NEUTROPEN  IA  :..........................................................................................................................  . 
ANTIMICROBIAL  THERAPY  &  LEVELS: 
.................................................................................. 
CRP  LEVELS:  ................................................................................................................................ 
92 episode.  Bacteraemia  was  defined  as  the  presence  of  bacteria  in  the  blood. 
Neutropenia  was  defined  as  a  neutrophil  count  of  <  1.0  x  109/L  and  fever  as  an  oral 
temperature  of  >  38.5°C  once  or  >  38°C  on  two  or  more  occasions  during  a  12  hour 
period.  Septic  shock  was  defined  as  sepsis-induced  hypotension  (systolic  blood 
pressure  <90  mm  Hg)  or  the  requirement  for  vasopressors/inotropes  to  maintain 
blood  pressure  despite  adequate  fluid  resuscitation  along  with  the  presence  of 
perfusion  abnormalities  that  included,  but  were  not  limited  to,  lactic  acidosis,  oliguria, 
or  acute  alteration  in  mental  status  (Bone  et  al.,  1992).  Acute  respiratory  distress 
syndrome  (ARDS)  was  defined  as  a  condition  involving  impaired  oxygenation  with 
evidence  of  new,  bilateral,  diffuse,  patchy  or  homogeneous  pulmonary  infiltrates  on 
chest  radiograph  and  a  pulmonary  artery  occlusion  pressure  <  18  mm  Hg  when 
measured  or  no  clinical  evidence  of  left  atrial  hypertension  (Bernard  et  al.,  1994). 
Oral  mucositis  was  defined  as  inflammation  with  or  without  ulceration  of  the  oral 
mucosa  (Lavelle,  Jackin  &  Morry,  1984). 
4.1.4  Compilation  of  data 
To  accommodate  the  total  data  collected  in  the  case  record  forms,  two  spreadsheets 
were  constructed  using  Excel.  Spreadsheet  1  contained  patients'  names  and 
underlying  malignancies,  most  recent  chemotherapy,  dates  of  episodes  of  viridans 
streptococcal  bacteraemia  and  episode  reference  numbers,  the  presence  or 
absence  of  neutropenia,  oral  complications  and/or  diarrhoea  and  clinical  features 
associated  with  infection  -  duration  of  pyrexia,  development  of  septic  shock  (with 
blood  pressure  readings)  and/or  respiratory  distress  and  clinical  outcome. 
Details  of  severity  of  oral  mucositis  were  recorded  directly  from  case  notes.  Oral 
examination  was  performed  daily  by  various  physicians,  and  mucositis  recorded 
according  to  the  ward  scoring  system,  whereby  `+',  '++'  and  `+++',  corresponded  to 
93 mild,  moderate  and  severe  symptoms  respectively.  The  spectrum  of  symptoms 
ranged  from  erythema  with  few  or  no  ulcers  and  some  discomfort  (mild),  through  to 
extensive  erythema  and  severe  ulceration  with  pain  and  dysphagia  leading  to  the 
inability  to  consume  food  by  the  oral  route  (severe).  This  mucositis  scoring  system, 
although  relatively  simple,  and  influenced  to  some  extent  by  subjective  interpretation, 
provided  useful  indications  of  the  severity  of  symptoms. 
Degree  of  respiratory  distress  was  also  recorded.  Mild  symptoms  were  scored  as  `+' 
and  corresponded  to  symptoms  of  respiratory  compromise  with  chest  X-ray  changes, 
and  a  requirement  of  up  to  3L  of  oxygen.  Moderate  symptoms  were  scored  as  `++' 
and  corresponded  to  respiratory  compromise  with  chest  X-ray  changes  and  a 
requirement  of  up  to  10L  of  oxygen  and  severe  symptoms  were  scored  as  `+++' 
corresponding  to  ARDS  as  defined  in  Section  4.1.3. 
Spreadsheet  2  contained  patients'  names,  dates  of  episodes  of  viridans 
streptococcal  bacteraemia  and  episode  reference  numbers,  as  in  spreadsheet  1, 
plus  species  of  viridans  streptococcus  isolated  from  blood  culture  with  Rapid  ID  32 
Strep  (BioMerieux)  profile.  From  this  information,  the  total  number  of  episodes  of 
viridans  streptococcal  bacteraemia  was  calculated,  as  was  the  prevalence  of 
bacteraemia  by  particular  species.  Relationships  between  recent  chemotherapeutic 
regimens,  potential  predisposing  factors  and  viridans  streptococcal  bacteraemia 
were  investigated,  as  were  the  various  associated  clinical  features. 
For  comparison  of  frequency  of  viridans  streptococcal  bacteraemia  with  that  caused 
by  other  bacteria  in  immunocompromised  patients,  records  routinely  compiled  by  the 
author  were  consulted.  These  records  are  prepared  on  an  annual  basis,  as  part  of 
an  audit  programme  to  monitor  the  pattern  of  infection  within  this  patient  population. 
94 4.2  Isolation  of  viridans  streptococci  from  clinical  specimens 
Throughout  the  study  period,  from  1St  December  1994  until  31st  December  2000,  all 
significant  isolates  of  viridans  streptococci  isolated  from  blood  culture  of  paediatric 
haematology/oncology  patients  were  subcultured  and  stored.  The  composition  of 
media  used  for  isolation  and  culture  is  presented  in  Table  4.1. 
Table  4.1  Composition  of  culture  media 
Medium  Composition 
BacTAlert  aerobic  Pancreatic  digest  of  casein  (1.95%  w/v) 
culture  bottles  Papaic  digest  of  soybean  meal  (0.3%  w/v) 
Sodium  polyanetholesulfonate  (0.035%  w/v) 
Pyridoxine  HCI  (0.001%  w/v) 
(Other  complex  amino  acids  and  carbohydrates  in  purified  water) 
BacTAlert  anaerobic  Pancreatic  digest  of  casein  (1.95%  w/v) 
culture  bottles  Papaic  digest  of  soybean  meal  (0.3%  w/v) 
Sodium  polyanetholesulfonate  (0.035%  w/v) 
Menadione  (0.00005%  w/v),  Haemin  (0.0005%  w/v) 
Reducing  agents 
0.  Other  complex  amino  acids  and  carbohydrates  in  purified  water) 
Columbia  blood  agar  Special  peptone  (23.0  g/L),  Starch  (1.0  g/L) 
Sodium  chloride  (5.0  g/L),  Agar  (10.0  g/L) 
Sterile  defibrinated  blood  (5%)  (pH  7.3  +  0.2) 
Columbia  blood  agar  As  above  except: 
with  Crystal  Violet  Sterile  defibrinated  blood  (7%) 
with  Crystal  Violet  0.0038/L  (pH  7.3  ±  0.2) 
Diagnostic  Sensitivity  Proteose  peptone,  Veal  infusion  solids 
Test  Agar  Glucose  (2.0  g/L),  Sodium  chloride  (3.0  g/L) 
Disodium  phosphate  (2.0  g/L),  Sodium  acetate  (1.0  g/L),  Adenine 
sulphate  (0.01  g/L) 
Guanine  hydrochloride  (0.01  g/L),  Uracil  (0.01  g/L),  Xanthine  (0.01 
g/L),  Aneurine  (0.00002  g/L), 
Agar  No.  1  (12.0  g/L)  (pH  7.4  ±  a.  2) 
Brain  heart  infusion  broth  Calf  brain  infusion  solids  (12.5  g/L) 
Beef  heart  infusion  solids  (5.0  g/L) 
Proteose  peptone  (10.0  g/L),  Glucose  (2.0  g/L) 
Sodium  chloride  (5.0  g/L), 
Disodium  phosphate  (2.5  g/L)  (pH  7.4  ±  0.2 
95 4.2.1  Collection  of  blood  specimens  for  culture 
Blood  was  collected  (generally  via  Hickman  line),  from  febrile  patients  in  the 
haematology/  oncology  ward  and  transferred  into  BacTAlert  culture  bottles  (5  to  10 
ml  of  blood  for  each  of  the  aerobic  and  anaerobic  bottles)  using  aseptic  technique. 
After  receipt  at  the  Diagnostic  Microbiology  Laboratory,  inoculated  bottles  were 
incubated  in  the  BacTAlert  blood  culture  system  (Organon  Teknika  Limited, 
Cambridge,  U.  K.  ). 
4.2.2  Processing  of  positive  blood  cultures 
Any  blood  culture  bottles  which  signalled  positive,  were  removed  from  the  BacTAlert 
incubation  cabinet,  and  an  aliquot  of  fluid  was  removed  and  Gram  stained  (Table 
4.2).  If  the  bacteria  were  Gram-positive  cocci  resembling  streptococci,  an  aliquot  of 
blood  culture  fluid  was  tested  using  the  Streptex  latex  agglutination  test  (Murex 
Biotech  Limited,  Dartford,  U.  K.  ).  Although  this  test  is  designed  for  identification  of 
streptococci  possessing  Lancefield  group  antigens  using  colonies  from  a  culture 
plate  (Table  4.2),  useful  results  have  also  been  obtained  from  liquid  cultures 
((Facklam,  Cooksey  &  Wortham,  1979).  A  negative  reaction  with  Streptex  from 
blood  culture  fluid  may  suggest,  by  elimination,  the  possibility  of  the  presence  of 
viridans  streptococci  rather  than  that  of  Strep  pyogenes,  Strep  agalactiae  or 
Enterococcus  spp.  Columbia  blood  agar  and  chocolate  blood  agar  plates  (E  &0 
Laboratories,  Bonnybridge,  U.  K.  )  were  inoculated  with  an  aliquot  of  blood  culture 
fluid,  as  were  direct  sensitivity  plates  (Diagnostic  Sensitivity  Test  Agar  with  5%  lysed 
horse  blood  (E  &0  Laboratories,  Bonnybridge,  U.  K.  ))  according  to  the  Standard 
Operating  Procedures  of  the  Diagnostic  Microbiology  Laboratory.  An  optochin  disc 
was  placed  on  the  inoculated  blood  agar  plate.  Cultures  of  all  isolates  of  viridans 
streptococci  from  blood  cultures  were  collected  for  the  present  study. 
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Test  Method 
Gram  stain  The  prepared  slide  was  flooded  with  crystal  violet  and  stained  for  30 
seconds.  The  slide  was  rinsed  with  iodine  and  then  stained  with 
iodine  for  30  seconds,  followed  by  rinsing  with  water.  Acetone  or 
alcohol  was  applied  (for  4-5  seconds)  to  decolourise.  The  slide  was 
flooded  with  dilute  carbol  fuchsin  counterstain.  After  30  seconds  the 
slide  was  washed  in  water  and  then  dried  on  a  slide  dryer.  One  drop 
of  immersion  oil  was  placed  on  the  area  of  the  slide  and  examined 
using  the  X  100  oil  immersion  lens  of  a  light  microscope.  Bacteria 
stained  a  deep  purple  colour  were  termed  `Gram-positive'.  (Bacteria 
stained  pink  were  termed  `Gram-negative'.  ) 
Catalase  A  few  drops  of  hydrogen  peroxide  were  added  to  a  test  tube.  Using  a 
capillary  tube,  part  of  an  isolated  colony  was  added.  The  evolution  of 
gas  bubbles  indicated  catalase  activity. 
Streptex  400  pI  of  Extraction  Enzyme  were  added  to  a  labelled  test  tube.  A 
(Murex)  single  sweep  of  growth  from  the  test  streptococcal  culture  was  added 
to  the  tube  to  form  a  light  suspension,  which  was  then  incubated  at 
37°C  in  a  water  bath  for  between  10  and  60  minutes.  After  5  minutes 
incubation,  the  tube  was  shaken.  One  drop  (20  p  L)  of  each  latex 
suspension  was  dropped  on  to  a  separate  circle  on  a  Reaction  Card. 
Using  a  pipette,  one  drop  (40  p  L)  of  prepared  extract  was  placed  in 
each  of  the  six  circles  on  the  card.  The  contents  of  each  circle  were 
mixed  with  a  separate  mixing  stick.  A  positive  result  was  indicated  by 
the  development  of  an  agglutinated  pattern  showing  clearly  visible 
clumping  of  the  latex  particles. 
Any  organisms  isolated  concomitantly  with  viridans  streptococci  were  identified  using 
standard  methods  (Murray  et  al.,  1999).  Three  isolates  of  viridans  streptococci  were 
later  excluded  as  probable  contaminants  after  discussion  of  laboratory  and  clinical 
findings  with  a  Consultant  Haematologist  and  repeating  blood  culture. 
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Viridans  streptococci  were  also  collected  from  mouth  swabs.  After  discussion  with 
clinical  staff,  it  was  decided  that  although  oral  rinses  would  probably  provide  a 
superior  yield  of  bacteria  (Spijkervet,  1991),  swabs  were  practically  more  appropriate 
-  particularly  for  very  young  patients  and  for  some  of  the  more  seriously  ill  children. 
In  order  to  cause  minimal  disruption  to  established  practice  in  the  busy  haematology/ 
oncology  ward,  it  was  agreed  that  the  nursing  staff  who  routinely  swabbed  the 
patients'  mouths  as  part  of  the  general  microbiology  surveillance  scheme  should 
continue  to  do  so.  A  single  swab  was  used  to  sample  buccal  mucosa,  gingivae, 
teeth,  hard  palate  and  tongue.  Mouth  swabs  were  dispatched  to  the  Department  of 
Microbiology  for  culture.  Each  mouth  swab  was  plated  out  on  to  a  Columbia  blood 
agar  plate,  a  Sabouraud  dextrose  agar  plate  (both  incubated  in  5%  CO2)  and  a 
Columbia  blood  agar  plate  with  Crystal  Violet  (incubated  in  anaerobic  conditions). 
4.2.3.1  Surveillance  cultures 
Routine  surveillance  swabs  were  collected  from  neutropenic  patients  weekly.  These 
specimens  usually  included  a  combined  mouth/throat  swab.  Blood  agar  plates  with 
evidence  of  viridans  streptococci  from  these  specimens  were  stored  at  4°C  for  2 
weeks.  The  relevant  patient's  name  was  marked  on  the  base  of  the  plates.  If  the 
patient  developed  viridans  streptococcal  bacteraemia  within  the  2-week  period,  the 
stored  culture  plates  from  mouth/throat  swabs  were  retrieved  and  subculture  of 
isolates  of  viridans  streptococci  performed.  On  suspicion  of  viridans  streptococcal 
bacteraemia  from  Gram-stain  of  blood  culture  fluid,  a  fresh  mouth  swab  was  also 
requested.  For  some  patients,  surveillance  cultures  were  not  available  before 
viridans  streptococcal  bacteraemia  was  confirmed.  In  these  cases,  a  mouth  swab 
taken  shortly  after  the  blood  culture  signalled  positive  was  the  only  oral  specimen 
available. 
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All  isolates  of  viridans  streptococci  were  stored  at  -70°C  in  Microbank  vials 
containing  cryopreservative  fluid  and  porous  beads  (Pro-Lab  Diagnostics,  Cheshire, 
U.  K.  ).  Vials  were  labelled  with  isolate  reference  number  and  date  of  specimen. 
Cryopreservative  fluid  was  inoculated  with  young  colonial  growth  (18-24  hours) 
picked  from  a  pure  culture  to  a  density  of  a4  McFarland  standard  (BioMerieux, 
Basingstoke,  U.  K.  ).  After  swirling  the  contents  of  the  vial  for  thirty  seconds,  the 
cryopreservative  fluid  was  removed  using  a  syringe  and  needle  to  leave  the 
inoculated  beads  as  free  of  liquid  as  possible.  The  vials  of  inoculated  beads  were 
then  placed  in  polystyrene  containers  with  appropriately  labelled  inserts  and  stored 
at  -70°C. 
4.4  Recovery  of  isolates  of  viridans  streptococci 
When  required  for  identification  tests,  antibiotic  susceptibility  tests  or  pulsed-  field  gel 
electrophoretic  analysis,  the  appropriate  cryovials  were  removed  from  storage.  One 
bead  was  removed  from  each  vial  using  a  sterile  needle  and  directly  streaked  on  to 
the  surface  of  a  Columbia  blood  agar  plate,  which  was  then  incubated  overnight  at 
37°C  in  5%  CO2.  From  these  cultures  a  further  subculture  (on  Columbia  blood  agar) 
was  performed  before  any  tests  were  carried  out. 
4.5  Identification  of  viridans  streptococci 
Preliminary  identification  of  viridans  streptococci  was  performed  by  visual  inspection 
of  colonial  morphology  on  Columbia  blood  agar.  All  organisms  studied  were 
catalase  negative,  Gram-positive  cocci,  resistant  to  optochin.  The  Rapid  ID  32  Strep 
system  (BioMerieux,  Basingstoke,  U.  K)  was  then  used  according  to  the 
manufacturer's  instructions  (BioMerieux,  1994  &1998)  to  identify  further  each  isolate. 
After  inoculation  of  the  Rapid  ID  32  Strep  strip  with  bacterial  suspension,  followed  by 
99 incubation  for  4  hours,  reactions  were  read,  with  positive  tests  indicated  by  colour 
change  (Figure  4.2).  A  numerical  identification  profile  was  obtained  which  was  then 
interpreted  using  API  LAB  Plus  software. 
Figure  4.2  Rapid  ID  32  Strep  strip  following  inoculation  and  incubation 
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Until  March  1998,  the  API  1.1  database  was  used  for  the  present  study.  When  the 
updated  database  (Version  2.0)  became  available,  it  was  used  to  identify  all  new 
strains  and,  for  continuity,  to  re-identify  all  earlier  isolates. 
In  instances  when  a  low  identification  probability  (<  90%)  or  an  equivocal  result  was 
obtained  or  when  no  species  result  was  acceptable,  the  organism  was  subcultured 
on  to  a  fresh  blood  agar  plate,  incubated  overnight  and  identification  repeated.  If 
definitive  identification  was  still  not  achieved,  a  culture  was  dispatched  to  the 
Streptococcal  Reference  Laboratory,  PHLS  Central  Public  Health  Laboratory, 
London,  U.  K.  for  further  tests  and  identification.  In  total,  seven  isolates  of  viridans 
streptococci  from  blood  cultures  were  sent. 
4.6  Identification  of  coagulase-negative  staphylococci 
Staphylococci  were  initially  identified  visually  by  colonial  morphology.  Gram-positive 
cocci  with  a  positive  catalase  reaction  were  tested  using  the  Staphaurex  slide 
100 agglutination  test  (Murex  Biotech  Limited,  Dartford,  U.  K.  ),  which  differentiates 
staphylococci  which  possess  coagulase  and/or  protein  A  from  those  which  produce 
neither  of  these  factors.  The  staphylococcal  isolates  from  both  blood  culture  and 
mouth  swab  of  the  present  study  were  Staphaurex  negative.  The  organisms  were 
then  speciated  using  the  API  Staph  system  (BioMerieux,  Basingstoke,  U.  K.  ). 
Preparation,  inoculation  and  incubation  of  API  Staph  strips  were  carried  out 
according  to  the  manufacturer's  instructions  (BioMerieux,  2000).  Results  were 
recorded  according  to  the  API  Staph  Reading  Table  and  the  numerical  identification 
profile  was  then  interpreted  using  API  LAB  Plus  software. 
4.7,  Genotypic  analysis 
The  following  procedures  were  used  for  all  strains  of  viridans  streptococci 
investigated  in  Chapter  7  and  for  the  isolates  of  Staphylococcus  epidermidis  isolated 
concomitantly  with  one  of  these. 
4.7.1  Preparation  of  cells  and  agarose  blocks 
Cultures  were  grown  overnight  in  brain  heart  infusion  broth,  0.5  ml  was  washed  with 
NET  buffer  (10mM  Tris,  1  mM  EDTA,  10  mM  NaCI)  and  resuspended  in  0.25  ml  of 
NET  buffer.  Lysozyme  (1  mg),  mutanolysin  (100  units)  and  RNAase  (25  p  g)  were 
added  to  the  cell  suspension  and  mixed  with  an  equal  volume  of  SeaPlaque  GTG 
agarose  (Flowgen)  2%  at  50°C.  The  cell/agarose  suspension  was  pipetted  into  a 
block  mould  and  allowed  to  solidify  at  4°C. 
Cells  were  lysed  by  dispensing  blocks  into  lysis  buffer  (lysozyme  1  mg/ml,  RNAase 
25  p  g/mI,  6  mM  Tris,  100  mM  EDTA,  1M  NaCl,  Brij  58  0.5%,  sodium  deoxycholate 
0.2%,  lauroyl  sarcosine  0.5%)  and  incubating  for  2-3  hours  at  37°C.  Lysis  buffer  was 
then  removed,  and  1  ml  of  proteolysis  buffer  (proteinase  K  100  p  g/ml,  lauroyl 
101 sarcosine  1%  in  0.5  M  EDTA)  was  added  and  incubation  continued  for  16-24  hours 
at  50°C.  After  incubation,  the  blocks  were  washed  three  times  for  10  minutes  each 
in  TE  buffer  (10  mM  Tris,  1  mM  EDTA). 
4.7.2  Digestion  of  DNA  with  restriction  endonuclease 
Gel  plugs  were  cut  from  the  blocks  and  digested  with  30  units  of  Sma  I  at  30°C  for  3 
hours  in  a  total  volume  of  100  pL  of  the  appropriate  restriction  buffer  (87  pL  sterile 
distilled  water  +  10  pL  10  X  restriction  buffer). 
4.7.3  Pulsed-field  gel  electrophoresis 
Gels  were  prepared  as  1%  (w/v)  PFGE  grade  agarose  (BioRad  Laboratories,  Herts, 
U.  K.  )  in  0.5  x  TBE  buffer  (44.5  mM  Tris,  44.5  mM  boric  acid,  1  mM  EDTA).  Gel 
plugs  containing  Sma  I  digested  DNA  were  loaded  and  sealed  with  1%  SeaPlaque 
agarose  (Flowgen). 
Electrophoresis  was  carried  out  in  0.5  x  TBE  buffer  using  the  contour-clamped 
homogeneous  electric  field  (CHEF)  method  with  a  CHEF-Mapper  drive  module 
(BioRad  Laboratories).  The  gel  was  run  for  23  hours  with  a  linear  ramped  pulse  time 
of  6.75-63.8  seconds.  A  lambda  ladder  was  used  as  a  molecular  size  marker.  After 
the  electrophoresis  run  was  complete  the  gel  was  removed,  stained  with  ethidium 
bromide  1p  g/ml  for  30  minutes  and  photographed  under  ultraviolet  transillumination. 
4.7.4  Analysis  of  PFGE  profiles 
Analysis  of  PFGE  profiles  was  performed  by  visual  inspection  of  band  patterns.  The 
total  numbers  of  visible  bands  were  counted  for  each  isolate,  and  patterns  were 
102 compared.  Isolates  which  differed  by  more  than  three  bands  were  considered 
unrelated  (Rudolf,  Parkinson  &  Roberts,  1998). 
4.8  Antibiotic  studies 
4.8.1  Determination  of  antibiotic  MICs  using  the  Etest  method 
MICs  were  determined  on  Diagnostic  Sensitivity  Test  (DST)  Agar  with  5%  lysed 
horse  blood  (E  &0  Laboratories,  Bonnybridge,  U.  K.  )  using  antibiotic  Etests  (AB 
Biodisk,  Solna,  Sweden).  The  Etest  has  been  shown  to  be  a  reliable  method  for 
determination  of  antibiotic  susceptibility  of  viridans  streptococci  (Hall,  Heimdahl  & 
Nord,  1998;  Lewis  et  al.,  2000).  Prior  to  this,  its  reliability  versus  those  of  reference 
methods  for  susceptibility  testing  of  S.  pneumoniae  had  been  established  (Macias  et 
al.,  1994;  Tenover,  Baker  &  Swenson,  1996). 
Antimicrobial  agents  tested  in  the  present  study  were  ceftazidime,  piperacillin/ 
tazobactam,  meropenem,  penicillin  G,  cefaclor,  cefpirome,  vancomycin, 
quinupristin/dalfopristin  and  linezolid.  Cefpirome  and  quinupristin/dalfopristin  Etest 
strips  were  kindly  supplied  by  Aventis  Pharma  (Kent,  U.  K.  )  and  Linezolid  Etest  strips 
were  supplied  by  Pharmacia  Limited  (Milton  Keynes,  U.  K.  ). 
From  an  overnight  plate  culture,  viridans  streptococci  were  suspended  in  4  ml  of 
sterile  distilled  water  to  achieve  0.5  McFarland  turbidity.  The  suspension  was  used 
within  15  minutes  of  preparation.  A  sterile  swab  was  dipped  into  the  suspension  and 
excess  fluid  was  then  removed  by  pressing  the  swab  against  the  inside  wall  of  the 
tube.  The  surface  of  a  DST  agar  plate  (90mm  diameter)  was  swabbed  three  times, 
rotating  the  plate  through  approximately  90  degrees  each  time  to  ensure  an  even 
distribution  of  inoculum.  Inoculated  plates  were  left  for  15  minutes  to  ensure  that  the 
surface  of  the  agar  was  dry  before  applying  Etest  strips.  Using  a  pair  of  forceps,  the 
103 appropriate  Etest  strip  was  applied  to  the  inoculated  agar  surface.  Care  was  taken 
to  ensure  that  the  whole  length  of  the  strip  was  in  contact  with  the  agar  surface  and 
any  air  pockets  were  removed  by  gently  pressing  on  the  strip  with  forceps,  moving 
from  the  minimum  concentration  upwards.  Plates  were  then  incubated  in  aerobic 
conditions  at  37°C  for  24  hours. 
After  incubation,  the  MIC  value  was  read  at  the  point  of  intersection  between  the 
inhibition  ellipse  edge  and  the  Etest  strip.  Staphylococcus  aureus  NCTC  6571  was 
used  as  control  organism.  MIC  results  were  presented  as  number  (and  percentage) 
of  strains  inhibited  at  stated  MICs  (mg/L)  and  geometric  mean  MICs  were  calculated. 
4.8.2  Determination  of  antibiotic  susceptibility  using  the  modified  Stokes' 
disc  diffusion  method 
At  the  commencement  of  this  study,  the  modified  Stokes'  disc  diffusion  method 
(Stokes  &  Ridgway,  1980)  was  used  routinely  in  the  clinical  microbiology  laboratory 
at  RHSC,  as  was  the  case  in  the  majority  of  laboratories  in  the  U.  K.  The  use  of  this 
method  allowed  each  isolate  to  be  compared  with  a  sensitive  control  organism  which 
was  subjected  to  the  same  technical  conditions  of  medium,  incubation  time, 
atmosphere,  temperature  and  disc  content.  As  control  organisms  were  adjacent  on 
the  same  plate,  the  difference  between  respective  zone  sizes  could  be  measured 
directly.  Antibiotic  susceptibilities  of  all  isolates  of  viridans  streptococci  from  blood 
culture  were  determined  using  the  Stokes'  method  with  S.  aureus  NCTC  6571  as 
control  organism  (as  recommended  in  the  BSAC  Guide  to  Sensitivity  Testing,  1991). 
4.8.2.1  Preparation  of  inoculum 
An  inoculum  which  resulted  in  semi-confluent  growth  of  colonies  following  overnight 
incubation,  was  used.  For  antibiotic  disc  susceptibility  tests  using  viridans 
104 streptococci,  colonies  were  taken  directly  from  a  blood  agar  plate  into  sterile  distilled 
water  to  produce  a  suspension  with  a  density  equivalent  to  a  0.5  McFarland 
standard.  This  suspension  was  then  used  directly  to  inoculate  the  sensitivity  test 
plate.  In  a  minority  of  cases,  when  the  resulting  inoculum  was  too  heavy,  the  test 
was  repeated  using  a  1:  10  dilution  of  a  freshly  prepared  bacterial  suspension. 
For  antibiotic  disc  susceptibility  tests  using  coagulase-negative  staphylococci  and  for 
the  control  organism,  S.  aureus  NCTC  6571  a  suspension  with  a  density  equivalent 
to  a  0.5  McFarland  standard  was  diluted  1:  10  to  result  in  semi-confluent  growth 
following  overnight  incubation. 
4.8.2.2  Inoculation  of  agar  plates 
A  sterile  cotton-wool  swab  was  dipped  into  the  test  bacterial  suspension  and  excess 
liquid  removed  by  turning  the  swab  against  the  side  of  the  tube.  The  swab  was  then 
placed  on  the  surface  of  a  DST  agar  plate  on  the  platform  of  a  rotary  plater  and  was 
moved  at  an  even  pace  from  the  periphery  inwards  to  form  a  1.5  cm  inoculated 
band.  The  control  organism  was  then  applied  to  the  centre  of  the  plate.  After  the 
inoculum  had  dried,  antibiotic  discs  were  applied  to  the  surface  of  the  plate. 
Antibiotic  discs  tested  against  viridans  streptococci  were  penicillin  G  (1  unit),  cefaclor 
(30  p  g),  ceftazidime  (30  p  g),  piperacillin  (30  pg  and  75  p  g),  piperacillin/tazobactam 
(75  +  10  p  g),  meropenem  (10  p  g),  vancomycin  (30  p  g)  and  trimethoprim/ 
sulphamethoxazole  (25  p  g).  Two  inoculated  plates  for  each  isolate  were  used  to 
accommodate  the  above  discs.  Antibiotic  discs  used  for  coagulase-negative 
staphylococci  were  vancomycin  (30  p  g),  clindamycin  (2  p  g),  rifampicin  (2  p  g),  fusidic 
acid  (10  p  g),  amikacin  (30  p  g),  and  ciprofloxacin  (1  p  g).  Methicillin  susceptibility  was 
tested  with  25  pg  strips  on  inoculated  Columbia  blood  agar  plates,  incubated 
105 overnight  at  30°C.  All  other  inoculated  sensitivity  plates  were  incubated  overnight  at 
37°C  in  aerobic  conditions. 
4.8.2.3  Measurement  of  zones  and  interpretation  of  results 
Zone  sizes  were  measured  using  dividers  with  a  ruler  and  were  interpreted 
according  to  the  criteria  of  the  Stokes'  method  as  follows: 
Sensitive:  zone  radius  equal  to,  wider  than,  or  not  more  than  3  mm  smaller  than  the 
control. 
Intermediate:  zone  radius  greater  than  2  mm  but  smaller  than  the  control  by  more 
than  3  mm. 
Resistant:  zone  radius  2  mm  or  less. 
Percentage  susceptibility  figures  were  calculated  and  compared  with  those 
generated  using  MIC  methods. 
4.9  Statistical  tests 
The  following  statistical  tests  were  employed  in  this  thesis. 
The  Chi-squared  (X2)  test 
Differences  between  categorical  variables  were  tested  for  significance  using  the  X2 
test.  P  values  of  <  0.05  were  considered  statistically  significant. 
Exact  probability  test 
When  the  sample  size  was  too  small  for  the  X2  test  to  be  appropriate,  Fisher's  exact 
test  was  used. 
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The  arithmetic  mean  was  calculated  when  the  distribution  of  a  set  of  figures  was 
symmetrical  and  unimodal.  The  geometric  mean  was  calculated  when  the 
distribution  was  skewed,  as  may  be  observed  for  antibiotic  MICs. 
The  t  test 
The  t  test  was  used  to  compare  the  means  of  two  samples  in  order  to  determine 
whether  the  samples  were  from  the  same  or  different  populations  (Statworks  - 
Cricket  Software).  P  values  of  <  0.05  were  considered  statistically  significant. 
Correlation  and  linear  regression 
Statistical  software  StatWorks  (Cricket  Software)  was  used  to  analyse  correlation 
(which  measures  the  closeness  of  an  association  between  different  variables),  and 
linear  regression  (which  produces  the  equation  of  the  straight  line  that  best  describes 
the  association). 
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5.1  Introduction 
Throughout  the  period  of  this  study,  the  number  of  episodes  of  viridans  streptococcal 
bacteraemia  was  recorded  and  compared  with  that  of  total  episodes  of 
microbiologically  documented  bloodstream  infection  (bacteraemia  plus  fungaemia)  in 
paediatric  immunocompromised  patients  at  RHSC.  In  addition,  the  frequency  of 
isolation  of  viridans  streptococci  as  a  group  was  compared  with  that  of  other  major 
groups  of  organisms  responsible  for  infection  in  this  patient  population.  Episodes  of 
viridans  streptococcal  bacteraemia  were  also  expressed  as  proportion  of  total  febrile 
episodes. 
The  distribution  of  different  species  of  viridans  streptococci  from  blood  culture  was 
determined  to  investigate  whether  particular  species  were  associated  with  this 
infection.  Cases  of  polymicrobial  bacteraemia  were  monitored  to  investigate  the 
possible  role  of  co-infecting  bacteria  or  yeasts  with  viridans  streptococci.  Episodes 
of  streptococcal  bacteraemia  with  concomitant  viral  infection  were  also  evaluated  to 
determine  whether  this  combination  influenced  clinical  outcome. 
This  study  included  all  paediatric  patients  with  malignant  disease  who  developed 
viridans  streptococcal  bacteraemia.  It  should  be  appreciated  that  this  in  itself  is  a 
fairly  heterogeneous  group.  A  diverse  range  of  malignancies  was  involved  and 
many  different  chemotherapeutic  protocols  and  modalities  of  therapy  were  used. 
However  the  major  advantage  in  studying  this  broad  group  was  that  the  maximum 
number  of  organisms  could  be  obtained  for  in  vitro  studies.  It  should  be  appreciated 
however,  that  the  number  of  episodes  involved  in  this  study  (69)  still  represents  a 
fairly  small  sample  size.  For  analysis  of  some  of  the  findings  from  this  study,  a  more 
110 uniform  sample  population  was  required  therefore  specific  patients  or  episodes  were 
considered  e.  g.  all  episodes  of  viridans  streptococcal  bacteraemia  following  a 
particular  course  of  chemotherapy  containing  high-dose  cytosine  arabinoside. 
While  this  approach  provided  a  more  narrowly  defined  population  for  analysis,  the 
disadvantage  was  that  it  further  reduced  the  sample  size.  However  limited  statistical 
analysis  of  this  group  could  still  be  performed  to  provide  useful  information. 
The  epidemiological  study  presented  in  this  thesis  was  descriptive  rather  than  case- 
controlled.  Earlier  investigators  had  completed  case  control  studies  before  the 
present  work  was  started  and  several  of  their  findings  will  be  discussed  (Kern,  Kurrle 
&  Schmeiser,  1990;  Elting,  Bodey  &  Keefe,  1992;  Bochud  et  al.,  1994).  The  main 
purpose  of  this  part  of  the  work  was  to  determine  the  recent  epidemiology  of  viridans 
streptococcal  bacteraemia  in  a  paediatric  group  and  to  provide  a  background  to  the 
practical  aspects  of  the  study. 
5.2  The  haematology/oncology  unit 
The  Royal  Hospital  for  Sick  Children,  Glasgow,  is  the  largest  paediatric  hospital  in 
Scotland  (320  beds)  with  an  in-patient  population  representing  a  variety  of  medical 
and  surgical  specialities,  including  haematology,  oncology,  renal  transplantation  and 
cardiac  surgery. 
The  haematology/oncology  clinical  service  is  located  on  the  first-floor  of  the  hospital 
in  a  dedicated  unit  -  `Schiehallion'.  The  ward  area  has  facilities  for  21  inpatients  and 
an  adjacent  day-care  facility.  The  unit  provides  a  comprehensive  service  for  the 
diagnosis  and  management  of  children  with  leukaemia,  solid  tumours  or  benign 
haematological  conditions.  It  houses  the  National  Paediatric  Bone  Marrow 
Transplantation  Unit  and  the  Regional  Haemophilia  Centre.  The  department  cares 
111 for  approximately  two  thirds  of  the  children  in  Scotland  with  malignant  disease  or 
benign  haematological  conditions,  with  a  catchment  area  covering  the  West  of 
Scotland,  with  shared  care  arrangements  with  Dumfries  and  Inverness.  Ward 
admissions  average  1000  per  year,  representing  around  350  patients,  35-40%  of 
whom  have  leukaemia.  At  present,  approximately  25  new  cases  of  leukaemia  and 
50  new  cases  with  solid  tumours  are  referred  annually.  Around  750  children  with 
various  haematological/oncological  disorders  are  on  regular  treatment  or  follow-up. 
The  average  annual  increase  in  patient  numbers  is  greater  than  10%.  Children  with 
malignancy  are  treated  on  national  Medical  Research  Council  (MRC),  United 
Kingdom  Children  Cancer  Study  Group  (UKCCSG)  or  International  Paediatric 
Oncology  Society  (STOP)  trials. 
5.3  Episodes  of  viridans  streptococcal  bacteraemia. 
Figure  5.1  Annual  episodes  of  microbiologically  documented  bloodstream  infection, 
with  annual  episodes  of  viridans  streptococci  bacteraemia,  1993-2000* 
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*:  Figures  for  1993  and  '94  prior  to  the  start  of  the  study  are  included  for  reference. 
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Year Figure  5.1  shows  the  annual  total  of  microbiologically  documented  bloodstream 
infections  in  paediatric  patients  with  cancer  at  RHSC  from  1993  to  2000  inclusive. 
Also  presented  are  annual  episodes  of  viridans  streptococcal  bacteraemia 
throughout  the  same  period.  In  1993  there  were  10  episodes  of  viridans 
streptococcal  bacteraemia  accounting  for  12%  of  all  cases  of  microbiologically 
documented  bloodstream  infection.  In  1994  there  was  an  increase  to  18  episodes  of 
this  infection  (representing  22%  of  total).  In  1995  there  were  15  episodes  (15%  of 
total),  followed  by  a  continued  decrease  throughout  the  time  interval  of  the  study.  By 
the  end  of  the  year  2000,  annual  episodes  of  viridans  streptococcal  bacteraemia,  as 
proportion  of  microbiologically  documented  bloodstream  infections,  had  decreased  to 
around  one-fifth  of  that  for  1994  (P  <  0.001). 
Figure  5.2  shows  episodes  of  viridans  streptococcal  bacteraemia  with  total  febrile 
episodes  as  denominator. 
Figure  5.2  Annual  episodes  of  viridans  streptococcal  bacteraemia  as  percentage  of 
annual  total  febrile  episodes,  1993-2000  * 
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Year Unfortunately,  exact  figures  for  total  febrile  episodes  for  the  early  years  of  this  project 
were  not  available.  However,  it  was  felt  acceptable  to  obtain  estimated  figures  for 
these  years  (1993-96)  by  calculation  based  on  the  consistency  of  rates  of 
microbiologically  documented  bloodstream  infection  from  febrile  episodes  for  1997- 
2000  (26%  of  all  febrile  episodes  in  1997,28%  in  1998,26%  in  1999  and  27%  in 
2000).  The  majority  of  febrile  episodes  amongst  the  patients  of  the  haematology/ 
oncology  unit  were  associated  with  neutropenia. 
Figure  5.2,  in  common  with  the  previous  figure,  demonstrates  a  maximum  frequency 
of  viridans  streptococcal  bacteraemia  in  1994,  decreasing  to  a  minimum  in  2000. 
Although  there  were  more  episodes  of  infection  in  1994  than  in  1995  (5.9%  versus 
4.0%,  of  all  febrile  episodes,  respectively),  the  most  severe  cases  of  the  entire  study 
occurred  during  1995,  and  these  included  two  fatalities.  In  1996,  there  were  14 
episodes  of  viridans  streptococcal  bacteraemia  (3.4%  of  all  febrile  episodes), 
associated  with  less  severe  symptoms  than  during  the  previous  year.  By  the  end  of 
the  year  2000,  episodes  of  viridans  streptococcal  bacteraemia  as  proportion  of  total 
febrile  episodes  had  decreased  to  around  one-fifth  of  those  for  1994  (1.2% 
compared  with  5.9%,  respectively,  P<0.001). 
5.4  Viridans  streptococcal  bacteraemia  compared  with  bacteraemia  caused  by 
other  micro-organisms 
For  epidemiological  purposes,  the  frequency  of  isolation  of  viridans  streptococci  from 
blood  culture  relative  to  that  of  other  organism  groups  was  investigated.  This  form  of 
analysis  included  total  microbial  yield  from  blood  culture,  incorporating  individual 
organisms  from  polymicrobial  infection.  Figure  5.3  shows  the  position  of  viridans 
streptococci  in  the  context  of  bacteraemia  due  to  other  Gram-positive  organisms, 
from  1993  to  2000. 
114 Figure  5.3  Gram-positive  bacteria  isolated  from  blood  culture  of  paediatric  patients 
with  cancer,  1993-2000 
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Coagulase-negative  staphylococci  were  consistently  the  most  commonly  isolated 
Gram-positive  bacteria.  Until  the  year  2000,  viridans  streptococci  comprised  the 
second  most  commonly  isolated  group.  In  1994,  these  organisms  represented  29% 
of  total  Gram-positives,  decreasing  to  13.5%  in  1999.  In  the  year  2000,  viridans 
streptococci  represented  9%  of  total  isolates  of  Gram-positive  bacteria.  During  this 
year,  the  proportion  of  isolates  of  viridans  streptococci  decreased  to  become 
identical  to  that  of  Staphylococcus  aureus,  and  was  exceeded  by  that  of 
Corynebacterium  spp.  and  related  genera. 
The  position  of  viridans  streptococcal  isolates  relative  to  other  major  groups  of 
organisms  causing  bacteraemia  in  paediatric  patients  with  cancer  is  presented  in 
Figure  5.4.  This  demonstrates  once  more  that  the  bacteria  most  commonly  isolated 
from  blood  culture  of  patients  with  malignant  disease  were  coagulase-negative 
staphylococci.  Of  the  Gram-negative  bacteria,  those  belonging  to  the  tribe 
Enterobacteriaceae  are  generally  encountered  most  frequently. 
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Year Figure  5.4  Major  groups  of  bacteria  isolated  from  blood  culture  of  paediatric 
patients  with  cancer,  1993-2000 
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During  1994,  total  isolates  of  viridans  streptococci  exceeded  those  of 
Enterobacteriaceae  (22%  versus  14%),  while  the  relative  proportions  of  both  groups 
were  either  identical  or  similar  during  1993,  '95,  '96  and  `97.  Throughout  the  last 
three  years  of  the  study,  the  proportion  of  Enterobacteriaceae  remained  fairly 
constant  at  17%  of  total  organisms  in  1998,18%  in  1999  and  16%  in  2000,  while 
viridans  streptococcal  isolates  decreased  in  percentage  (10%,  7%  and  5%  of  total 
isolates  respectively). 
5.5  Viridans  streptococcal  bacteraemia  and  interventions  associated  with  the 
present  study 
In  late  1994,  subsequent  to  the  occurrence  of  several  cases  of  viridans  streptococcal 
bacteraemia,  action  was  taken  to  improve  the  situation.  The  importance  of  mouth 
care  procedures  was  emphasized,  as  the  most  likely  source  of  viridans  streptococci 
was  the  oral  cavity.  It  was  reasoned  that  good  oral  hygiene  might  reduce  mucosal 
and  dental  complications  associated  with  anti-cancer  therapy  and  possibly  prevent 
overgrowth  of  viridans  streptococci  in  patients'  mouths.  However,  in  1995,  as 
116 mentioned  earlier,  severity  of  symptoms  associated  with  viridans  streptococci  was 
greatest  and  there  were  two  fatalities. 
Around  this  time,  if  initial  Gram-stain  of  positive  blood  culture  suggested  the 
presence  of  streptococci,  vancomycin  was  generally  added  to  first-line  empirical 
therapy  of  ceftazidime  plus  amikacin.  However  first-line  therapy  with  better  activity 
against  streptococci  was  also  desirable.  In  the  mid  -1990s  there  were  few  agents 
licensed  for  use  in  children,  with  good  activity  against  both  streptococci  and  Gram- 
negative  pathogens  which  would  be  suitable  in  this  clinical  setting.  Piperacillin/ 
tazobactam  (in  combination  with  amikacin)  had  been  used  successfully  in  the 
haematology/oncology  ward  of  RHSC  on  a  named-patient  basis  during  participation 
in  IATCG/EORTC  Trial  IX.  Preliminary  susceptibility  test  results  of  the  present  study 
indicated  that  its  activity  against  viridans  streptococci  was  superior  to  that  of 
ceftazidime,  and  disc  diffusion  tests  performed  in  the  diagnostic  laboratory  indicated 
that  it  was  active  against  piperacillin-resistant  strains  of  E.  coil.  In  July  1996, 
piperacillin/tazobactam  was  substituted  for  ceftazidime,  as  empirical  0  -lactam 
therapy. 
5.6  Patient  numbers  and  episodes  of  viridans  streptococcal  bacteraemia 
Fifty-four  patients  developed  viridans  streptococcal  bacteraemia  throughout  the 
study  period  (i.  e.  between  the  beginning  of  December  1994  and  the  end  of 
December  2000).  Patient  details  are  presented  in  Table  5.1. 
117 Table  5.1  Patient  demographics  (and  episodes  of  viridans  streptococcal  bacteraemia) 
Patient  Number 
(No.  of  episodes  if  >  1) 
Age  Gender  Underlying  Malignancy 
1  (4)  3  months  Female  AML 
2  (2)  11  years  Male  AML 
3  1  year  Male  Neuroblastoma 
4  4  ears  Female  T-cell  lymphoma 
5  2  years  Male  AML 
6  1  year  Male  ALL 
7  14  years  Male  ALL 
8(2)  12  years  Female  AML 
9  5  years  Female  ALL 
10  6  years  Female  B-cell  lymphoma 
11  14  years  Female  AML 
12  11  years  Female  AML 
13  (2)  3  years  Male  ALL 
14  2  years  Male  ALL 
15  3  years  Male  B-cell  lymphoma 
16  14  years  Male  T-cell  lymphoma 
17  3  years  Male  ALL 
18  3  years  Male  ALL 
19  1  year  Male  ALL 
20  1  year  Male  AML 
21  10  years  Male  ALL 
22  11  ears  Male  ALL 
23  8  years  Female  ALL 
24  4  years  Female  ALL 
25  14  years  Male  CML 
26  2  years  Female  Wilms'  tumour 
27  1  year  Female  ALL 
28  3  years  Male  ALL 
29  7  years  Male  ALL 
30  2  years  Male  ALL 
31  12  years  Female  ALL 
32  12  years  Male  AML 
33  6  years  Female  Rhabdomyosarcoma 
34(3)  11  years  Female  ALL 
35  12  years  Female  ALL 
36  12  years  Male  AML 
37  7  years  Male  ALL 
38  3  years  Female  ALL 
39(3)  14  years  Male  AML 
40  (2)  12  years  Male  ALL 
41  13  years  Female  ALL  { 
42  2  years  Female  ALL 
43  3  years  Female  ALL 
44(4)  2  years  Male  AML 
45  (2)  7  years  Male  ALL 
46  14  years  Male  AML 
47  10  years  Male  AML 
48  1  year  Female  AML 
49  1  year  Male  AML 
50  8  years  Female  ALL 
51  14  years  Female  Rhabdomyosarcoma 
52  10  years  Male  ALL 
53  7  years  Male  Osteosarcoma 
54  6  years  Male  L.  C.  A.  L 
118 Figure  5.5  shows  the  annual  number  of  patients  developing  one  or  more  episodes  of 
viridans  streptococcal  bacteraemia. 
Figure  5.5  Patients  with  viridans  streptococcal  bacteraemia,  1993  -2000* 
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*:  Figures  for  1993  and  '94  prior  to  the  start  of  the  study  are  included  for  reference. 
Patients  with  multiple  episodes  of  viridans  streptococcal  infection  are  represented 
only  once  in  Figure  5.5  -  by  the  first  episode  of  infection.  From  the  start  of  the  study 
period  (1St  December  1994),  fifty-four  patients  developed  viridans  streptococcal 
bacteraemia.  Although  there  was  a  decrease  in  the  number  of  individual  patients 
who  developed  one  or  more  episodes  of  viridans  streptococcal  bacteraemia  from 
1994  to  1995,  an  increase  followed  in  1996.  From  1997  onwards,  the  number  of 
patients  with  viridans  streptococcal  bacteraemia  decreased  steadily. 
During  the  study  period,  forty-five  patients  experienced  one  episode  of  infection. 
Five  patients  experienced  two  separate  episodes,  two  experienced  three  episodes 
and  two  experienced  four.  For  the  group  of  patients  experiencing  multiple  episodes 
of  viridans  streptococcal  bacteraemia,  there  elapsed  a  time  interval  of  between  1  to  6 
months  between  each  episode,  with  negative  blood  cultures  intervening. 
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1993  1994  1995  1996  1997  1998  1999  2000 Figure  5.6  demonstrates  that  in  1993,  '94,  '95,  '97  and  '99  the  number  of  episodes  of 
viridans  streptococcal  bacteraemia  was  identical  to  the  number  of  strains  of  viridans 
streptococci  cultured  from  blood.  However  during  1996,  '98  and  2000,  five  episodes 
were  associated  with  multiple  strains  of  these  organisms. 
Figure  5.6  Episodes  of  viridans  streptococcal  bacteraemia  and  total  isolates  of  the 
causative  organisms,  1993-2000* 
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E  Episodes 
D  Isolates 
In  total,  69  episodes  of  viridans  streptococcal  bacteraemia  occurred  during  the 
period  of  this  study,  with  a  maximum  of  15  in  1995  and  a  minimum  of  5  in  2000.  In 
three  cases,  2  different  species  of  viridans  streptococci  were  isolated  from  a  single 
blood  culture  and  in  two  cases,  3  different  species  or  strains  were  cultured,  resulting 
in  a  final  total  of  76  organisms. 
5.7  Species  of  viridans  streptococci  causing  bacteraemia 
The  Rapid  ID  32  Strep  method  (BioMerieux,  Basingstoke,  U.  K.  )  was  used  to  identify 
isolates  of  viridans  streptococci  to  species  level  (Figure  5.7).  On  7  occasions  an 
120 
1993  1994  1995  1996  1997  1998  1999  2000 equivocal  identification  was  obtained  or  no  species  result  was  acceptable,  therefore 
a  fresh  culture  was  prepared  and  sent  to  the  Streptococcal  Reference  Laboratory, 
PHLS  Central  Public  Health  Laboratory,  London  for  further  tests  and  identification. 
Figure  5.7  Species  of  viridans  streptococci  from  blood  cultures 
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The  results  of  the  present  study  differed  from  those  of  several  earlier  publications 
which  cited  S.  mitis  and  S.  sanguis  as  the  most  commonly  isolated  species  of 
viridans  streptococcus  from  blood  cultures  of  neutropenic  patients  (Cohen  et  al., 
1983;  Henslee  et  al.,  1984;  Leblanc  et  al.,  1989;  Guiot  et  al.,  1990;  Classen  et  al., 
1990;  McWhinney  et  al.,  1991;  Burden  et  al.,  1991;  Awada  et  al.,  1992;  Elting,  Bodey 
&  Keefe,  1992;  Bochud  et  al.,  1994).  Only  two  studies  from  the  early  1990s, 
demonstrated  a  predominance  of  S.  oralis  from  cases  of  viridans  streptococcal 
bacteraemia  (McWhinney  et  al.,  1993;  Beighton,  Carr  &  Oppenheim,  1994). 
121 The  earlier  studies  used  a  variety  of  streptococcal  identification  schemes,  both 
conventional  and  commercial,  however  the  most  commonly  used  system  was  API  20 
Strep  (BioMerieux).  Throughout  the  1980s  and  `90s  this  commercial  method  was 
also  used  in  the  diagnostic  microbiology  laboratory  of  RHSC.  The  species 
identification  results  of  the  present  study,  could  therefore  be  compared 
retrospectively  with  those  obtained  for  the  same  isolates  using  the  API  20  Strep 
method  (Table  5.2). 
Table  5.2  Identification  of  76  isolates  of  viridans  streptococci  from  blood  culture 
using  Rapid  ID  32  Strep  compared  with  API  20  Strep 
Species  Number  of  isolates  (%) 
-  Rapid  ID  32  STREP 
Number  of  isolates  (%) 
-  API  20  STREP 
S.  oralis  48  (63)  9  (12) 
S.  mitis  19  (25)  55  (72) 
S.  sanguis  5(7)  11(15) 
S.  parasanguis  2  (3)  0  (0) 
S.  salivarius  1  (1)  1  (1) 
S.  gordonii  1  (1)  0  (0) 
TOTAL  76  (100)  76  (100) 
Table  5.2  demonstrates  that  the  proportion  of  isolates  identified  as  S.  oralis  and  S. 
mitis  by  the  two  systems  differed  significantly,  to  the  extent  that  the  numbers  of  S. 
oralis  identified  by  the  more  modern  system  approached  the  proportion  of  S.  mitis 
identified  by  the  older  system.  The  Rapid  ID  32  Strep  system  incorporates  more 
tests  and  can  identify  a  wider  range  of  species  than  the  API  20  Strep  system  and  the 
122 revised  BioMerieux  identification  database,  used  in  the  present  study,  now 
incorporates  some  of  the  recent  revisions  in  the  taxonomy  of  viridans  streptococci. 
5.8  Polymicrobial  bloodstream  infection 
In  16  of  the  69  episodes  of  viridans  streptococcal  bacteraemia  (i.  e.  23%),  co- 
infecting  micro-organisms  were  present  (sometimes  more  than  one  strain  or  species 
of  viridans  streptococcus).  Yeasts  were  present  in  three  of  these  episodes.  Details 
of  these  organisms  are  presented  in  Table  5.3. 
Table  5.3  Micro-organisms  causing  polymicrobial  bloodstream  infection 
Patient  No.  Organisms  causing  polymicrobial  infection 
10  S.  oralis  II,  Enterococcus  faecalis 
13  S.  mitis  1,  S.  mitis  11 
17  S.  sanguis,  Micrococcus  sp. 
18  S.  oralis  11  (2  strains),  S  mitis  I,  Haemophilus  parainfluenzae, 
Moraxella  catarrhalis 
22  S.  oralis  II,  S.  parasanguis 
24  S.  mitis  1,  Candida  albicans 
25  S.  oralis  I,  Coagulase-negative  staphylococci 
28  S.  oxalis  II,  Rhodotorula  rubra 
30  S.  mitis  1,  Candida  lusitaniae 
34  S.  oralis  II,  Microaerophilic  streptococci 
35  S.  oralis  II,  Enterobacter  cloacae 
38  S.  sanguis  (2  strains),  S.  salivarius 
40  S.  sanguis,  Coagulase-negative  staphylococci 
41  S.  oralis  II,  Bacillus  sp.,  Coagulase-negative  staphylococci 
49  S.  oralis  1,  Enterococcus  faecium 
53  S.  oralis  1,  S.  mitis  I 
123 In  each  of  four  episodes,  two  species  of  viridans  streptococci  were  isolated  from 
blood  culture  (Table  5.3).  If  the  mouth  were  the  source  of  organisms  causing 
bacteraemia  through  oral  mucositis,  it  was  possible  that  more  than  one  species  or 
strain  of  viridans  streptococcus  could  have  reached  the  bloodstream.  A  further 
episode  involved  S.  mitis,  2  different  strains  of  S.  oralis,  Haemophilus  parainfluenzae 
and  Moraxella  catarrhalis  -  all  organisms  associated  with  the  oropharynx.  Three 
episodes  involved  viridans  streptococci  and  coagulase-negative  staphylococci,  one 
of  which  will  be  investigated  further  in  Chapter  7. 
In  two  cases,  the  combination  of  S.  oralis  and  Enterococcus  spp.  was  isolated  from 
blood  cultures  of  patients  with  oral  compromise  and  diarrhoea,  suggesting  a 
common  source  in  the  oropharynx  or  gastro-intestinal  tract.  A  single  episode 
involved  the  combination  of  viridans  streptococci  and  Enterobacter  cloacae  -a 
coliform  most  commonly  associated  with  the  gastro-intestinal  tract,  but  also  isolated 
from  the  mouths  of  cancer  patients.  One  episode  involved  the  combination  of  S. 
oralis,  coagulase-negative  staphylococci  and  Bacillus  sp.  Bacillus  spp.  are  most 
commonly  found  in  the  environment  rather  than  colonizing  humans.  Repeat  blood 
cultures  from  the  patient  in  question,  again  yielded  this  organism,  excluding  the 
possibility  of  contamination.  It  is  possible  that  the  origin  of  infection  was  the  patient's 
Hickman  line. 
Two  episodes  involved  viridans  streptococci  and  Candida  spp.,  both  of  which  can  be 
found  in  the  oral  cavity  and  gastrointestinal  tract  of  cancer  patients.  Candida  spp. 
can  also  cause  line-associated  fungaemia  in  this  patient  group.  Another  episode 
featured  the  combination  of  Rhodotorula  rubra  and  S.  oralis  from  blood  culture.  The 
habitat  of  R.  rubra  is  most  often  the  environment. 
124 5.9  Viridans  streptococcal  bacteraemia  and  concomitant  viral  infection 
Concomitant  infection  with  viruses  occurred  in  6  episodes  (Table  5.4).  The 
respiratory  viruses,  Parainfluenza  virus  and  Influenza  A  virus  were  diagnosed  from 
nasopharyngeal  aspirates  (NPA)  by  rapid  immunofluorescence  assay.  Picorna  virus 
infection  was  diagnosed  from  NPA  by  PCR.  In  one  case,  oral  mucosal  infection  by 
Herpes  simplex  virus  typet  (HSV-1)  was  diagnosed  by  shell  vial  culture,  and  in 
another,  pulmonary  cytomegalovirus  (CMV)  infection  was  diagnosed  post-mortem. 
Table  5.4  Cases  of  concomitant  viral  infection  in  patients  with  viridans 
streptococcal  bacteraemia 
Patient  No.  Viral  infection 
1  Influenzae  A 
9  CMV 
19  Parainfluenzae 
41  Parainfluenzae 
52  HSV1 
54  Picorna 
5.10  Viridans  streptococcal  bacteraemia  and  concomitant  infection  with 
Pneumocystis  carinii 
One  episode  of  viridans  streptococcal  infection  occurred  in  a  patient  from  whom 
P.  carinii  was  also  detected  (by  immunofluorescence),  from  endo-tracheal  secretions 
(patient  No.  10). 
125 5.11  Patient  characteristics  and  clinical  features  of  infection 
5.11.1  Gender  and  age 
Thirty-two  boys  developed  viridans  streptococcal  bacteraemia  compared  with  22 
girls.  The  median  age  of  the  patients  was  6.5  years  (range  3  months  to  14  years). 
Male  and  female  age  distribution  graphs  (Figure  5.8)  indicate  that,  while  the  majority 
of  cases  of  viridans  streptococcal  bacteraemia  in  boys  occurred  between  the  ages  of 
1  and  3  years  (44%)  or  between  the  ages  of  10  and  14  (41  %),  a  more  even 
distribution  of  cases  with  age  was  observed  for  girls. 
Figure  5.8  Age  distribution  of  patients  developing  viridans  streptococcal 
bacteraemia 
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126 5.11.2  General  clinical  characteristics 
Only  one  patient  (proceeding  through  ALL  induction  therapy)  did  not  have  a  Hickman 
line.  Patients  were  receiving  or  recovering  from  chemotherapy  with  the  exception  of 
two.  In  the  first  of  these,  viridans  streptococcal  bacteraemia  with  concomitant 
candidaemia  occurred  in  a  febrile,  non-neutropenic  patient  several  weeks  after  the 
completion  of  a  block  of  chemotherapy.  In  the  second  (also  non-neutropenic 
patient),  an  assessment  pre-high  dose  chemotherapy  and  stem  cell  rescue  revealed 
viridans  streptococci  from  blood  cultured  from  Hickman  line  on  two  consecutive 
days.  This  finding  raised  the  possibility  of  line-associated  colonization. 
Unfortunately  peripheral  blood  specimens  could  not  be  obtained.  (This  particular 
case  will  be  discussed  further  in  Section  7.3.3.  ) 
Only  three  patients  were  not  neutropenic  at  the  time  of  development  of  viridans 
streptococcal  bacteraemia.  The  remaining  66  episodes  of  viridans  streptococcal 
bacteraemia  (96%  of  total  episodes)  occurred  in  neutropenic  patients  (neutrophil 
count  <  1.0  x  109/L). 
5.11.3  Clinical  features  associated  with  viridans  streptococcal  bacteraemia 
Fever  was  the  most  consistent  clinical  feature  of  viridans  streptococcal  bacteraemia 
(98.6%  of  episodes)  with  a  median  duration  of  fever  of  6  days  (range:  1  to  27  days). 
In  the  single  afebrile  episode  (to  be  discussed  in  Section  7.3.3),  viridans  streptococci 
were  isolated  from  two  sets  of  line  blood  cultures  taken  on  consecutive  days  from  a 
non-neutropenic  patient. 
Viridans  streptococcal  bacteraemia  occurred  after  a  median  duration  of  3  days  of 
neutropenia  (range:  1-  22  days).  Bacteraemia  was  associated  with  an  increase  in 
127 C-reactive  protein,  with  a  median  level  of  206  mg/L  (range:  20-480mg/L).  In  the 
majority  of  cases  (82%),  maximum  CRP  level  was  reached  within  3  days  of  positive 
blood  culture. 
In  22  cases  (32%),  a  maculo-papular  rash  developed,  however  drug  allergies  could 
not  be  excluded  as  the  cause.  In  48  cases  (70%  of  total),  patients  responded  to 
antimicrobial  therapy  without  developing  further  clinical  complications.  However,  in 
21  cases  (30%  of  total),  pulmonary  complications  developed,  with  8  of  these 
requiring  mechanical  ventilation  and  supplemental  oxygen.  Five  of  these  8  cases 
also  developed  septic  shock,  one  of  which  was  further  complicated  by  meningitis. 
Clinical  characteristics  associated  with  cases  with  respiratory  compromise  and  septic 
shock  will  be  discussed  further  in  Section  5.12.  Two  deaths  were  associated  with 
viridans  streptococcal  bacteraemia.  One  girl  died  of  the  severe  form  of  viridans 
streptococcal  bacteraemia  with  meningitis.  The  other,  who  had  a  history  of  recurrent 
chest  infections,  and  was  being.  treated  for  a  second  malignancy,  developed  ARDS 
and  septic  shock  and  died  a  few  hours  later  following  cardiopulmonary  arrest. 
Viridans  streptococcal  endocarditis  has  been  reported  as  a  complication  of 
bacteraemia  in  neutropenic  patients  by  other  investigators  (Elting,  Bodey  &  Keefe, 
1992;  Bochud  et  al.,  1994).  None  of  the  patients  in  the  present  study  developed  this 
condition.  Clinical  features  were  not  helpful  in  distinguishing  infections  caused  by 
one  species  of  viridans  streptococcus  from  those  caused  by  another. 
Figure  5.9  shows  the  spectrum  of  severity  of  symptoms  associated  with  viridans 
streptococcal  bacteraemia  in  the  patients  of  this  study. 
128 Figure  5.9  Episodes  of  viridans  streptococcal  bacteraemia  and  spectrum  of 
symptoms. 
70 
N  60 
a) 
ö  50 
U) 
ý  40 
°  30 
m E  20 
Z 
Z  10 
0 
5.11.4  Underlying  malignancies 
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Viridans  streptococcal  bacteraemia  occurred  more  commonly  in  children  suffering 
from  acute  leukaemia  than  in  those  with  other  malignancies  (Table  5.5).  The  median 
age  of  patients  with  ALL  (n  =  29)  was  6  years  (range:  1-  14  years)  and  for  those 
with  AML  (n  =  14)  was  10  years  (range:  3  months  -  14  years).  In  the  study 
population,  ALL  and  AML  were  both  more  common  in  boys  than  in  girls  (17  versus 
12  for  the  former  and  9  versus  5  for  the  latter). 
Although  there  were  approximately  twice  as  many  ALL  patients  with  viridans 
streptococcal  bacteraemia  as  AML  patients  (29  versus  14),  it  is  important  to 
acknowledge  that  the  latter  form  comprises  only  15-20%  of  all  childhood  acute 
Ieukaemias.  As  a  consequence,  viridans  streptococcal  bacteraemia  appears  to  be 
more  strongly  associated  with  AML  than  with  ALL.  However,  the  very  intensive 
therapy  for  AML,  more  than  the  disease  itself,  may  be  the  predisposing  factor  among 
this  group  of  patients  -  as  discussed  in  the  following  section. 
129 Table  5.5  Underlying  malignancies 
Malignancy  n  (%)  Male/female  ratio 
ALL  (5  Allo.  BMT)  29  (54)  17:  12 
AML  (1  Auto.  BMT)  14  (26)  9:  5 
CML  (1  Allo.  BMT)  1(2)  1:  0 
T  cell  lymphoma  2  (4)  1:  1 
B  cell  lymphoma  2  (4)  11 
Large  cell  anaplastic 
lymphoma 
1(2)  1:  0 
Rhabdomyosarcoma  2  (4)  0:  2 
Neuroblastoma  1(2)  1:  0 
Osteosarcoma  1  (2)  1:  0 
Wilms'  tumour  1  (2)  0:  1 
One  teenage  boy  (14  years)  developed  viridans  streptococcal  bacteraemia  post 
allogeneic  bone  marrow  transplantation  as  therapy  for  CML.  Five  patients  were 
being  treated  for  lymphoma  (3  boys  and  2  girls).  Two  girls  were  undergoing  therapy 
for  Rhabdomyosarcoma  and  one  for  Wilms'  tumour.  There  was  one  case  of 
Osteosarcoma  and  one  of  Neuroblastoma  (both  boys). 
5.11.5  Chemotherapeutic  protocols  and  bone  marrow  transplantation 
The  cytotoxic  chemotherapy  regimens  used  to  treat  the  above  malignancies  are 
listed  in  Table  5.6.  Full  details  of  the  individual  protocols  are  provided  in  Appendix  I. 
130 Table  5.6  Chemotherapeutic  protocols  and  bone  marrow  transplantation  prior  to 
the  development  of  viridans  streptococcal  bacteraemia 
Chemotherapy  Regimen 
Number  of  episodes  of 
viridans  streptococcal 
bacteraemia 
Induction  (ALL)  1 
DATES  11 
rd  Intensification  block  (ALL)  3 
Regimen  B  consolidation  (ALL)  1 
Relapse  protocol  (ALL)  4 
ADE  2 
MAE  4 
MACE  2 
MidAC  7 
FLAG  7 
CLASP  11 
Allogeneic  BMT  6 
Autologous  BMT  1 
CYT/ETOP  1 
COPADM2  1 
CYM  1 
OPEC  1 
CDDP  +  DOX  1 
H.  D.  Cyclophosphamide  (MMT 
98) 
1 
'mini'-  BEAM  1 
The  DATES  regimen  comprised  standard  consolidation  blocks  1  and  2  of  the  MRC 
protocols  for  treatment  of  childhood  ALL  until  the  end  of  1999.  As  ALL  is  the  most 
common  childhood  malignancy,  DATES  was  the  regimen  of  intensive  chemotherapy 
used  most  often  in  the  haematology/oncology  unit  during  the  course  of  this  study. 
From  the  beginning  of  December  1994  to  the  end  of  December  1999,  in  excess  of 
200  courses  of  this  form  of  chemotherapy  were  administered.  Viridans  streptococcal 
131 bacteraemia  developed  following  administration  of  11  courses  (Table  5.6).  This 
represented  <  5%  of  total  courses  of  the  DATES  regimen. 
Other  components  of  standard  therapy  for  ALL  which  featured  in  this  study,  were 
induction,  the  3rd  intensification  block  and  the  consolidation  phase  of  one  of  the 
more  recently  introduced  MRC  ALL  protocols  -  MRC  ALL  97  (modified  1999) 
Regimen  B  (introduced  at  RHSC  at  the  beginning  of  2000).  Induction  and 
consolidation  (B)  preceded  viridans  streptococcal  bacteraemia  on  one  occasion  only 
and  3rd  block  preceded  this  infection  three  times.  Four  episodes  of  viridans 
streptococcal  bacteraemia  were  associated  with  the  ALL  relapse  protocol. 
Standard  courses  of  induction  therapy  for  childhood  AML  generally  consist  of  ADE  or 
MAE.  Patients  who  have  completed  two  courses  of  induction  chemotherapy  and  are 
then  in  complete  remission,  generally  receive  one  course  of  MACE  consolidation 
chemotherapy.  For  patients  who  are  considered  good  risk,  a  second  course  of 
consolidation  chemotherapy,  usually  -  MidAC  is  administered,  to  complete  a  total 
treatment  course  of  4  blocks.  For  AML  patients  in  poorer  prognosis  categories,  who 
require  a  total  of  5  blocks  of  chemotherapy,  the  CLASP  regimen  may  also  be 
administered.  MidAC  and  CLASP  are  also  used  to  treat  some  cases  of  refractory 
ALL.  The  FLAG  regimen  may  be  used  for  therapy  of  acute  leukaemia,  when 
conventional  therapy  is  not  appropriate. 
Episodes  of  viridans  streptococcal  bacteraemia  occurred,  following  each  one  of  the 
above  courses  of  chemotherapy;  2  episodes  following  ADE,  4  following  MAE,  2 
following  MACE,  7  following  MidAC,  7  following  FLAG  and  11  following  CLASP. 
However,  to  determine  whether  there  is  an  association  between  viridans 
streptococcal  bacteraemia  and  one  of  these  chemotherapeutic  regimens,  the  total 
number  of  courses  of  each  chemotherapy  schedule  administered  to  all  patients 
132 receiving  'AML-type  therapy'  throughout  the  study  period  was  required.  The  ratio  of 
episodes  of  viridans  streptococci  to  total  courses  of  each  chemotherapeutic  regimen 
is  expressed  as  a  percentage  in  Figure  5.10.  The  number  of  courses  of  each 
regimen  administered  was  within  a  fairly  narrow  range  (22  -  34).  Viridans 
streptococcal  bacteraemia  occurred  after  9%  of  total  courses  of  ADE,  after  14%  of 
total  courses  of  MAE,  and  after  8%,  23%,  23%  and  32%  of  total  courses  of  MACE, 
MidAC,  FLAG  and  CLASP  respectively.  The  resulting  trend  (Figure  5.10)  indicates 
that  viridans  streptococcal  bacteraemia  occurred  more  often  after  therapy  with  high 
doses  of  cytosine  arabinoside  than  after  the  lower  dose  schedules  (See  Table  5.7  for 
cytosine  arabinoside  dose  per  regimen). 
Figure  5.10  Viridans  streptococcal  bacteraemia  following  individual  courses  of 
chemotherapy  for  AML  -  as  proportion  (%)  of  total  courses  of  each 
regimen  administered 
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133 Table  5.7  Chemotherapeutic  protocols  with  dose  of  cytosine  arabinoside 
Chemotherapy 
regimen 
Dose  of  cytosine 
arabinoside 
ADE  100  mg/m2,12-hourly 
MAE  100  Mg/M2,12-hourly 
MACE  200  mg/m  , 
daily 
MidAC  1.0  g/m  , 
12-hourly 
('intermediate-high  dose') 
FLAG  2.0  g/m2,  daily 
('intermediate-high  dose') 
CLASP  3.0  g/m  , 
12-hourly 
(`hi  h-dose') 
It  has  been  proposed  previously  that  there  is  a  relationship  between  the  use  of  high- 
doses  of  this  agent  and  the  incidence  of  viridans  streptococcal  bacteraemia  (Bochud 
et  al.,  1994;  Richard  et  a!.,  1995).  The  regression  analysis  of  Figure  5.11 
demonstrates  the  influence  of  increasing  doses  of  cytosine  arabinoside  on  frequency 
of  viridans  streptococcal  bacteraemia. 
Figure  5.11  Regression  analysis  of  dose  of  cytosine  arabinoside  and  viridans 
streptococcal  bacteraemia 
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134 The  development  of  viridans  streptococcal  bacteraemia  was  less  common  following 
chemotherapy  for  solid  tumours.  One  episode  of  infection  occurred  following  each  of 
CYT/ETOP,  COPADM2,  CYM,  OPEC,  CDDP  +  DOX,  high-dose  cyclophosphamide 
(MMT  `98)  and  `mini'-  BEAM. 
Seven  episodes  of  viridans  streptococcal  bacteraemia  followed  bone  marrow 
transplantation,  predominantly  in  recipients  of  allogeneic  rather  than  autologous 
transplants  (6  versus  1).  The  ratio  of  episodes  of  viridans  streptococcal  bacteraemia 
to  total  transplants  performed  throughout  the  study  period  were  12.5%  (6/48) 
following  allogeneic  transplantation  and  9.1%  (1/11)  following  autologous 
transplantation.  Of  the  allogeneic  transplants,  viridans  streptococcal  bacteraemia 
was  more  common  following  transplantation  using  a  matched  unrelated  donor  (16% 
of  a  total  of  25),  than  following  transplantation  using  marrow  from  a  sibling  donor 
(8.7%  of  a  total  of  23). 
5.11.6  Adverse  effects  of  cytotoxic  chemotherapy 
Adverse  effects  of  chemotherapeutic  agents,  such  as  neutropenia  and  mucositis 
have  been  described  previously  in  Sections  2.3.1.2  and  2.3.4.  Ninety-six  percent  of 
the  episodes  of  viridans  streptococcal  bacteraemia  in  this  study  were  associated  with 
neutropenia.  Apart  from  mucositis,  cytotoxic  chemotherapy  can  cause  other  forms  of 
oral  compromise,  such  as  gingivitis  and  pharyngitis.  These  symptoms  were  also 
monitored  and  recorded,  as  were  other  oral  complications,  such  as  dental  or 
mucosal  infection,  which  could  conceivably  contribute  to  the  development  of  viridans 
streptococcal  bacteraemia  (Table  5.8). 
Classical  chemotherapy-induced  mucositis  was  associated  with  33  episodes  i.  e. 
48%  of  total  episodes.  (Severe  mucositis  was  associated  with  7  episodes,  moderate 
135 mucositis  with  14  and  mild  mucositis  with  12.  )  However  if  the  other  clinical  features 
of  Table  5.8  are  included,  oral  complications  were  associated  with  45  episodes  (65% 
of  total). 
Table  5.8  Oral  compromise  and  episodes  of  viridans  streptococcal  bacteraemia 
Oral  compromise  Description  No.  of  episodes  (%  of 
total  episodes) 
Mucositis  Inflammation  +/-  33  (48) 
ulceration  of  oral 
mucosa 
Gingivitis  Inflammation  of  the  6  (9) 
gingivae  +/- 
spontaneous  gingival 
bleeding 
Bleeding  Lips  -  4  (6) 
Pharyngitis  -  2  (3) 
Caries  -  2  (3) 
Oozing  sockets  -  following  tooth  3  (4) 
extraction 
Loose  teeth  -  1  (1) 
'Teething'  -  1  (1) 
Candidiasis  Clinical  oral  thrush  6  (9) 
with  isolation  of 
Candida  spp  from 
culture. 
Herpes  simplex  Infection  Ulceration,  with  HSV  1  (1) 
isolated  from  viral 
culture 
Chemotherapy-induced  damage  to  gastro-intestinal  mucosal  barriers  is  more  difficult 
to  monitor.  Symptoms  include  vomiting,  abdominal  pain  and  diarrhoea,  sometimes 
accompanied  by  bleeding.  Obviously,  infection  has  to  be  excluded  as  a  cause  of 
diarrhoea.  Symptoms,  which  may  have  been  related  to  intestinal  mucosal  injury 
were  associated  with  32  episodes  of  viridans  streptococcal  bacteraemia  (Table  5.9). 
136 In  total,  84%  (58/69)  of  episodes  were  associated  with  one  or  more  signs  of  oral 
compromise  +/-  gut  mucosal  damage. 
Table  5.9  Gastro-intestinal  symptoms  of  patients  with  episodes  of  viridans 
streptococcal  bacteraemia 
Symptom  No.  of  episodes 
(%  of  total  episodes) 
Diarrhoea  29  (42) 
G.  I.  bleeding  2  (3) 
Rectal  mucositis  1  (1) 
In  addition  to  producing  profound  and  protracted  neutropenia  with  severe  mucositis, 
high-dose  cytosine  arabinoside  can  also  produce  pulmonary  toxic  effects  which  have 
been  associated  with  the  development  of  ARDS  in  neutropenic  patients  with  viridans 
streptococcal  bacteraemia.  The  association  of  this  agent  with  respiratory 
complications  and  the  severe  form  of  viridans  streptococcal  sepsis  in  the  patients  of 
the  present  study  will  be  examined  further  in  Sections  5.12.3  and  5.12.5. 
It  should  also  be  acknowledged  that  the  severity  of  adverse  effects  associated  with 
chemotherapy,  and  consequently  the  contribution  to  infectious  risk,  may  also  depend 
on  the  combined  effects  of  the  different  drugs  employed  in  the  same  protocol. 
Daunorubicin,  Mitozantrone  and  Amsacrine  (Appendix  I),  which  feature  in  some  of 
the  regimens  of  Table  5.7,  also  produce  the  adverse  effects  of  neutropenia  and 
mucositis. 
137 5.11.7  Antibiotic  prophylaxis  and  empirical  therapy 
Patients  with  viridans  streptococcal  bacteraemia  who  had  received  conventional 
cytotoxic  chemotherapy  for  leukaemia  and  the  two  patients  with  T-cell  lymphoma 
received  cotrimoxazole  prophylaxis  as  per  protocol.  Bone  marrow  transplantation 
patients  also  received  cotrimoxazole  prophylaxis  -  from  Day  -8  to  Day  -1,  and  post 
transplantation  once  neutrophil  counts  >  0.5  x  1091L.  The  remaining  patients  with 
viridans  streptococcal  bacteraemia  did  not  receive  antibiotic  prophylaxis. 
Empirical  therapy  for  episodes  of  febrile  neutropenia  consisted  of  aß  -lactam 
antibiotic  plus  an  aminoglycoside  throughout  the  period  of  this  study.  Until  summer 
of  1996  this  comprised  ceftazidime  plus  amikacin.  After  this  time  the  combination  of 
piperacillin/tazobactam  plus  amikacin  was  used.  Patient  number  23  (Table  5.1)  was 
the  first  to  receive  the  new  combination.  Vancomycin  was  used  as  second-line 
empirical  therapy  throughout.  This  antibiotic  was  also  added  to  first-line  therapy  for 
cases  of  viridans  streptococcal  bacteraemia  if  clinical  response  was  sub-optimal 
and/or  in  cases  of  in  vitro  resistance  to  first-line  antibiotics.  Findings  from  this 
investigation  in  terms  of  the  antimicrobial  susceptibility  of  viridans  streptococcal 
isolates  will  be  presented  in  Chapter  6. 
5.12  Investigation  of  episodes  of  viridans  streptococcal  bacteraemia  with 
accompanying  respiratory  complications  +/-  septic  shock 
The  uncommon,  but  severe  form  of  viridans  streptococcal  sepsis  has  been  termed 
`viridans  streptococcal  shock  syndrome'  (Steiner  et  a!.,  1993),  and  may  result  in 
severe  hypotension  requiring  intravascular  expansion  and/or  vasopressor  support. 
Acute  respiratory  distress  is  usually  an  accompanying  feature  -  described  as 
138 respiratory  insufficiency  with  diffuse  bilateral  pulmonary  infiltrates  on  chest 
radiography  necessitating  oxygen  supplementation  and  ventilation. 
However,  there  is  a  group  of  patients  with  viridans  streptococcal  bacteraemia  who 
neither  develop  septic  shock  nor  require  mechanical  ventilation,  but  do  exhibit  some 
degree  of  respiratory  distress  requiring  supplemental  oxygen  (Figure  5.9).  This 
particular  group  has  been  studied  to  a  lesser  extent  in  the  past.  The  present  study 
sought  to  investigate  why  there  is  such  a  spectrum  of  severity  of  clinical  symptoms 
associated  with  viridans  streptococcal  bacteraemia  and  included  patients  with  mild  to 
severe  pulmonary  complications.  Previously  proposed  risk  factors  will  be  considered, 
but  the  effect  of  other  possible  contributory  factors  will  also  be  explored. 
5.12.1  Respiratory  complications  associated  with  viridans  streptococcal 
bacteraemia 
Some  form  of  respiratory  distress  was  associated  temporally  with  21  episodes  of 
viridans  streptococcal  bacteraemia,  (21/69  =30%  of  total  episodes).  These 
symptoms  varied  from  an  increased  respiratory  rate  with  the  requirement  of  1  litre  of 
supplemental  oxygen,  to  ARDS  requiring  mechanical  ventilation.  It  is  difficult  to 
separate  the  range  of  symptoms  into  specific  categories  of  severity,  however  cases 
were  divided  into  three  fairly  broad  groups  according  to  the  definitions  of  Sections 
4.1.3  and  4.1.4.  Mild  respiratory  symptoms  were  associated  with  10  episodes, 
moderate  with  3  and  severe  with  8.  (One  case  with  severe  respiratory  distress  also 
featured  cardiomyopathy  and  thus  did  not  satisfy  the  definition  of  ARDS.  )  Patient 
demograhics  and  respiratory  complications  are  presented  in  Table  5.10. 
139 Table  5.10  Viridans  streptococcal  bacteraemia  and  respiratory  complications 
following  chemotherapy 
Patient  Underlying  Chemotherapy  Severity  of  Additional  factors 
Number  malignancy  regimen  prior  to  respiratory 
(Gender,  episode  of  complications 
Age)  bacteraemia 
1  AML  ADE  +++  (ARDS)  Septic  shock. 
(F,  3  months)  Immaturity  of  lungs 
1  CLASP  +++  (ARDS)  Septic  shock 
F,  6  months 
1  MACE  +  -  F,  11  months 
1  Auto.  BMT  +  Influenza  A  virus 
(F,  1  year)  infection 
5  AML  CLASP  +++  (ARDS)  -  M,  2  years) 
8  AML  MidAC  +  - 
F,  12  ears 
ALL  CLASP  +++  (ARDS)  Septic  shock, 
9  meningitis, 
(F,  5  years)  Pulmonary  CMV 
infection 
10  B-cell  CYT/ETOP  +++  (ARDS)  Septic  shock, 
(F,  6  years)  Lymphoma  P.  carinii  infection 
11  AML  CLASP  +  - 
(F,  14  years) 
AML  ADE  +++  (ARDS)  Septic  shock. 
12  Recurrent  chest 
(F,  11  years)  infections.  2nd 
malignancy. 
13  ALL  Allo.  (sibling)  +  - 
(M,  3  years)  BMT 
16  T-cell  CLASP  ++  - 
(M,  14  years)  lymphoma 
18  ALL  Block  ++  - 
(M,  3  years) 
19  ALL  MidAC  +  Parainfluenza  virus 
(M,  1  year) 
infection 
29  ALL  FLAG  +  - 
(M,  1  year) 
32  AML  MidAC  +  - 
(M,  12  years) 
39  AML  MidAC  +++  Cardiomyopathy 
(M,  14  years) 
43  ALL  DATES  +  - 
(F,  3  years) 
44  AML  CLASP  +  - 
(M,  2  years) 
51  Rhabdo-  High-dose  cyclo-  ++  - 
(F,  14  years)  myosarcoma  phosphamide 
LCAL  'Mini'-BEAM  +++  (ARDS)  Probable  infiltration 
54 
of  lymphoma. 
Picorna  virus 
(M,  6  years)  infection 
M'  Male,  F:  Female 
140 Eight  girls  and  ten  boys  developed  some  degree  of  respiratory  compromise  shortly 
after  the  development  of  viridans  streptococcal  bacteraemia  (Table  5.10).  Their 
ages  ranged  from  3  months  to  14  years  (with  a  median  age  of  5  years). 
Malignancies  comprised  AML  (11  episodes,  8  patients),  ALL  (6  episodes),  B-cell 
lymphoma  (1  episode),  T-cell  lymphoma  (1  episode),  large  cell  anaplastic  lymphoma 
(1  episode)  and  rhabdomyosarcoma  (1  episode).  All  patients  were  neutropenic.  In 
19  cases  (90%)  there  was  evidence  of  chemotherapy  -  induced  oral  compromise  or 
possible  gastro-intestinal  toxicity.  Of  these,  4  episodes  were  associated  with 
evidence  of  mild  oral  mucositis,  4  with  moderate  mucositis  and  2  with  severe 
mucositis.  Five  patients  developed  septic  shock  (Table  5.10). 
Of  the  total  episodes  with  respiratory  complications  (21),  a  single  strain  of  S.  oralis 
was  cultured  from  blood  in  14  (67%)  and  S.  mitis  from  5  (24%)  (Table  5.11).  In  one 
case,  2  different  strains  of  S.  mitis  were  isolated  and  in  one,  2  strains  of  S.  oralis  and 
1  strain  of  S.  mitis  were  involved.  Overall,  S.  oralis  represented  67%  of  total  isolates 
of  viridans  streptococci  associated  with  respiratory  complications,  while  S.  mitis 
represented  33%.  In  common  with  its  predominance  amongst  total  blood  culture 
isolates  (63%),  S.  oralis  was  the  species  most  often  associated  with  patients  with 
respiratory  compromise. 
Table  5.11  Species  of  viridans  streptococci  from  blood  culture  of  patients  with 
bacteraemia  and  respiratory  complications 
Species  No.  of  episodes  (%  of  total 
episodes  with  respiratory 
symptoms)  n=  21 
S.  oralis  (single  strain)  14  (67%) 
S.  mitis  (single  strain)  5  (24%) 
Multiple  strains  or  species  2(9%) 
((a)  S.  mitis  -2  strains 
(b)  S.  oralis  (2  strains)  +  S.  mitis) 
141 On  two  occasions,  blood  cultures  yielding  organisms  of  different  genera  were 
associated  with  episodes  of  bacteraemia  with  respiratory  complications.  These 
represented  12.5%  of  all  polymicrobial  blood  cultures.  From  one  patient  (No.  10),  S. 
oralis  and  Enterococcus  faecalis  were  isolated,  and  from  the  other  (No.  18)  S.  oralis 
(2  strains),  S.  mitis,  Haemophilus  parainfluenza  and  Moraxella  catarrhalis  were 
isolated.  Both  patients  suffered  from  oral  mucositis  and  diarrhoea. 
5.12.2  Viruses,  Pneumocystis  carinii,  respiratory  complications  and  viridans 
streptococcal  bacteraemia 
In  four  of  the  five  cases  of  viridans  streptococcal  bacteraemia  with  concomitant 
respiratory  viral  infection  some  form  of  respiratory  distress  (2  ARDS,  1  moderate  and 
1  mild)  developed  -  as  presented  in  Table  5.10.  Patient  No.  10,  with  viridans 
streptococcal  bacteraemia  and  P.  carinii  infection  developed  ARDS. 
PCR-based  detection  of  respiratory  viruses  was  not  available  as  a  routine  diagnostic 
service  until  late  2000,  therefore  prior  to  this,  some  patients  may  have  been  infected 
by  respiratory  viruses  not  detectable  by  immunofluorescence  alone. 
5.12.3  Chemotherapeutic  regimens  and  respiratory  symptoms 
Respiratory  complications  were  associated  temporally  with  six  of  the  eleven 
episodes  of  viridans  streptococcal  bacteraemia  following  the  CLASP  regimen  (54%). 
In  three  of  these  episodes,  patients'  clinical  symptoms  and  radiographic  findings 
were  consistent  with  ARDS,  and  mechanical  ventilation  and  supplemental  oxygen 
were  required.  CMV  pulmonary  infection  also  occurred  in  one  of  the  episodes  with 
ARDS.  This  was  diagnosed  post-mortem.  The  remaining  three  patients  suffered 
from  less  severe  respiratory  complications,  but  required  supplemental  oxygen. 
(Table  5.12). 
142 Table  5.12  Respiratory  complications  following  chemotherapy 
Chemotherapy  regimen 
administered  prior  to 
episode  of  infection 
No.  of  cases  with 
respiratory 
complications 
Severity  of 
respiratory 
symptoms  (No.  of 
episodes) 
CLASP  6  +++  (x  3)  (ARDS) 
++  (x  1) 
+  x2 
MidAC  4  +++  (x  1) 
+  x3 
ADE  2  +++  (x  2)  (ARDS) 
FLAG  1  + 
MACE  1  + 
DATES  1  + 
3rd  Block  1  ++ 
H.  D.  cyclophosphamide  1  ++ 
Mini-BEAM  1  +++  (ARDS) 
CYT/ETOP  1  +++  (ARDS) 
Sibling  BMT  1  + 
Auto  BMT  1  + 
*:  Associated  with  cardiomyopathy 
Four  of  the  seven  episodes  of  viridans  streptococcal  bacteraemia  following  MidAC 
chemotherapy  (57%)  were  associated  with  respiratory  complications  -1  with  severe 
symptoms  (associated,  in  part,  with  cardiomyopathy)  and  3  with  milder  symptoms 
(Table  5.12).  One  of  the  milder  cases  also  featured  infection  by  parainfluenza  virus 
(Table  5.10).  Two  cases  of  ARDS  occurred  following  ADE  chemotherapy. 
The  remaining  courses  of  chemotherapy  preceding  single  episodes  with  respiratory 
complications  were  FLAG,  MACE,  DATES,  3rd  Intensification  block  (for  ALL), 
CYT/ETOP,  high-dose  cyclophosphamide  and  'mini'-BEAM  (Table  5.12).  Two  cases 
of  mild  respiratory  symptoms  occurred  following  bone  marrow  transplantation. 
143 Several  of  the  chemotherapy  regimens  of  Table  5.12  contain  agents  with  side  effects 
which  include  pulmonary  toxicity  (e.  g.  high-dose  cytosine  arabinoside,  high-dose 
cyclophosphamide  and  BCNU  (in  BEAM  chemotherapy). 
One  child  (patient  No.  1)  developed  respiratory  complications  associated  with  four 
different  episodes  of  viridans  streptococcal  bacteraemia.  This  patient  was  3  months 
old  when  she  received  her  first  course  of  chemotherapy  (ADE)  for  AML.  Following 
this  course,  and  following  the  subsequent  one  (CLASP  -3  months  later),  she 
developed  ARDS  and  septic  shock.  After  a  further  course  (MACE)  at  11  months  of 
age  and  following  autologous  bone  marrow  transplantation  at  14  months,  she  again 
developed  respiratory  complications,  but  of  a  milder  nature  on  both  of  these 
occasions.  The  combination  of  lung  immaturity  in  this  infant,  drug  toxicity  and  severe 
sepsis  may  all  have  contributed  to  such  marked  respiratory  problems.  The  final 
patient  of  this  study,  a  five-year  old  boy  receiving  treatment  for  large  cell  anaplastic 
lymphoma  developed  severe  respiratory  failure  with  clinical  features  and  chest  X-ray 
findings  consistent  with  ARDS.  In  addition  to  viridans  streptococcal  bacteraemia, 
this  child  had  concomitant  picorna  virus  infection,  which  although  not  usually 
associated  with  lower  respiratory  tract  symptoms,  may  have  played  a  minor  part.  A 
major  complicating  factor  was  probable  pulmonary  relapse  of  lymphoma,  which  may 
be  indistinguishable  from  other  causes  of  ARDS  on  radiography. 
5.12.4  Viridans  streptococcal  bacteraemia  and  septic  shock 
Five  episodes  of  viridans  streptococcal  bacteraemia  (in  4  patients)  were  associated 
with  the  development  of  septic  shock  (Table  5.13).  All  four  patients  were  female  and 
their  ages  ranged  from  3  months  to  11  years.  One  patient  (No.  1)  developed  two 
episodes  of  septic  shock.  Two  were  receiving  therapy  for  AML  and  one  for  ALL 
(which  was  refractory  to  conventional  chemotherapy).  The  fourth  patient  was  being 
144 treated  for  disseminated  B-cell  lymphoma  with  central  nervous  system  involvement. 
All  suffered  from  oral  mucositis  (mild  symptoms  associated  with  two  episodes, 
moderate  symptoms  with  two  and  severe  symptoms  with  one),  with  probable 
gastrointestinal  involvement  and  all  were  profoundly  neutropenic  when  viridans 
streptococcal  bacteraemia  occurred.  One  child  (patient  No.  9)  also  developed 
viridans  streptococcal  meningitis.  All  received  ITU  support  and  monitoring,  but  in 
spite  of  this  two  died  (patients  9  and  12). 
Table  5.13  Episodes  of  viridans  streptococcal  bacteraemia  with  septic  shock 
Patient  Malignancy  Chemotherapy  Mucosal  Additional  Additional 
No.  (Age)  damage  symptoms  factors 
1  AML  ADE  Mild  ARDS  Immaturity  of 
1St  episode  lungs. 
(3  months) 
1  AML  CLASP  Mild  ARDS 
2nd  episode  It 
(6  months) 
9  ALL  CLASP  Severe  ARDS  CMV 
(5  years)  Meningitis  pulmonary 
infection 
10  B-cell  CYT/ETOP  Moderate  ARDS  P.  carinii 
(6  years)  lymphoma  infection. 
12  AML  ADE  Moderate  ARDS  Recurrent 
(11  years)  chest 
infections. 
2nd 
malignancy. 
The  species  isolated  from  blood  culture  in  all  five  episodes  of  septic  shock,  was  S. 
oralis.  As  discussed  in  Section  5.8,  one  of  the  cases  of  septic  shock  (patient  No.  10) 
was  associated  with  the  isolation  of  S.  oralis  plus  E.  faecalis  from  blood  culture.  E. 
faecalis  is  rarely  associated  with  the  development  of  severe  sepsis.  Even  in 
immunocompromised  patients,  E.  faecalis  bacteraemia  generally  runs  a  fairly  benign 
course. 
145 5.12.5  Chemotherapeutic  regimens  and  viridans  streptococcal  septic  shock 
Following  the  CLASP  regimen,  two  episodes  of  viridans  streptococcal  bacteraemia 
progressed  to  septic  shock  with  ARDS.  The  other  courses  of  chemotherapy 
associated  with  the  combination  of  these  symptoms  were  ADE  in  2  cases,  and 
CYT/ETOP  in  the  other  (Table  5.13).  Pulmonary  toxicity  associated  with  the 
administration  of  cytosine  arabinoside  in  these  cases  may  have  directly  contributed 
to  the  development  of  ARDS,  however  cytokine  mediated  respiratory  compromise 
may  also  have  resulted  as  a  consequence  of  septic  shock.  All  of  these  patients 
suffered  from  oral  mucositis  and  possible  gastrointestinal  mucositis  (all  suffered  from 
diarrhoea)  therefore  if  a  particularly  high  bacterial  load  of  viridans  streptococci 
accessed  the  blood  stream,  this  may  have  elicited  the  release  of  sufficient  cytokines 
to  cause  septic  shock  and  to  trigger  the  development  of  ARDS. 
5.13  Summary 
Episodes  of  viridans  streptococcal  bacteraemia  decreased  in  frequency  over  the 
period  of  this  study,  from  22%  of  all  microbiologically  documented  episodes  of 
bloodstream  infection  in  1994  to  4%  in  2000  (P  <  0.001).  In  1994,  viridans 
streptococcal  bacteraemia  was  associated  with  5.9%  of  all  febrile  episodes 
compared  with  1.2%  in  2000  (P  <  0.001).  S.  oralis  was  the  species  of  viridans 
streptococcus  most  commonly  isolated  from  blood  culture  (63%  of  total  isolates  of 
viridans  streptococci).  S.  mitis  represented  25%  of  total  isolates.  Polymicrobial 
bloodstream  infection  occurred  in  23%  of  episodes,  however  the  combination  of 
viridans  streptococci  plus  other  micro-organisms  was  not  significantly  associated 
with  inferior  outcome. 
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develop  viridans  streptococcal  bacteraemia,  than  those  with  solid  tumours.  Some 
form  of  oral  compromise  +/-  possible  gastrointestinal  mucositis  was  associated  with 
58  episodes.  In  48  cases,  (70%  of  total),  patients  responded  readily  to  antimicrobial 
therapy  without  developing  further  clinical  complications.  Mild  to  severe  respiratory 
complications  were  associated  with  the  remainder,  with  mechanical  ventilation  and 
supplemental  oxygen  required  in  eight  episodes.  Five  of  these  also  featured  septic 
shock.  S.  oralis  again  predominated  in  cases  of  bacteraemia  with  respiratory 
complications  (67%)  and  was  the  species  isolated  from  blood  culture  of  all  5  patients 
with  septic  shock. 
Viridans  streptococcal  bacteraemia  was  associated  with  cytotoxic  chemotherapy 
regimens  containing  high  doses  of  cytosine  arabinoside,  particularly  the  CLASP 
regimen;  32%  of  all  courses  administered  during  the  study  period  (11/34)  preceded 
this  infection.  This  pattern  is  consistent  with  the  proposal  by  other  investigators  that 
intensive  chemotherapy  with  high-dose  cytosine  arabinoside,  used  particularly  in  the 
therapy  of  AML,  predisposes  to  viridans  streptococcal  bacteraemia.  CLASP 
chemotherapy  was  also  associated  with  the  development  of  respiratory 
complications  in  6  of  the  11  cases  mentioned  above  (54%),  with  2  of  these  also 
developing  septic  shock. 
Concomitant  infection  with  respiratory  viruses  or  P.  carinii,  occurred  in  6  cases  of 
viridans  streptococcal  bacteraemia  (9%  of  total  cases)  and  5  of  these  exhibited 
respiratory  complications,  with  3  progressing  to  ARDS. 
These  findings  indicate  that  the  aetiology  of  complications  associated  with  viridans 
streptococcal  bacteraemia  is  complex  and  may  be  multifactorial  -  with  sepsis,  toxicity 
of  chemotherapeutic  agents,  and  concomitant  viral  infections  playing  a  part. 
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6.1  Introduction 
Viridans  streptococci  were  traditionally  regarded  as  being  almost  uniformly 
susceptible  to  penicillin  and  a  wide  variety  of  other  antibiotics.  At  the 
commencement  of  the  present  study  (late  1994),  a  limited  number  of  reports  of 
reduced  susceptibility  or  resistance  amongst  these  organisms  existed  in  the 
literature  (Krumweide,  1949;  Sprunt,  Redman  &  Leidy,  1968;  Phillips  et  al.,  1976; 
Southall  et  al.,  1983;  Woodman  et  al.,  1985;  Kern,  Linzmeier  &  Kurle,  1989; 
Potgieter  et  al.,  1992;  McWhinney  et  al.,  1993;  Bochud  et  al.,  1994;  Guiot,  Corel  & 
Vossen,  1994).  Today,  resistance  rates  to  penicillins  are  generally  higher,  with  some 
strains  also  resistant  to  cephalosporins,  tetracyclines,  macrolides,  quinolones, 
chloramphenicol  and  cotrimoxazole.  The  emergence  of  resistance  to  multiple 
antibiotics  has  complicated  the  therapy  of  infection  by  viridans  streptococci, 
particularly  in  the  immunocompromised  host. 
This  study  examined  the  in  vitro  activity  of  several  antibiotics,  including  those 
commonly  used  for  empirical  therapy  of  febrile  neutropenia  and  newer  agents  which 
may  be  useful  in  the  future.  In  the  first  category,  the  antibiotics  chosen  were  the 
broad-spectrum,  0  -lactam  agents,  ceftazidime,  piperacillin/tazobactam  and 
meropenem.  Susceptibility  to  vancomycin  was  also  investigated,  as  this  antibiotic  is 
often  used  to  treat  infection  by  various  Gram-positive  bacteria  causing  bacteraemia 
in  neutropenic  patients.  Two  of  the  older  ß  -Iactam  agents,  penicillin,  and  the  first 
generation  cephalosporin,  cefaclor  were  also  included,  for  comparison  with  the 
newer,  broader  spectrum  agents.  More  recently  introduced  antimicrobials  which 
were  tested,  comprised  the  fourth  generation  cephalosporin,  cefpirome  and  two 
agents  reported  to  have  particularly  good  activity  against  multiply-resistant  Gram- 
149 positive  bacteria  -  quinupristin/dalfopristin  and  linezolid.  Susceptibility  of  the  isolates 
of  viridans  streptococci  to  cotrimoxazole  was  also  determined  as  the  majority  of 
patients  (85%)  received  this  agent  as  prophylaxis  against  P.  carinii  pneumonia. 
An  investigation  into  species-specific  susceptibility  was  performed,  in  an  attempt  to 
establish  whether  S.  oralis  and  S.  mitis  differed  significantly  in  antibiotic  susceptibility 
patterns. 
Results  of  both  MIC  methods  and  disc  methods  were  compared  for  all  isolates  of 
viridans  streptococci  from  blood  cultures  and  interpretative  aspects  of  these  tests  are 
discussed. 
Antibiotic  susceptibility  of  endogenous  flora  can  be  influenced  by  prior  antimicrobial 
therapy.  As  many  immunocompromised  patients  require  several  courses  of 
antibiotics  to  treat  different  episodes  of  febrile  neutropenia,  the  potential  exists  for 
selection  of  resistant  strains.  This  study  investigated  the  antimicrobial  susceptibility 
of  viridans  streptococci  isolated  from  blood  culture  while  empirical  therapy  at  RHSC 
was  ceftazidime  plus  amikacin  and  compared  this  with  the  susceptibility  of  viridans 
streptococci  isolated  from  blood  culture  after  a  change  to  piperacillin/tazobactam 
plus  amikacin.  The  majority  of  patients  from  both  time  intervals  had  been  exposed  to 
prior  empirical  therapy. 
Based  on  the  observation  that  both  the  prevalence  of  and  the  severity  of  symptoms 
associated  with  viridans  streptococcal  bacteraemia  decreased  after  the  change  in 
empirical  therapy  (Chapter  5),  a  further  study  attempted  to  determine  whether 
resistance  to  antibiotics  used  as  empirical  therapy  might  influence  clinical  course  of 
infection. 
150 6.2  Susceptibility  of  76  isolates  of  viridans  streptococci  to  six  antibiotics 
Antibiotic  susceptibilities  of  all  isolates  of  viridans  streptococci  from  blood  cultures 
were  determined  as  described  in  Chapter  4  and  the  results  presented  in  Table  6.1. 
Table  6.1  MICs  of  six  antibiotics  against  76  isolates  of  viridans  streptococci 
Antibiotic  Cumulative  %  of  strain 
0.064  0.125  0.25  0.5 
s  with  stated  MIC  (mg/L) 
1248  16  32  64  128  >256 
Ceftazidime  0  9  18  20  40  46  51  57  63  78  87  96  100 
Piperacillin/ 
tazobactam 
20  28  36  42  49  53  60  83  97  100  --- 
Meropenem  42  53  62  83  100  -  -  -  ----- 
Penicillin  33  42  47  51  60  75  95  100  ----- 
Cefaclor  0  0  3  8  25  37  42  46  50  50  53  55  100 
Vancomycin  0  0  0  17  97  100  -  -  ----- 
The  results  indicated  that  of  the  ß  -lactam  antibiotics,  meropenem  had  the  greatest  in- 
vitro  activity,  with  an  MIC50  of  0.125  mg/L  and  MIC90  of  1.0  mg/L.  Vancomycin  also 
showed  considerable  activity,  over  a  narrow  range,  with  both  MIC50  and  MIC90  of  1.0 
mg/L.  MICs  of  penicillin  and  piperacillin/  tazobactam  covered  a  wider  range  -  from 
0.064  -  8.0  mg/L  and  0.064-32  mg/L  respectively,  with  MIC50  of  0.5  mg/L  and  MICgo 
of  4  mg/L  for  the  former  and  MIC50  of  2.0  mg/L  and  MIC90  of  16  mg/L  for  the  latter. 
Of  all  antibiotics  tested,  the  two  cephalosporins  demonstrated  the  poorest  activity 
against  viridans  streptococci.  MIC50  and  MIC90  results  for  ceftazidime  were  4  mg/L 
and  128  mg/L  respectively,  while  those  for  cefaclor  were  16  mg/L  and  >  256  mg/L. 
MIC  distributions  for  the  above  antibiotics  against  viridans  streptococci  are  presented 
graphically  in  Figure  6.1. 
151 Figure  6.1  Distribution  of  MIC  values  for  six  antibiotics  against  76  isolates  of 
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1248  16  32  64  128  256 
MIC  (mg/L) The  MIC  results  for  penicillin,  piperacillin/tazobactam  and  meropenem  against 
viridans  streptococci  followed  a  bimodal  distribution  -  with  one  of  the  two  populations 
of  organisms  exhibiting  greater  susceptibility  than  the  other.  For  ceftazidime  and 
cefaclor,  MIC  values  were  generally  more  dispersed  over  a  wider  range  of 
concentrations.  In  contrast,  for  vancomycin  a  normal  distribution  over  a  narrow  range 
was  observed. 
Geometric  means  MICs  for  each  antibiotic  were  calculated  and  are  presented  in 
Table  6.2. 
Table  6.2  Geometric  mean  MICs  of  six  antibiotics  against  76  isolates  of  viridans 
streptococci 
Antibiotic  Geometric  mean  MIC  (mg/L) 
Ceftazidime  5.1 
Piperacillin/tazobactam  1.3 
Meropenem  0.2 
Penicillin  0.5 
Cefaclor  19.9 
Vancomycin  0.9 
The  geometric  mean  MIC  results  again  indicated  that  amongst  these  six  antibiotics 
there  was  a  wide  range  of  activity  against  viridans  streptococci.  Meropenem,  the 
most  active  0  -lactam  agent  against  viridans  streptococci  in  vitro,  had  a  geometric 
mean  MIC  of  0.2  mg/L,  while  that  of  cefaclor,  the  least  active  agent  was  19.9  mg/L. 
The  geometric  mean  MIC  of  vancomycin  was  0.9  mg/L,  consistent  with  its  high 
activity  against  viridans  streptococci. 
153 6.3  Comparative  susceptibilities  of  S.  oralis  and  S.  mitis  to  six  antibiotics 
It  was  important  to  determine  whether  certain  species  of  viridans  streptococci  are 
generally  more  resistant  to  antibiotics  than  others.  If  this  were  the  case,  rapid 
identification  could  guide  antimicrobial  therapy  -  even  before  in  vitro  susceptibility 
results  were  available.  MIC  distributions  were  analysed  for  all  isolates  of  S.  oralis 
(n=48)  from  the  present  study  and  were  compared  with  those  for  all  isolates  of  S. 
mitis  (n=19).  There  were  too  few  isolates  of  S.  sanguis,  S.  parasanguis,  S.  salivarius 
and  S.  gordonii  for  inclusion  in  this  analysis.  The  results  are  presented  in  Table  6.3. 
Table  6.3(a)  MICs  of  six  antibiotics  against  48  isolates  of  S.  oralis 
Antibiotic  Cumulative  %  of  strains  with  stated  MIC  (mg/L) 
0.064  0.125  0.25  0.5  1248  16  32  64  128  >256 
Ceftazidime  0  4  12  15  35  40  48  56  65  85  98  100  - 
Piperacillin/ 
tazobactam 
21  27  33  38  46  48  58  88  100  ---- 
Meropenem  40  50  62  90  100  -  -  -  ----- 
Penicillin  29  38  44  48  56  77  100  -  ----- 
Cefaclor  0  0  4  8  23  33  40  44  48  48  50  50  100 
Vancomycin  0  0  0  21  96  100  -  -  ----- 
Table  6.3(b)  MICs  of  six  antibiotics  against  19  isolates  of  S.  mitis 
Antibiotic  Cumulative  %  of  strains  with  stated  MIC  (mg/L) 
0.064  0.125  0.25  0.5  1248  16  32  64  128  >256 
Ceftazidime  0  16  26  26  42  53  53  53  53  53  58  84  100 
Piperacillin/ 
tazobactam 
26  32  42  53  53  53  53  68  90  100  --- 
Meropenem  53  53  53  63  100  -  -  -  -  ---- 
Penicillin  42  53  53  53  58  58  79  100  -  ---- 
Cefaclor  0  0  0  10  32  47  53  53  53  53  53  53  100 
Vancomycin  0  0  0  10  100  -  -  -  -  ---- 
154 The  isolates  of  S.  oralis  and  S.  mitis  had  similar  ranges  of  MICs  for  all  antibiotics 
tested  with  no  more  than  one  doubling  dilution's  difference  between  them. 
The  MIC  ranges  for  piperacillin/tazobactam  against  S.  oralis  were  0.064  -16  mg/L 
versus  0.064  -32  mg/L  for  S.  mitis,  while  those  for  penicillin  were  0.064  -4  mg/L 
versus  0.064  -8  mg/L.  Geometric  mean  MICs  for  piperacillin/  tazobactam  were  1.3 
mg/L  for  S.  oralis  versus  1.2  mg/L  for  S.  mitis,  while  those  for  penicillin  for  both 
species  were  identical  (0.5  mg/L)  (Table  6.4). 
The  meropenem  geometric  mean  MICs  for  both  species  were  also  identical  (0.2 
mg/L),  as  were  the  MIC  ranges  (0.064  -  1.0  mg/L).  For  ceftazidime,  the  MIC  range 
for  S.  oralis  was  0.25  -  128  mg/L  compared  with  the  range  for  S.  mitis  of  0.125  -> 
256  mg/L  with  geometric  mean  MICs  of  5.3  and  7.2  mg/L  respectively.  For  cefaclor 
the  respective  ranges  were  0.25  ->  256  mg/L  versus  0.5  ->  256  mg/L  with 
geometric  mean  MICs  of  23  and  15.4  mg/L.  The  vancomycin  geometric  mean  MICs 
were  identical  (0.9  mg/L)  with  a  range  of  0.5  -  2.0  mg/L  for  S.  oralis  and  a  range  of 
0.5  -  1.0  mg/L  for  S.  mitis. 
Table  6.4  Geometric  mean  MICs  of  six  antibiotics  against  48  isolates  of  S.  oralis 
and  19  isolates  of  S.  mitis. 
Antibiotic  Geometric  mean  MIC 
(mg/L)  against  S.  oralis 
Geometric  mean  MIC 
(mg/L)  against  S.  mitis 
Ceftazidime  5.3  7.2 
Piperacillin/tazobactam  1.3  1.2 
Meropenem  0.2  0.2 
Penicillin  0.5  0.5 
Cefaclor  23.0  15.4 
Vancomycin  0.9  0.9 
155 Larger  sample  sizes,  particularly  of  S.  mitis  would  have  yielded  more  information, 
however  these  results  suggest  that  identification  of  an  isolate  of  viridans 
streptococcus  as  either  S.  oralis  or  S.  mitis  does  not  predict  antibiotic  susceptibility, 
and  although  S.  oralis  may  appear  less  susceptible  to  cefaclor  than  S.  mitis  the 
difference  in  geometric  mean  MICs  at  these  elevated  levels  is  probably  not  clinically 
relevant,  as  the  results  suggest  that  this  antibiotic  would  be  ineffective  against  the 
majority  of  isolates  of  viridans  streptococci  tested. 
6.4  Susceptibility  of  76  isolates  of  viridans  streptococci  to  cotrimoxazole 
As  detailed  in  Section  5.11.7,  cotrimoxazole  prophylaxis  was  administered  to  the 
majority  of  patients  (85%)  in  this  study.  The  exceptions  were  patients  number:  3,10, 
15,26,33,51,53  and  54.  Susceptibility  to  this  agent,  of  all  isolates  of  viridans 
streptococci  isolated  from  blood  culture  was  determined  using  the  Stokes'  disc 
diffusion  method.  In  total,  74%  (56/76)  of  isolates  were  resistant  to  cotrimoxazole. 
Other  investigators  have  also  reported  high  rates  of  resistance  to  this  antibiotic 
amongst  viridans  streptococci  (Cohen  et  al.,  1983;  Wisplinghoff  et  al.,  1999). 
6.5  Interpretation  of  in  vitro  sensitivity  test  results 
The  purpose  of  in-vitro  sensitivity  testing  is  to  provide  an  indication  of  an  organism's 
susceptibility  to  a  particular  antibiotic  (i.  e.  whether  it  is  sensitive,  intermediately 
susceptible  or  resistant)  to  guide  antimicrobial  therapy.  However,  in  vivo,  there  are 
considerable  individual  variations  in  antibiotic  pharmacokinetics  in  health  and 
disease.  Immunocompetence  of  the  patient  may  influence  response  to  infection, 
such  that  an  organism  deemed  sensitive  to  an  antibiotic  may  be  more  easily 
eradicated  in  a  healthy  individual  than  in  one  who  is  profoundly  neutropenic.  The 
use  of  combination  antibiotic  therapy  may  further  influence  clinical  response.  The 
rationale  for  using  aß  -lactam  antibiotic  plus  an  aminoglycoside  is  based  on  the 
156 argument  that  synergy  will  result  in  enhanced  bacterial  killing  (Eliopoulos  & 
Eliopoulos,  1988). 
Antibiotic  susceptibility  reference  points,  such  as  MIC  breakpoints  provide  guidance 
on  the  suitability  of  an  antibiotic  against  a  particular  organism.  However  it  must  be 
appreciated  that  the  MIC  itself  has  the  disadvantage  of  being  a  static  end-point 
response  to,  a  defined  concentration  of  antibiotic,  dissimilar  to  conditions  found  in 
vivo.  Differing  techniques  are  used  to  determine  antimicrobial  susceptibility  in 
different  parts  of  the  world  and  differing  breakpoints  are  used  (British  Society  for 
Antimicrobial  Therapy,  1991  and  1996;  National  Committee  for  Clinical  and 
Laboratory  Standards,  1998).  The  following  section  will  discuss  the  antibiotic  MIC 
results  against  viridans  streptococci  relative  to  the  breakpoint  recommendations  of 
the  British  Society  for  Antimicrobial  Chemotherapy  (BSAC). 
The  BSAC  does  not  provide  breakpoint  references  specifically  for  viridans 
streptococci  (except  for  penicillin  -  in  endocarditis  (see  below)),  therefore  those  for 
Streptococcus  spp.  in  general  have  been  utilized  (British  Society  for  Antimicrobial 
Therapy,  1991  and  1996).  The  BSAC  MIC  breakpoint  for  both  ceftazidime  and 
piperacillin/tazobactam  against  Streptococcus  spp,  is 2  mg/L,  while  that  for  cefaclor  is 
1  mg/L  and  that  for  meropenem  is  4  mg/L. 
For  penicillin  against  Streptococcus  spp  the  recommended  breakpoint  is  0.12  mg/L, 
and  for  cases  of  viridans  streptococcal  endocarditis,  the  Endocarditis  Working  Party 
of  the  BSAC  (1998)  recommends  the  penicillin  MIC  breakpoint  of  0.1  mg/L.  The  MIC 
breakpoint  for  vancomycin  against  Streptococcus  spp.  is  4  mg/L. 
Applying  these  interpretive  criteria  to  the  MIC  results  of  this  study  provided  the 
information  presented  in  Table  6.5. 
157 Table  6.5  Susceptibility  of  76  isolates  of  viridans  streptococci  to  6  antibiotics 
according  to  MIC  breakpoints  recommended  by  the  BSAC. 
Antibiotic  Number  (%)  of 
susceptible  isolates 
Ceftazidime  35  (46) 
Piperacillin/tazobactam  40  (53) 
Meropenem  76  (100) 
Penicillin  32  (42) 
Cefaclor  19  (25) 
Vancomycin  76  (100) 
Using  BSAC  MIC  breakpoint  guidelines,  all  isolates  of  viridans  streptococci  were 
susceptible  to  meropenem  and  vancomycin  (Tables  6.5).  As  expected  from  the  MIC 
distribution  results  (Table  6.1)  and  geometric  mean  MIC  results  (Table  6.2), 
susceptibility  rates  to  cefaclor  were  very  low  at  only  25%  (Table  6.5). 
6.6  Interpretation  of  susceptibility  of  viridans  streptococci  to  antibiotics  using 
the  Stokes'  disc  diffusion  method 
The  relatively  simple  technique  used  in  disc  diffusion  methods  involves  placing 
antimicrobial  impregnated  discs  onto  the  surface  of  agar  after  inoculation  of  an 
organism.  Antimicrobial  activity  is  indicated  by  inhibition  of  bacterial  growth  around 
the  disc.  Although  this  may  be  a  straightforward  test,  it  is  important  that  it  is 
performed  accurately  with  the  correct  inoculum  and  incubation  conditions  and 
interpreted  with  care,  because  these  results  often  dictate  choice  of  antimicrobial 
agent. 
158 At  the  commencement  of  the  present  study,  the  disc  diffusion  method  used  in  the 
clinical  microbiology  laboratory  at  RHSC,  as  in  the  majority  of  laboratories  in  the  U.  K. 
was  that  of  Stokes'  (Stokes  &  Ridgway,  1980).  This  method  allowed  each  individual 
isolate  to  be  compared  with  a  sensitive  control  organism  which  was  subjected  to  the 
same  technical  conditions  of  medium,  incubation  time,  atmosphere,  temperature  and 
disc  content.  As  control  organisms  were  adjacent  on  the  same  plate  the  difference 
between  respective  zone  sizes  could  be  measured  directly. 
Antibiotic  susceptibilities  of  all  isolates  of  viridans  streptococci  from  blood  cultures 
were  determined  using  the  Stokes'  method  with  S.  aureus  NCTC  6571  as  control 
organism  (Chapter  4).  The  proportions  of  total  isolates  determined  as  susceptible  to 
each  antibiotic  using  this  technique  are  presented  in  Table  6.6. 
Table  6.6  Susceptibility  of  76  isolates  of  viridans  streptococci  to  six  antibiotics  using 
the  Stokes'  disc  diffusion  method. 
Antibiotic  Code  &  concentration  Number  (%)  of 
susceptible  isolates 
Ceftazidime  CAZ  (30  p  g)  45  (59) 
Piperacillin/tazobactam  TZP  (75  +  10  p  g)  43  (57) 
Meropenem  MEM  (10  p  g)  76(100) 
Penicillin  P  (1  unit)  32  (42) 
Cefaclor  CEC  (30  p  g)  31  (41) 
Vancomycin  VA  (30  p  g)  76(100) 
Comparison  of  these  results  with  the  MIC  results  of  Table  6.5  indicated  that  the 
Stokes'  disc  diffusion  method  corresponded  exactly  with  results  using  BSAC  MIC 
breakpoints  for  meropenem,  penicillin  and  vancomycin.  High  levels  of  agreement 
were  obtained  for  piperacillin/tazobactam. 
159 For  both  ceftazidime  and  cefaclor,  the  proportion  of  susceptible  isolates  determined 
by  disc  diffusion  exceeded  those  determined  by  the  MIC  method  (59%  versus  46% 
and  41%  versus  25%  respectively).  For  ceftazidime  this  difference  represented  10 
isolates  of  viridans  streptococci  and  for  cefaclor  12  isolates.  The  disagreements 
between  MICs  and  disc  tests  for  these  two  antibiotics  and  for  piperacillin/tazobactam 
are  detailed  in  Table  6.7. 
Table  6.7  MIC  values  at  which  discordance  between  the  MIC  method  and  Stokes' 
disc  diffusion  method  occurred,  with  frequency 
Antibiotic  MIC  values 
(frequency  of  discordant  results) 
Ceftazidime  4  mg/L  (x  4) 
8  mg/L  (x  4) 
16m/L  (x  2) 
Cefaclor  2  mg/L  (x  9) 
4  mg/L  (x  3) 
Pi  eraciIlin/tazobactam  P  4m  /L  (x  3)  9 
An  unacceptably  high  proportion  of  isolates  of  viridans  streptococci,  determined  as 
sensitive  to  cefaclor  by  disc  diffusion  tests  were  interpreted  as  resistant  by  MIC  (n  = 
12  (16%)).  The  majority  of  these  isolates  (Table  6.7)  possessed  cefaclor  MICs  of  2 
mg/L  -  one  doubling  dilution  above  the  MIC  breakpoint  of  1  mg/L  and  the  remainder 
had  cefaclor  MICs  of  4mg/L. 
However,  the  situation  with  ceftazidime  is  of  greater  concern.  Four  isolates  termed 
sensitive  by  disc  diffusion  possessed  ceftazidime  MICs  one  doubling  dilution  above 
the  breakpoint,  4  had  MICs  two  doubling  dilutions  above  and  2  had  MICs  three 
doubling  dilutions  above.  At  MICs  of  16  mg/L  the  activity  of  ceftazidime  would 
160 certainly  be  sub-optimal,  and  reporting  an  organism  with  such  MICs  as  sensitive  by 
disc  testing  may  adversely  affect  patient  outcome. 
Correlation  between  MIC  and  disc  test  results  for  piperacillin/tazobactam  was  much 
better.  There  were  only  3  discordant  results,  all  occurring  at  the  MIC  value  of  4 
mg/L.  This  level  of  discordance  is  less  significant  clinically  than  that  described  for 
ceftazidime,  as  considerable  activity  would  still  be  expected  against  organisms  with 
this  MIC. 
The  generally  good  correlation  between  the  MIC  determinations  and  disc  tests  for 
piperacillin/tazobactam  were  somewhat  unexpected  in  view  of  the  high  concentration 
of  the  TZP  75  +  10  pg  disc.  Disc  tests  were  also  performed  using  piperacillin  discs 
at  two  different  strengths:  PRL  75  pg  and  PRL  30p  g.  As  expected,  the  results  using 
PRL  75  pg  discs  were  superimposable  on  those  using  TZP  75  +  10  p  g,  because  the 
addition  of  tazobactam  as  aß  -lactamase  inhibitor  does  not  increase  the  activity  of 
piperacillin  against  viridans  streptococci.  The  use  of  PRL  30  pg  discs  made  no 
difference  to  the  interpreted  results,  however  reduced  susceptibility  of  viridans 
streptococci  could  be  more  readily  detected  by  eye  using  this  disc  than  using  the 
PRL  75  pg  or  TZP  75  +  10  pg  discs. 
6.7  Antimicrobial  susceptibility  of  blood  culture  isolates  of  viridans 
streptococci  before  and  after  a  change  in  empirical  antibiotic  therapy 
for  episodes  of  febrile  neutropenia 
As  the  study  progressed  into  1997,  it  appeared  that  the  ß  -lactam  MICs  of  isolates  of 
viridans  streptococci  from  blood  cultures  from  around  that  time,  tended  to  be  lower 
than  those  of  viridans  streptococci  from  blood  cultures  from  the  beginning  of  the 
study.  A  possible  temporal  association  with  this  trend,  was  the  change  of  empirical 
161 antibiotic  therapy  (in  Summer  1996),  from  ceftazidime  plus  amikacin  to 
piperacillin/tazobactam  plus  amikacin.  An  investigation  was  then  conducted  to 
determine  whether  or  not  there  existed  a  statistically  significant  difference  in 
antibiotic  MICs  for  organisms  isolated  before  and  after  this  change.  First,  the  in  vitro 
antimicrobial  susceptibilities  of  viridans  streptococci  isolated  from  blood  cultures  from 
the  beginning  of  December  1994  to  the  end  of  June  1996  (period  1),  were  compared 
with  those  of  strains  isolated  after  the  change,  until  the  end  of  December  2000 
(period  2).  During  period  1,  a  time  interval  of  19  months,  31  isolates  of  viridans 
streptococci  were  collected  from  blood  culture  from  28  episodes  of  bacteraemia. 
The  MIC  distributions  for  these  organisms  are  shown  in  Table  6.8 
Table  6.8  MIC  distributions  for  viridans  streptococci  isolated  during  period  1 
(ceftazidime  +  amikacin  as  empirical  therapy)  n=  31 
Antibiotic  Cumulative  %  of  strains  with  stated  MIC  (mg/L) 
0.064  0.125  0.25  0.5  1248  16  32  64  128  >256 
Ceftazidime  0  3  10  10  29  39.  42  42  52  71  84  94  100 
Piperacillin/ 
tazobactam 
13  19  23  32  39  45  45  71  97  100  --- 
Meropenem  29  42  52  90  100  -  -  -  ----- 
Penicillin  23  32  42  42  55  81  90  100  ----- 
Cefaclor  0  0  0  6  13  29  29  36  42  42  42  45  100 
Vancomycin  0  0  0  23  100  -  -  -  ----- 
During  period  2,  a  time  interval  of  54  months,  45  isolates  of  viridans  streptococci 
were  collected  from  41  episodes  of  bacteraemia,  with  MIC  distributions  shown  in 
Table  6.9. 
162 Table  6.9  MIC  distributions  for  viridans  streptococci  isolated  during  period  2 
(piperacillin/tazobactam  +  amikacin  as  empirical  therapy)  n=  45 
Antibiotic  Cumulative  %  of  strains  wi 
0.064  0.125  0.25  0.5  1 
th  stated  MIC  (mg/L) 
248  16  32  64  128  >256 
Ceftazidime  0  13  24  27  47  51  58  67  71  82  89  98  100 
Piperacillin/ 
tazobactam 
24  33  44  49  56  58  71  91  98  100  --- 
Meropenem  51  60  69  78  100  -  -  -  ----- 
Penicillin  40  49  52  58  64  71  98  100  ----- 
Cefaclor  0  0  4  9  33  42  51  53  56  56  60  62  100 
Vancomycin  0  0  0  13  96  100  -  -  ----- 
Comparison  of  the  results  from  these  tables  demonstrated  that  between  periods  1  and 
2,  the  MIC50  values  for  ceftazidime  and  piperacillin/tazobactam  decreased  eight-fold, 
from  16  mg/L  to  2  mg/L  and  8  mg/L  to  1  mg/L  respectively.  The  MIC50  values  for 
penicillin  and  meropenem  decreased  four-fold,  from  1  mg/L  to  0.25  mg/L  and  0.25  mg/L 
to  0.064  mg/L.  The  MIC50  for  cefaclor  decreased  from  >  256  mg/L  to  4  mg/L. 
The  shifts  in  MIC  distributions  for  these  antibiotics  are  presented  graphically  as 
frequency  (%)  of  isolates  with  stated  MICs  (Figure  6.2  (a)-(e)),  illustrating  the  increased 
frequency  of  isolates  with  lower  ß  -lactam  MICs  when  empirical  therapy  was  changed  to 
piperacillin/tazobactam  plus  amikacin. 
163 Figure  6.2  MIC  distributions  of  31  isolates  of  viridans  streptococci  from  blood  culture 
prior  to  a  change  in  empirical  antibiotic  therapy,  compared  with  45  isolates 
following  this  change 
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The  MIC50  for  vancomycin  for  isolates  of  viridans  streptococci  from  both  period  1  and 
period  2  was  1.0  mg/L.  Figure  6.2  (f)  demonstrates  a  minimal  difference  in  distribution 
of  vancomycin  MICs  between  the  two  time  intervals,  indicating  that  change  in  empirical 
therapy  had  no  influence  on  the  susceptibility  of  viridans  streptococci  to  this  antibiotic. 
165 For  ß  -lactam  agents,  the  geometric  mean  MICs  for  isolates  collected  during  period  1 
compared  with  those  of  period  2  (Table  6.10),  demonstrated  lower  susceptibility 
amongst  strains  from  the  earlier  period  of  time.  The  geometric  mean  MICs  of 
ceftazidime  and  piperacillin/tazobactam  for  organisms  isolated  prior  to  the  change  in 
empirical  therapy  were  2.9-fold  greater  and  2.8-fold  greater  respectively,  than  those 
following  the  change  (P  <  0.05).  Piperacillin/tazobactam  was  consistently  more 
active  in  vitro  than  ceftazidime. 
For  penicillin  and  meropenem,  decreases  in  geometric  MICs  between  the  two  time 
intervals  were  more  modest  then  those  for  ceftazidime  and  piperacillin/tazobactam. 
Meropenem  demonstrated  significant  activity  against  viridans  streptococcal  strains 
throughout  both  study  periods. 
Table  6.10  Comparative  geometric  mean  MICs  of  six  antibiotics  against  viridans 
streptococci  from  blood  cultures  -  periods  1  and  2 
Antibiotic  Period  I 
Geometric  mean  MICs 
Period  2 
Geometric  mean  MICs 
Ceftazidime  9.6  3.3 
Piperacillin/tazobactam  2.2  0.8 
Meropenem  0.23  0.17 
Penicillin  0.6  0.4 
Cefaclor  35.8  13.3 
Vancomycin  0.9  0.9 
Period  1:  ceftazidime  +  amikacin  as  empirical  therapy 
Period  2:  piperacillin/tazobactam  +  amikacin  as  empirical  therapy 
166 With  the  demonstration  that  geometric  mean  MICs  of  all  ß  -lactam  agents  tested 
against  viridans  streptococci  isolated  from  blood  culture  during  period  1  were  higher 
than  for  those  for  the  isolates  of  period  2,  with  MICs  for  ceftazidime  and 
piperacillin/tazobactam  significantly  so,  an  investigation  into  possible  contributory 
factors  such  as  antimicrobial  prophylaxis  and  prior  antibiotic  therapy,  was  conducted. 
6.7.1  Comparison  of  study  groups  -  period  I  versus  period  2 
The  following  data  were  collected  for  each  patient  with  viridans  streptococcal 
bacteraemia  during  periods  1  or  2:  age,  gender,  underlying  disease  (as  presented  in 
Table  5.1),  the  presence  or  absence  of  a  central  venous  catheter,  neutropenia, 
mucocutaneous  lesions,  chemotherapy  regimen  administered,  the  use  of 
antibacterial  prophylaxis,  and  previous  courses  of  empirical  antibiotic  therapy  with 
agents  used.  During  period  1,  empirical  therapy  consisted  of  ceftazidime  (50  mg/kg 
every  8  hours)  plus  amikacin  (7.5  mg/kg  every  12  hours).  During  period  2,  empirical 
antibiotic  therapy  consisted  of  piperacillin/  tazobactam  (90  mg/kg  every  8  hours)  plus 
amikacin  (7.5  mg/kg  every  12  hours).  All  antibiotics  were  administered  by 
intravenous  injection.  The  first  patient  to  receive  piperacillin/tazobactam  plus 
amikacin  was  patient  number  23  of  Table  5.1. 
The  mean  age  of  the  22  patients  who  developed  viridans  streptococcal  bacteraemia 
during  period  1  was  6.0  years  (range  3  months  -  14  years),  and  of  the  32  patients  of 
period  2  was  7.7  years  (range  1  year  -  14  years).  The  male  to  female  ratio  for 
period  1  was  2.1:  1  and  for  period  2  was  1 
. 
1:  1.  All  patients  from  period  1  had  central 
venous  catheters  and  only  one  child  from  Period  2  did  not.  Management  of  central 
venous  lines  remained  essentially  unchanged  throughout  the  entire  study  period,  as 
did  the  mouth  care  protocol  (Appendix  11).  During  period  1,  episodes  of  viridans 
streptococcal  bacteraemia  occurred  in  patients  with  leukaemia  on  23  occasions  (= 
167 82%  of  total  episodes  during  period  1)  compared  with  36  occasions  (=  88%  of 
episodes)  during  period  2.  During  period  1,  viridans  streptococcal  bacteraemia  was 
associated  with  the  presence  of  mucosal  damage  in  25  episodes  (=  89%  of  total  for 
period  1)  and  during  period  2,  with  33  episodes  (=  80.5%  of  total  episodes  for  period 
2)  (P  >  0.25).  Although  a  wide  variety  of  chemotherapeutic  regimens  were  employed 
during  periods  1  and  2,  there  was  no  statistically  significant  difference  between  the 
proportion  of  episodes  of  viridans  streptococcal  bacteraemia  associated  with  high- 
dose  or  intermediate-high-dose  cytosine  arabinoside  or  allogeneic  BMT  i.  e.  the 
therapies  most  associated  with  mucositis  (54%  of  episodes  during  period  1,  versus 
42%  during  period  2,  P>0.25).  During  period  1,  neutropenia  was  associated  with 
96.4%  of  total  episodes  and  during  period  2,  with  95.1  %.  Throughout  both  time 
intervals,  cotrimoxazole  was  the  sole  agent  of  antibiotic  prophylaxis,  associated  with 
93%  of  episodes  in  period  1  and  88%  in  period  2.  Resistance  rates  to  this  agent, 
during  the  two  time  intervals,  were  74%  and  73%  respectively.  Prior  empirical 
antibiotic  therapy  of  ceftazidime  +  amikacin  had  been  administered  in  26  of  the 
cases  of  period  1  (=  93%  of  total  in  period  1),  and  prior  empirical  antibiotic  therapy  of 
piperacillin/  tazobactam  +  amikacin  had  been  administered  in  35  of  the  cases  of 
period  2  (85%  of  total  in  period  2).  The  first  two  patients  receiving  empirical  therapy 
during  period  2  had  received  recent  prior  empirical  therapy  with  ceftazidime,  which 
may  have  influenced  susceptibility  patterns  of  viridans  streptococci  isolated  after  the 
change.  However  the  date  of  change  was  considered  the  most  appropriate  point  of 
comparison  of  the  two  populations  and  any  effects  of  prior  therapy  with  ceftazidime 
on  the  second  group  would  cease  to  exist  with  time. 
The  above  investigations  demonstrated  that  there  was  no  statistical  difference 
between  the  patient  groups  with  viridans  streptococcal  bacteraemia  during  period  1 
compared  with  period  2  with  regard  to  haematological  versus  solid  malignancy,  the 
presence  of  central  lines,  mucosal  lesions  or  neutropenia,  therapy  with  high-  or 
168 intermediate-high-dose  cytosine  arabinoside  or  allogeneic  BMT,  frequency  of  use  of 
antimicrobial  prophylaxis  or  resistance  rates  to  cotrimoxazole,  previous  receipt  of 
empirical  antibiotic  therapy  or  time  intervals  between  administration  of  antibiotics.  A 
major  difference  between  the  two  patient  groups  was  the  change  of  ß  -lactam  agent 
for  empirical  antibiotic  therapy. 
A  second  observation  -  that  fewer  cases  of  viridans  streptococcal  bacteraemia 
occurred  during  period  2  than  during  period  1  had  also  been  made.  The  prevalence 
of  viridans  streptococcal  bacteraemia  as  proportion  of  total  microbiologically- 
documented  episodes  for  period  1  was  17%  versus  8%  for  period  2  (P  <  0.001),  and 
as  proportion  of  all  febrile  episodes  was  4.6%  for  period  1  versus  2.2%  for  period  2 
(P  <  0.005).  Could  there  be  any  link  between  in  vitro  susceptibility  to  empirical 
antibiotics  and  development  of  infection? 
To  explore  this  possibility,  parameters  for  all  febrile  patients  in  the  haematology/ 
oncology  unit  during  periods  1  and  2  should  be  compared  in  a  retrospective 
sequential  analysis.  However,  due,  in  part,  to  the  very  nature  of  such  analyses,  it  is 
sometimes  difficult  or  impossible  to  retrieve  all  the  relevant  information.  Another 
possible  complicating  factor,  in  this  instance,  is  the  markedly  different  time  span  of 
periods  1  and  2.  This,  in  turn,  was  due  to  the  natural  progression  of  the  study  itself; 
at  the  outset,  one  could  not  predict  that  such  a  comparison  would  be  relevant.  It  is 
generally  preferable  to  conduct  this  type  of  study  with  both  time  intervals  of  similar  or 
identical  duration.  However,  could  such  an  analysis  still  be  performed?  Episodes  of 
viridans  streptococcal  bacteraemia  during  1993  and  January-November  1994,  prior 
to  the  commencement  of  this  study  were  presented  in  Figure  5.1  for  reference. 
Inclusion  of  specific  details  of  all  of  these  patients  and  episodes  of  infection  would 
certainly  produce  a  time  interval  ('extended  period  1)  with  a  duration  closer  to  that  of 
period  2.  However,  several  complicating  variables  would  also  be  introduced,  due  to 
169 the  multiple  different  empirical  antibiotic  regimens  which  were  administered 
throughout  1993;  ceftazidime  +  amikacin  or  meropenem  for  patients  on 
IATCG/EORTC  Trial  IX  and  piperacillin  +  amikacin  for  non-trial  patients. 
Consequently,  this  approach  was  not  pursued. 
In  early  1994,  by  which  time  participation  in  IATCG/EORTC  Trial  IX  was  complete, 
RHSC  standard  empirical  therapy  was  changed  to  ceftazidime  plus  amikacin.  To 
compare  prevalence  of  viridans  streptococcal  bacteraemia  during  two  time  intervals 
of  acceptable  and  equivalent  lengths,  before  and  after  change  of  empirical  antibiotic 
therapy,  figures  for  January  1994  -  June  1996  inclusive,  versus  those  for  July  1996  - 
December  1998  inclusive  were  used.  Between  these  two  time  intervals,  episodes  of 
viridans  streptococcal  bacteraemia  as  proportion  of  total  febrile  episodes  decreased 
significantly  from  4.4%  to  2.2%  (P  <  0.05).  This  finding  concurred  with  the  decrease 
in  prevalence  between  periods  1  and  2,  of  unequal  duration,  described  previously. 
Factors  that  may  have  influenced  the  development  of  bacteraemia,  such  as  mouth 
care  protocols  and  patients'  line  management,  as  discussed  earlier,  remained 
essentially  unchanged  throughout  the  entire  period  of  this  study.  Although  figures  for 
total  patients  receiving  antibiotic  prophylaxis  were  not  available,  guidelines  described 
previously  would  have  determined  which  patients  groups  received  such  treatment, 
i.  e.  cotrimoxazole  prophylaxis  for  high-risk  groups  only.  No  other  form  of  antibiotic 
prophylaxis  was  generally  used  in  the  total  patient  population. 
During  period  1  the  total  number  of  blood  cultures  collected  from  febrile 
haematology/oncology  patients  in  the  unit  was  1169  compared  with  4539  during 
period  2.  Although  different  numbers  of  blood  cultures  were  collected  each  month, 
the  average  monthly  figure  for  period  1  would  be  62  and  for  period  2  would  be  84. 
170 Figures  for  total  admissions,  or  those  for  admissions  of  patients  with  specific 
malignancies  during  periods  1  and  2  were  not  available,  however  the  general  annual 
distribution  of  malignancies  was  not  markedly  different  from  one  year  of  the  study  to 
another. 
The  same  chemotherapy  regimens  were  used  in  the  haematology/oncology  unit 
during  periods  1  and  2,  with  the  exception  of  the  new  MRC  ALL  treatment  protocol, 
introduced  at  the  beginning  of  2000.  Chemotherapy  regimens  commonly  associated 
with  mild  to  severe  mucositis  were  used  throughout  both  periods.  However,  the 
frequency  of  administration  of  courses  of  the  various  chemotherapeutic  regimens, 
varied,  to  some  extent,  as  one  would  expect.  For  this  reason,  to  investigate  whether 
the  number  of  courses  of  intensive  chemotherapy  per  time  interval  was  related  to  the 
prevalence  of  viridans  streptococcal  bacteraemia,  and  to  compare  like  with  like, 
analysis  of  a  distinct  group  -  all  patients  in  the  haematology/  oncology  unit  who 
received  the  CLASP  regimen  was  performed  -  as  described  in  the  following  section. 
6.7.2  The  CLASP  regimen  and  viridans  streptococcal  bacteraemia 
-  period  I  versus  period  2 
All  patients  who  received  CLASP  chemotherapy  between  the  start  of  December 
1994  and  the  end  of  December  2000  were  selected  because  of  all  regimens 
administered,  CLASP  was  associated  with  the  greatest  number  of  cases  of  viridans 
streptococcal  bacteraemia  and  would  therefore  yield  the  largest  sample  sizes  for 
statistical  analysis.  A  total  of  34  courses  of  CLASP  were  administered  over  the  six 
years  of  this  study.  Viridans  streptococcal  bacteraemia  developed  following  11  of 
these.  Comparison  of  cases  throughout  this  time  (Figure  6.3),  revealed  that  there 
were  more  cases  of  viridans  streptococcal  bacteraemia  following  CLASP 
chemotherapy  during  the  early  years  of  the  study  than  during  the  later  years. 
171 Figure  6.3  Courses  of  CLASP  chemotherapy  administered  throughout  the  study 
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In  the  context  of  periods  1  and  2  of  the  earlier  analyses,  there  occurred  7  cases  of 
viridans  streptococcal  bacteraemia  following  CLASP  chemotherapy  during  the 
former  period,  compared  with  4  cases  during  the  latter.  The  7  episodes  of  viridans 
streptococcal  bacteraemia  of  period  1  represented  64%  of  the  11  courses  of  CLASP 
chemotherapy  administered  during  that  time,  compared  with  the  4  episodes  of  period 
2  which  represented  17%  of  23  courses  of  CLASP.  This  difference  is  statistically 
significant  (P  <  0.01  Fisher's  exact  test). 
6.7.3  Antibiotic  susceptibility  and  severity  of  infection 
During  period  1,  complications  associated  with  viridans  streptococcal  bacteraemia 
occurred  more  frequently  than  during  period  2,  with  half  of  all  cases  (14/28)  during 
period  1  developing  respiratory  complications  compared  to  17%  (7/41)  of  cases 
during  period  2  (difference  statistically  significant,  (P<  0.005).  During  period  1,21% 
of  total  episodes  (6/28)  were  temporally  associated  with  ARDS  +/-  septic  shock. 
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1995  1996  1997  1998  1999  2000 septic  shock  and  only  one  of  a  total  of  41  episodes  of  viridans  streptococcal  infection 
was  temporally  associated  with  ARDS  (P<  0.025). 
From  previous  results  (Section  6.7),  it  was  obvious  that  MICs  generally,  were  higher 
during  period  1  than  period  2.  However,  were  the  more  resistant  isolates  associated 
with  increased  severity  of  infection?  During  period  1,  when  ceftazidime  was  used  as 
empirical  therapy,  17  of  the  28  episodes  (61  %)  of  viridans  streptococcal  bacteraemia 
yielded  organisms  with  ceftazidime  MICs  of  >  16mg/L,  (range:  16  -  256  mg/L)  (Table 
6.11).  Of  these,  14  (82%)  were  associated  with  mild  or  moderate  respiratory 
complications,  ARDS  or  septic  shock.  In  contrast,  during  period  2,  when 
piperacillin/tazobactam  was  being  used  as  empirical  therapy  and  respiratory 
complications  occurred  significantly  less,  there  were  only  4  of  41  episodes  (10%), 
which  featured  isolates  with  piperacillin/tazobactam  MICs  of  >  16  mg/L  (range:  16  - 
32  mg/L),  of  which  one  was  associated  with  mild  respiratory  complications  (Table 
6.11).  The  significance  of  these  findings  in  relation  to  those  preceding,  will  be 
discussed  in  Chapter  8. 
173 Table  6.11  Episodes  associated  with  isolates  of  viridans  streptococci  from  blood 
culture  with  MICs  of  ?  16  mg/L  for  0  -lactam  agent  being  used  as  empirical  therapy 
and  severity  of  symptoms  -  periods  1  and  2 
Period  I  Period  2 
Ceftazidime  +  amikacin  Piperacillin/tazobactam  + 
as  empirical  therapy  amikacin  as  empirical 
therapy 
Episodes  of  bacteraemia 
caused  by  viridans  17  4 
streptococci  with  MICs  >  (61  %  of  total  episodes)  (10%  of  total  episodes) 
16  mg/L  for  ß  -lactam 
agent  (P  <  0.001,  X2  test) 
Proportion  of  isolates  with 
MICs  >  16  mg/L  14/17  (82%)  1/4  (25%) 
associated  with  cases  with 
some  degree  of  (P  =  0.05,  Fisher's  Exact  test) 
respiratory  compromise 
Proportion  of  isolates  with  5/17  (29%) 
MICs  >  16  mg/L  0 
associated  with  cases  with  (ARDS  +  septic  shock:  4/17 
ARDS  +/-  septic  shock  ARDS  alone:  1/17) 
6.8  Susceptibility  of  viridans  streptococci  to  more  recently  introduced 
antibiotics 
Newer  agents  tested  against  viridans  streptococci  as  part  of  the  present  study 
comprised  cefpirome,  quinupristin/dalfopristin  and  linezolid.  Cefpirome  is  a  fourth 
generation  cephalosporin  reported  to  possess  significant  activity  against  Gram- 
positive,  as  well  as  against  Gram-negative  bacteria  (Spencer,  1993;  Wiseman  & 
Lamb,  1997;  Fernandes  et  al.,  1998;  Glauser,  1998).  Quinupristin/dalfopristin  is  a 
streptogramin  antibiotic  complex  of  two  synergistic  components,  and  linezolid 
belongs  to  a  new  class  of  antimicrobial  agents,  the  oxazolidinones. 
174 Quinupristin/dalfopristin  and  linezolid  were  investigational  antibiotics  at  the  time  of 
commencement  of  the  present  study.  Limited  reports  available  at  that  time, 
described  the  promising  in  vitro  activity  of  quinupristin/dalfopristin  against  Gram- 
positive  bacteria  (Brumfitt,  Hamilton-Hiller  &  Shah,  1992;  Appelbaum,  Spangler  & 
Jacobs,  1993).  Early  reports  of  linezolid's  in  vitro  activity  were  published  during  the 
second  half  of  the  1990s  (Zurenko  et  al.,  1996;  Jones,  Johnson  &  Erwin,  1996; 
Shinabarger  et  al.,  1997).  Of  particular  note  was  the  activity  of  both 
quinupristin/dalfopristin  and  linezolid  against  multiply-resistant  Gram-positive 
bacteria.  The  majority  of  reports  at  this  time  concentrated  on  antimicrobial  activity 
against  Staphylococcus  spp.,  Enterococcus  spp.  and  S.  pneumoniae  (Johnson  et  al., 
1995;  Mulazimoglu,  Drenning  &  Yu,  1996;  Pepper  &  Bouanchaud,  1996). 
Information  on  in  vitro  activity  against  viridans  streptococci  was  lacking. 
The  MIC  distributions  and  geometric  mean  MICs  for  these  agents  against  the  76 
isolates  of  viridans  streptococci  from  the  present  study  are  presented  in  Table  6.12. 
Table  6.12  MIC  distributions  for  cefpirome,  quinupristin/dalfopristin  and  linezolid 
against  76  isolates  of  viridans  streptococci  -  with  geometric  mean  MICs 
Antibiotic  Cumulative  %  of  strains  with  stated  MIC  (mg/L)  G.  M.  MIC 
0.064  0.125  0.25  0.5  1248  16 
(mg/L) 
Cefpirome  33  45  51  57  76  99  100  --  0.33 
Quinupristin/  0  0  1  25  87  99  100  --  0.92 
dalfopristin 
Linezolid  0  1  18  92  100  ----  0.46 
Cefpirome  exhibited  considerable  in-vitro  activity  against  these  organisms  with  an 
MIC  range  of  0.064  mg/L  to  4  mg/L,  with  MIC50  of  0.25  mg/L  and  MIC90  of  2  mg/L. 
The  MIC  breakpoint  of  the  BSAC  for  cefpirome  against  Streptococcus  spp.  is  2  mg/L. 
175 Only  one  isolate  exceeded  this  MIC 
bimodal  (Figure  6.4). 
The  distribution  of  cefpirome  MICs  was 
The  results  demonstrated  that  quinupristin/dalfopristin  was  also  highly  active  against 
the  isolates  of  viridans  streptococci,  with  an  MIC50  of  1  mg/L  and  MIC90  of  2  mg/L. 
The  BSAC  MIC  breakpoint  for  quinupristin/dalfopristin  against  S.  pneumoniae  is  2 
mg/L.  Only  one  isolate  of  viridans  streptococcus  exceeded  this  value.  (A  BSAC  MIC 
breakpoint  for  Streptococcus  spp  is  not  available  at  present.  )  Figure  6.4  Indicates 
that  the  MIC  distribution  for  quinupristin/dalfopristin  against  viridans  streptococci  was 
normal.  Linezolid  exhibited  excellent  in  vitro  activity  against  these  organisms  (with 
an  MIC50  and  MIC90  of  0.5  mg/L.  The  BSAC  breakpoint  for  linezolid  against 
Streptococcus  spp  is  2  mg/I,  therefore  all  isolates  would  be  termed  sensitive. 
Geometric  mean  MICs  for  these  three  antibiotics  are  presented  in  Table  6.12.  The 
low  geometric  mean  MIC  values  for  all  three  agents  are  indicative  of  their  impressive 
in  vitro  activity. 
Figure  6.4  Distribution  of  MICs  for  cefpirome,  quinupristin/dalfopristin  and  linezolid 
against  76  isolates  of  viridans  streptococci 
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176 6.8.1  Investigation  to  determine  whether  the  in  vitro  susceptibility  of 
viridans  streptococci  to  newer  antibiotics  may  be  influenced  by 
prior  empirical  antibiotic  therapy 
As  cefpirome  is  a0  -lactam  antibiotic,  susceptibility  of  endogenous  organisms,  such 
as  viridans  streptococci,  may  be  affected  by  prior  therapy  with  other,  less  active 
agents  such  as  ceftazidime.  To  investigate  whether  this  were  the  case,  sensitivities 
of  blood  culture  isolates  to  cefpirome  during  period  1  of  this  study  were  compared 
with  blood  culture  isolates  from  period  2.  Similar  analyses  were  performed  for 
quinupristin/dalfopristin  and  linezolid  (Tables  6.13  and  6.14). 
Table  6.13  MIC  distributions  of  cefpirome,  quinupristin/dalfopristin  and  linezolid 
against  31  isolates  of  viridans  streptococci  -  period  1 
(ceftazidime  +  amikacin  as  empirical  therapy) 
Antibiotic  Cumulative  %  of  strains  with  stated  MIC  (mg/L) 
0.064  0.125  0.25  0.5  1248  16 
G.  M.  MIC 
(mg/L) 
Cefpirome  26  32  42  45  77  97  100  --  0.4  (0.44) 
Quinupristin/ 
dalfopristin 
0  0  3  23  90  100  ---  0.9  (0.89) 
Linezolid  0  3  23  94  100  ----  0.4  (0.44) 
Table  6.14  MIC  distributions  of  cefpirome,  quinupristin/dalfopristin  and  linezolid 
against  45  isolates  of  viridans  streptococci  -  period  2 
(piperacillin/tazobactam  +  amikacin  as  empirical  therapy) 
Antibiotic  Cumulative  %  of  strains  with  stated  MIC  (mg/L) 
0.064  0.125  0.25  0.5  1248  16 
G.  M.  MIC 
(mg/L) 
Cefpirome  38  53  58  64  76  100  ---  0.3  (0.27) 
Quinupristin/ 
dalfo  ristin 
0  0  0  27  84  98  100  --  0.9  (0.94) 
Linezolid  0  0  16  91  100  ----  0.5  (0.48) 
177 For  cefpirome,  the  MIC50  during  period  2  was  3  doubling-dilutions  less  than  that  for 
period  1,  with  the  geometric  mean  MIC  for  the  later  period  minimally  less  than  that 
for  the  earlier  period.  The  shift  in  MIC  distribution  is  presented  in  Figure  6.5  (a).  For 
quinupristin/dalfopristin  and  linezolid,  MIC50  results  were  identical  for  isolates  of 
viridans  streptococci  isolated  during  both  periods  of  the  study  (1  mg/L  and  0.5  mg/L 
respectively)  and  geometric  mean  MIC  values  were  almost  identical  (0.89  mg/L 
versus  0.94  mg/L  and  0.44  mg/L  versus  0.48  respectively)  (Tables  6.13  and  6.14). 
Figure  6.5  Distributions  of  MICs  for  cefpirome,  quinupristin/dalfopristin  and 
linezolid  against  31  isolates  of  viridans  streptococci  from  blood  culture 
prior  to  a  change  in  empirical  antibiotic  therapy,  compared  with  45 
isolates  following  this  change 
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Graphical  representation  of  MIC  results  for  quinupristin/dalfopristin  for  periods  1  and 
2  demonstrate  distributions  which  are  almost  superimposable  -  as  is  also  the  case 
for  the  linezolid.  (Figure  6.5  (b)  and  (c)).  Resistance  of  viridans  streptococci  to  the 
cell-wall  active  (ß  -lactam)  agents  tested  in  this  study,  does  not  appear  to  be 
associated  with  reduced  susceptibility  to  these  two  new  antibiotics. 
6.9  Summary 
The  results  of  antimicrobial  sensitivity  testing  of  76  isolates  of  viridans  streptococci 
from  blood  culture,  demonstrated  considerable  variation  in  susceptibility  to  ß  -lactam 
agents  amongst  these  organisms.  Of  the  broad  spectrum  agents  commonly  used  for 
first-line  empirical  therapy  of  febrile  neutropenia,  the  rank  order  of  activity  was 
meropenem  >  piperacillin/  tazobactam  >  ceftazidime.  All  isolates  were  sensitive  to 
meropenem  with  a  geometric  mean  MIC  of  0.2  mg/I.  To  piperacillin/tazobactam 
there  was  a  broader  range  of  susceptibilities  from  0.064  -  32  mg/L,  with  a  geometric 
mean  MIC  of  1.3  mg/L.  Ceftazidime  MICs  ranged  from  0.125  to  >  256  mg/L  with  a 
geometric  mean  MIC  of  5.1  mg/L.  Susceptibility  to  penicillin  was  variable  (range: 
0.064  -8  mg/L),  with  a  geometric  mean  of  0.5  mg/L.  Cefaclor  demonstrated  poor 
activity  generally,  (MIC  range:  0.25  -?  256  mg/L  with  a  geometric  mean  MIC  of  19.9 
mg/L).  All  isolates  of  viridans  streptococci  were  sensitive  to  vancomycin  (range:  0.5 
179 -  2mg/L  with  a  geometric  mean  MIC  of  0.9mg/L.  A  comparison  of  the  MIC  breakpoint 
method  with  the  Stokes'  disc  diffusion  method  for  determination  of  susceptibilities  of 
viridans  streptococci  indicated  that  the  two  methods  agreed  or  produced  similar 
interpretations  of  susceptibility  for  vancomycin,  meropenem,  penicillin  and 
piperacillin/  tazobactam,  but  differed  unacceptably  for  ceftazidime  and  cefaclor.  The 
disc  method  failed  to  predict  reduced  susceptibility  to  ceftazidime  for  ten  isolates  and 
to  cefaclor  for  twelve. 
The  two  predominant  species  represented  in  this  study  -  S.  oralis  and  S.  mitis 
displayed  an  almost  identical  range  of  susceptibilities  to  piperacillin/  tazobactam, 
penicillin,  ceftazidime,  cefaclor,  meropenem  and  vancomycin,  indicating  that 
identification  of  either  to  species  level  was  not  useful  in  predicting  antibiotic 
sensitivity  patterns. 
This  study  monitored  antibiotic  susceptibility  of  viridans  streptococci  isolated  from 
blood  cultures  while  empirical  antibiotic  therapy  consisted  of  (i)  ceftazidime  plus 
amikacin  (period  1)  compared  with  (ii)  piperacillin/tazobactam  plus  amikacin  (period 
2).  A  significantly  higher  rate  of  resistance  to  chosen  empirical  ß  -lactam  therapy 
occurred  during  period  1  than  during  period  2  (P  <  0.05).  Of  note,  resistance  to  all  0- 
lactam  antibiotics  was  higher  during  period  1  than  period  2.  The  prevalence  of 
viridans  streptococcal  bacteraemia  was  also  higher  during  period  1  than  period  2 
(17%  of  all  culture-proven  episodes  versus  8%  respectively,  P  <0.001,  and  4.6%  of 
all  episodes  of  pyrexia  versus  2.2%  respectively,  P<0.005). 
Finally,  tests  of  the  newer  antimicrobial  agents,  cefpirome,  quinupristin/  dalfopristin 
and  linezolid  indicated  that  these  antibiotics  possess  considerable  in  vitro  activity 
against  viridans  streptococci. 
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7.1  Introduction 
Historically  it  has  been  generally  accepted  that  the  oral  cavity  is  the  most  likely 
source  of  viridans  streptococci  causing  bacteraemia  -  for  several  reasons. 
Colonization  by  viridans  streptococci  is  most  dense  at  this  site  and  it  is  well 
recognized  that  viridans  streptococcal  bacteraemia  may  develop  following  dental  and 
oral  procedures  (Heimdahl  et  al.,  1990;  Roberts  et  al.,  1997,  Daly  et  al.,  1997).  In 
the  context  of  this  study,  it  would  also  seem  reasonable  that  in  patients  with  cancer, 
chemotherapy-induced  oral  mucositis  or  other  forms  of  oral  compromise,  could 
potentially  provide  a  portal  of  entry  for  these  organisms  into  the  bloodstream. 
An  investigation  was  conducted  to  determine  the  distribution  of  different  species  of 
viridans  streptococci  in  the  mouths  of  paediatric  patients  with  cancer.  The  patients 
studied  comprised  those  who  developed  viridans  streptococcal  bacteraemia.  Three 
cases  were  selected,  and  viridans  streptococci  isolated  from  both  the  mouth  and 
blood  of  these  patients  were  compared  by  phenotypic  and  genotypic  methods. 
Finally,  the  ability  of  viridans  streptococci  to  colonize  tools  used  for  mouth  care  was 
investigated.  Viridans  streptococci  from  a  patient's  toothbrush,  teeth,  oral  mucosae 
and  blood  culture  were  compared  phenotypically  and  genotypically  to  determine 
whether  the  toothbrush  could  potentially  act  as  a  vector  of  infection. 
7.2  Distribution  of  species  of  viridans  streptococci  from  oral  swabs 
To  obtain  information  on  the  distribution  of  different  species  of  viridans  streptococci 
in  the  mouths  of  paediatric  patients  with  cancer,  mouth  swabs  were  taken  from 
182 cases  in  this  study  for  the  first  4  and  a  half  years  -  to  obtain  a  sample  size  of  100 
organisms  (from  44  patients).  For  patients  with  multiple  episodes  of  viridans 
streptococcal  bacteraemia,  isolates  of  viridans  streptococci  were  cultured  from  one 
mouth  swab  only  -  taken  around  the  time  of  the  first  episode. 
The  range  of  species  of  viridans  streptococci  isolated,  is  presented  in  Figure  7.1.  S. 
oralis  was  the  predominant  species,  representing  71  %  of  total  isolates.  The  proportion 
of  S.  mitis,  the  next  most  commonly  isolated  species  was  12%  -  only  slightly  greater 
than  that  of  S.  parasanguis  (10%).  The  remaining  species,  S.  sanguis,  S.  gordonii  and 
S.  salivarius,  each  represented  <  5%  of  total  isolates. 
Figure  7.1  Viridans  streptococcal  species  isolated  from  the  mouths  of  paediatric 
haematology/oncology  patients 
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Viridans  streptococci,  n=  100.  Patients,  n=  44. 
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S.  salivarius  S.  aordonii 7.2.1  Comparison  of  species  from  oral  swabs  with  species  from  blood 
cultures 
The  relative  proportions  of  different  species  of  viridans  streptococci  isolated  from  the 
oral  cavity  with  those  from  blood  cultures  are  presented  in  Table  7.1.  Blood  culture 
isolates  were  collected  over  a  longer  time  interval  than  those  from  mouth  swabs  to 
obtain  the  largest  possible  collection.  As  mentioned  earlier,  the  total  number  of 
blood  culture  isolates  was  76  (Section  5.6).  Although  lesser  in  magnitude,  a 
comparison  with  the  species  results  for  100  isolates  from  mouth  swabs  provided 
some  useful  information. 
Table  7.1  Comparison  of  species  of  viridans  streptococci  isolated  from  the  mouth  and 
blood  of  paediatric  haematology/oncology  patients. 
Species 
Number  of  isolates  (_%) 
RAPID  ID  32  Strep 
Mouth 
Number  of  isolates  (%) 
RAPID  ID  32  Strep 
Blood 
S.  oralis  71  48  (63) 
S.  mitis  12  19  (25) 
S.  sanguis  4  5  (7) 
S.  parasanguis  10  2  (3) 
S.  salivarius  1  1  (1) 
S.  gordonii  2  1  (1) 
TOTAL  100  76(100%) 
From  both  sites,  S.  oralis  was  the  predominant  species,  comprising  71%  of  total 
isolates  from  mouth  swabs  and  63%  from  blood.  S.  mitis  was  the  second  most 
commonly  isolated  species  representing  12%  from  the  oral  cavity  and  25%  from 
184 blood.  Other  species  of  viridans  streptococci  present  in  lower  numbers  at  both  sites, 
comprised  S.  parasanguis  (10%  in  the  mouth  and  3%  in  the  blood),  S.  sanguis  (4% 
versus  7%),  S.  gordonii  (2%  versus  1  %)  and  S.  salivarius  (1  %  at  both  sites). 
If  the  mouth  were  the  source  of  viridans  streptococci  causing  bacteraemia,  the 
predominance  of  S.  oralis  in  the  oral  cavity  of  these  patients  corresponds  well  to  its 
predominance  amongst  blood  culture  isolates  (71  %  and  63%  of  total  isolates 
respectively).  S.  mitis,  while  the  second  most  common  species  from  both  sites  was 
associated,  to  a  greater  extent  with  blood  cultures  than  the  mouth  (25%  versus  12%, 
P<0.05).  This  may  reflect  some  enhanced  ability  of  S.  mitis  to  access  the  blood 
stream,  or  may  be  related  to  the  location  of  this  species  in  the  oral  cavity  of  these 
patients.  The  difference  may  alternatively  be  related  to  sampling  method.  As 
mentioned  previously,  swabbing  the  mouth  is  not  the  most  efficient  method  of 
obtaining  total  oral  microbial  yield.  Oral  rinse  techniques  are  superior  (Spijkervet, 
1991),  but  would  not  have  been  suitable  for  some  of  the  very  young  or  very  sick 
patients  in  this  study.  As  a  consequence,  there  is  a  possibility  that  some  isolates  of 
viridans  streptococci  may  not  have  been  detected,  leading  to  an  underestimation  of 
their  contribution  to  the  overall  composition  of  viridans  streptococcal  flora  in  the  oral 
cavity.  A  further  complicating  factor  may  have  been  the  inevitable  variation  in 
swabbing  technique  used  by  many  different  nurses  over  the  period  of  this  study. 
Finally,  patient  compliance,  in  a  minority  of  cases,  was  not  optimal. 
7.3  Studies  to  determine  the  origin  of  viridans  streptococci  causing 
bacteraemia 
This  investigation  involved  phenotypic  and  genotypic  analyses  of  isolates  of  viridans 
streptococci  cultured  from  blood  and  oral  specimens  from  several  patients.  Case  1 
was  selected  because  this  represented  an  example  of  polymicrobial  bacteraemia 
185 caused  by  bacteria  of  two  different  genera,  which  also  colonize  the  mouth.  Case  2 
was  chosen  to  investigate  whether  oral  compromise  other  than  mucositis  could 
potentially  predispose  to  viridans  streptococcal  bacteraemia.  Case  3  was  selected 
because  this  patient  differed  from  the  majority  of  others;  she  was  not  neutropenic 
and  was  apyrexial,  with  no  evidence  of  mucositis,  but  viridans  streptococci  were 
isolated  from  multiple  blood  cultures.  The  results  are  preceded  by  a  short 
description  of  each  case. 
7.3.1  Case  I 
A  15-year-old  boy  with  chronic  myeloid  leukaemia  was  treated  with  hydroxyurea  from 
diagnosis,  followed  by  bone  marrow  transplantation  from  a  matched  unrelated  donor 
at  9  months  from  presentation.  On  day  7  post-transplant,  while  neutropenic  and 
suffering  from  severe  oral  mucositis,  the  patient  became  febrile.  Viridans 
streptococci  and  coagulase-negative  staphylococci  were  isolated  from  blood  culture. 
A  mouth  swab,  taken  4  days  post  transplant  yielded  normal  buccal  flora  (including 
viridans  streptococci)  plus  coagulase-negative  staphylococci.  Surveillance  cultures 
of  the  Hickman  line  exit  site,  faeces  and  urine  yielded  no  evidence  of  viridans 
streptococci  or  coagulase-negative  staphylococci.  All  distinct  colonial  types  of 
viridans  streptococci  from  the  mouth  swab  were  subcultured  and  identified  to  species 
level,  as  was  the  isolate  from  blood  culture.  The  isolates  of  coagulase-negative 
staphylococci  from  both  sites  were  also  identified  to  species  level  using  the  API 
Staph  method  (BioMerieux).  Antibiograms  for  all  isolates  were  obtained. 
The  viridans  streptococcal  isolate  from  blood  culture  and  one  isolate  from  the  mouth 
were  identified  as  S.  oralis  I.  A  further  isolate  from  the  mouth  was  identified  as  S. 
oralis  II.  The  biochemical  identification  profile  of  the  S.  oralis  I  from  blood  was 
identical  to  that  of  the  oral  isolate,  while  that  of  the  isolate  of  S.  oralis  II  was  distinct 
186 (Table  7.2).  All  isolates  of  viridans  streptococci  possessed  the  same  antibiogram 
(Table  7.2). 
Table  7.2  Case  1-  biotypes  and  antibiograms  of  viridans  streptococci  from  blood 
culture  and  mouth 
Site  Species  Biochemical  ID 
Profile 
Antibiogram 
PEN  CEFT  PIPIT  MER  CEFA  AMI  VA 
Blood  Strep.  oralis  l  46052643120  SSS  S  S  RS 
Mouth  Strep.  oralis  I  46052643120  SSS  S  S  RS 
Mouth  Strep.  oralis  11  44032441120  SSS  S  S  RS 
PEN:  Penicillin,  CEFT:  Ceftazidime,  PIP/T:  Piperacillin/tazobactam, 
MER:  Meropenem,  CEFA:  Cefaclor,  AMI:  Amikacin,  VA:  Vancomycin 
S:  Sensitive,  R:  Resistant 
Both  isolates  of  coagulase-negative  staphylococci  were  identified  as  Staph 
epidermidis  with  identical  biochemical  identification  profiles  and  antibiograms  (Table 
7.3). 
Table  7.3  Case  1-  biotypes  and  antibiograms  of  Staph  epidermidis  from  blood 
culture  and  mouth 
Site  Species  Biochemical 
ID  profile 
Antibiogram 
VA  MET  CLI  RIF  FUS  AMI  CIP 
Blood  Staph 
epidermidis 
6706112  SRSSRRR 
Mouth  Staph 
epidermidis 
6706112  SRSSRRR 
VA:  Vancomycin,  MET:  Methicillin,  CLI:  Clindamycin,  RIF:  Rifampicin, 
FUS:  Fusidic  acid,  AMI:  Amikacin,  CIP:  Ciprofloxacin 
S:  Sensitive,  R:  Resistant 
187 Pulsed-field  gel  electrophoresis  (PFGE)  of  chromosomal  DNA  digested  with  Sma  I 
restriction  endonuclease  was  used  to  compare  the  isolates  of  Strep.  oralis  I  and 
Staph.  epidermidis  from  blood  culture  with  those  from  the  mouth. 
Figure  7.2  Case  1-  PFGE  analysis  of  Staph.  epidermidis  and  Strep.  oralis  I  from 
blood  culture  and  mouth  swab 
Lane  1  DNA  molecular  weight  marker  (48.5  kb  Lambda  ladder) 
Lane  2  Staph.  epidermidis  from  blood 
Lane  3  Staph.  epidermidis  from  mouth 
Lane  4  Strep.  oralis  I  from  blood 
Lane  5  Strep.  oralis  I  from  mouth 
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12345 The  results  (Figure  7.2)  indicated  that  both  isolates  of  Strep.  oralis  I  were 
indistinguishable  and  that  both  isolates  of  Staph.  epidermidis  were  indistinguishable. 
These  findings  demonstrated  that  the  patient's  mouth  was  the  most  likely  source  of 
both  Strep.  oralis  I  and  Staph.  epidermidis  responsible  for  polymicrobial  bacteraemia 
and  provided  proof  that  classical  chemotherapy-induced  oral  mucositis  could  provide 
a  portal  of  entry.  When  the  patient's  Hickman  line  was  removed,  culture  yielded  no 
evidence  of  either  of  these  strains  (Kennedy  et  al.,  2000).  The  finding  that  both 
streptococci  and  staphylococci  from  the  oral  cavity  could  access  the  blood  stream 
suggests  that  other  combinations  of  micro-organisms  from  this  source  could  cause 
polymicrobial  bacteraemia.  In  this  particular  case,  biochemical  identification  profiles 
were  useful  in  distinguishing  between  different  strains  of  S.  oralis,  but  antibiograms 
were  not. 
7.3.2  Case  2 
A  12-year-old  boy  with  high-risk  AML,  had  completed  his  second  course  of  induction 
chemotherapy  (MAE).  Fourteen  days  later,  while  profoundly  neutropenic,  he 
became  febrile.  Blood  cultures  yielded  S.  oralis  I.  The  patient  was  not  suffering  from 
oral  mucositis,  but  did  have  severe  haemorrhagic  gingivitis  and  an  oozing  tooth 
socket.  S.  oralis  I  had  been  the  only  isolate  of  viridans  streptococcus  cultured  from 
a  surveillance  mouth  swab  taken  2  days  after  the  date  of  the  positive  blood  culture. 
The  isolate  from  the  mouth  and  that  from  blood  culture  had  identical  biochemical 
identification  profiles  and  antibiograms  (Table  7.4).  Surveillance  cultures  of  the 
patient's  Hickman  line  exit  site,  faeces  and  urine  yielded  no  evidence  of  viridans 
streptococci. 
189 Table  7.4  Case  2-  biotypes  and  antibiograms  of  viridans  streptococci  from  blood 
culture  and  mouth 
Site  Species  Biochemical 
ID  Profile 
Antibiogram 
PEN  CEFT  PIPIT  MER  CEFA  AMI  VA 
Blood  S.  oralis  I  46052443120  RRISRRS 
Mouth  S.  oralis  1  46052443120  RRISRRS 
PEN:  Penicillin,  CEFT:  Ceftazidime,  PIP/T:  Piperacillin/tazobactam, 
MER:  Meropenem,  CEFA:  Cefaclor,  AMI:  Amikacin,  VA:  Vancomycin 
S:  Sensitive,  R:  Resistant,  I:  Intermediately  susceptible 
PFGE  analysis  of  chromosomal  DNA  digested  with  Sma  I  restriction  endonuclease 
from  both  isolates  of  S.  oralis  I  demonstrated  that  these  organisms  shared  the  same 
PFGE  type,  i.  e.  were  genotypically  indistinguishable  (Figure  7.3),  indicating  that  the 
mouth  was  the  source  of  S.  oralis  I  responsible  for  the  episode  of  bacteraemia  and 
that  gingivitis  had  provided  a  portal  of  entry  into  the  blood  stream.  This  case  thus 
provided  evidence  that  oral  compromise  other  than  mucositis  may  be  associated 
with  the  development  of  viridans  streptococcal  bacteraemia. 
190 Figure  7.3  Case  2-  PFGE  analysis  of  isolates  of  S.  oralis  I  from  blood  culture 
and  mouth  swab 
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7.3.3  Case  3 
A  2-year-old  girl  with  relapsed  Wilms'  tumour  had  received  several  courses  of 
chemotherapy  and  had  recently  achieved  remission.  To  complete  her  therapy  she 
was  due  to  receive  high-dose  Melphalan  and  peripheral  blood  stem  cell  rescue. 
Three  days  after  stem  cell  harvest,  blood  cultures  were  performed  as  part  of  an 
assessment  prior  to  high-dose  chemotherapy.  The  patient  was  well,  afebrile,  was 
191 not  neutropenic,  and  had  no  symptoms  suggestive  of  oral  or  gastrointestinal  mucosal 
damage.  S.  oralis  I  was  cultured  from  blood  from  both  lumens  of  her  Hickman  line. 
When  the  initial  microscopy  results  for  these  specimens  were  telephoned  to  the 
ward,  line  blood  cultures  were  repeated  to  exclude  the  possibility  of  contamination. 
From  repeat  blood  cultures  S.  oralis  I  was  isolated  once  more.  All  three  isolates 
possessed  the  same  biochemical  identification  profile  and  antibiogram  (Table  7.5) 
Table  7.5  Case  3-  biotypes  and  antibiograms  of  viridans  streptococci  from  blood 
culture  and  mouth 
Site  Species  Biochemical  Antibiogram 
identification 
profile  PEN  CEFT  PIPIT  MER  CEFA  AMI  VA 
Blood  (day  1)  S.  oralis  I  46056643120  S  S  S  S  S  R  S 
red  lumen 
Blood  (day  1)  S.  oralis  I  46056643120  S  S  S  S  S  R  S 
white  lumen 
Blood  (day  2)  S.  oralis  I  46056643120  S  S  S  S  S  R  S 
Mouth  S.  oralis  I  46056643120  R  R  S  S  R  S  R 
S.  oralis  II  44016601120  R  R  I  S  R  S  R 
S.  oralis  II  40016641120  R  R  I  S  R  S  R 
PEN:  penicillin,  CEFT:  ceftazidime,  PIP/T:  piperacillin/tazobactam, 
MER:  meropenem,  CEFA:  Cefaclor,  AMI:  amikacin,  VA:  vancomycin 
S:  Sensitive,  R:  Resistant,  I:  Intermediately  susceptible 
From  a  mouth  swab  taken  within  the  next  72  hours,  one  strain  of  S.  oralis  I  and  two 
of  S.  oralis  II  were  cultured.  The  oral  strain  of  S.  oralis  I  had  an  identical  biochemical 
identification  profile  to  that  of  the  S.  oralis  I  cultured  from  blood  and  this  was  quite 
distinct  from  those  of  both  isolates  of  S.  oralis  II  from  the  mouth  (Table  7.5).  The 
antibiogram  of  the  S.  oralis  I  from  blood  culture  differed  from  all  isolates  of  viridans 
streptococci  from  the  oral  cavity  (Table  7.5). 
192 All  isolates  of  S.  oralis  I  (with  identical  biochemical  identification  profiles)  from  both 
sites  were  compared  by  PFGE.  The  results  revealed  that  all  three  isolates  of  S. 
oralis  I  from  blood  were  genotypically  indistinguishable,  while  the  isolate  from  the 
oral  cavity  was  distinct  (Figure  7.4).  In  this  case,  there  were  no  clinical  signs  of 
infection.  Culture  of  viridans  streptococci  from  line  blood  may  have  represented 
catheter  colonization  +/-  transient  bacteraemia.  Unfortunately,  blood  could  not  be 
obtained  from  a  peripheral  site  to  aid  diagnosis.  Confirmation  that  the  strain  of  S. 
oralis  I  from  the  oral  cavity  was  different  from  that  in  blood  was  in  accord  with  the 
finding  that  the  patient  had  no  signs  of  oral  or  gastrointestinal  tract  mucositis  and  no 
other  forms  of  oral  compromise  which  might  provide  a  portal  of  entry  into  the 
bloodstream. 
Surveillance  cultures  of  the  patient's  Hickman  line  site,  faeces  and  urine  yielded  no 
evidence  of  viridans  streptococci.  Although  line  site  culture  was  negative,  it  is  likely, 
that  in  this  particular  case,  the  line  itself  was  the  source  of  viridans  streptococci. 
193 Figure  7.4  Case  3-  PFGE  analysis  of  isolates  of  S.  oralis  I  from  blood  culture  and 
mouth  swab 
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The  results  of  this  part  of  the  study  also  demonstrated  that  isolates  with  the  same 
biochemical  identification  profile  may  not  necessarily  be  genotypically  identical. 
194 7.4  Tools  for  mouth  care  as  potential  vectors  of  infection. 
It  is  generally  agreed  that  a  toothbrush  is  the  most  efficient  (non-specialist)  tool  for 
removing  plaque  and  debris  from  the  teeth  and  mouth  (Campbell,  Evans  & 
MacTavish,  1995;  Gibson,  Horsford  &  Nelson,  1997).  However,  because  the  oral 
tissues  of  cancer  patients  are  particularly  sensitive,  foam  toothettes  have  traditionally 
been  used  to  clean  these  sites  (Figure  7.5).  Foam  toothettes  are  used  once  and 
then  discarded.  However,  today  the  staff  of  some  paediatric  haematology/  oncology 
units  actively  encourage  their  patients  to  use  special  soft  toothbrushes  (e.  g.  TePe 
Select  Special  Care,  Molar  Ltd.,  Mayfield,  U.  K.  ),  with  the  view  that  superior  cleaning 
will  be  achieved  while  still  avoiding  damage  to  fragile  oral  tissues  (Figure  7.5). 
It  should  be  acknowledged,  however,  that  unless  the  toothbrush  is  discarded  after 
one  use,  there  is  a  possibility  that  it  will  become  colonized  with  oral  bacteria.  If  this 
occurs,  the  toothbrush  itself  could  conceivably  become  a  vector  of  organisms 
capable  of  causing  systemic  infection  in  vulnerable  patients. 
Figure  7.5  Foam  toothette  and  TePe  Select  Special  Care  toothbrush 
195 The  12-year-old  boy  with  AML  (case  2)  described  earlier  (Section  7.3.2),  agreed  to 
use  a  soft  toothbrush  for  a  short  time  to  provide  information  to  determine  how  quickly 
the  toothbrush  became  colonized  with  oral  bacteria.  Regular  swabbing  of  the  brush, 
performed  prior  to  mouth  care,  revealed  that  after  2  weeks,  in  spite  of  thorough 
rinsing  after  use,  oral  flora  similar  in  general  appearance  to  that  isolated  from  his 
mouth  could  be  cultured  from  the  toothbrush.  All  distinct  colony  types  of  viridans 
streptococci  from  teeth  swabs,  general  mouth  swabs,  and  toothbrush  swabs  were 
cultured  and  identified.  Biochemical  identification  indicated  that  two  different  strains 
of  S.  oralis  I  were  present  on  the  teeth  and  that  a  strain  identical  phenotypically  to 
one  of  these  was  also  detected  from  the  mouth  swab  and  from  the  toothbrush 
(Table  7.6). 
Table  7.6  Biotypes  and  antibiograms  of  viridans  streptococci  from  mouth,  teeth  and 
toothbrush  swabs. 
Site  Species  Biochemical  Antibiogram 
identification 
profile  PEN  CEFT  PIPIT  MER  CEFA  AMI  VA 
Mouth  S.  oralis  1  46052443120  R  R  ISR  R  S 
Teeth  S.  oralis  I  42052643120  S  S  SSS  R  S 
S.  oralis  I  46052443120  R  R  ISR  R  S 
Toothbrush  S.  oralis  1  46052443120  R  R  ISR  R  S 
PEN:  Penicillin,  CEFT:  Ceftazidime,  PIP/T:  Piperacillin/tazobactam, 
MER:  Meropenem,  CEFA:  Cefaclor,  AMI:  Amikacin,  VA:  Vancomycin 
S:  Sensitive,  R:  Resistant,  I:  Intermediately  susceptible 
This  patient  had  suffered  an  episode  of  viridans  streptococcal  bacteraemia  2  months 
prior  to  starting  to  use  the  special  soft  toothbrush.  The  biochemical  identification 
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that  time  were  compared  with  those  of  viridans  streptococci  more  recently  isolated 
from  mouth,  teeth  and  toothbrush  swabs.  All  isolates  from  both  periods  of  time  had 
been  identified  as  S.  oralis  I  and,  with  the  exception  of  one  of  the  two  strains  from 
teeth  swabs,  all  organisms  had  the  same  biochemical  identification  profile  and 
antibiotic  susceptibility  pattern  (Tables  7.4  and  7.6). 
PFGE  of  Sma  I  chromosomal  DNA  digests  of  the  phenotypically  identical  isolates 
revealed  that  they  were  also  indistinguishable  genotypically  (Figure  7.6).  This 
suggested  that  certain  strains  may  persist  in  the  oral  cavity,  in  spite  of  antimicrobial 
therapy  and  that  the  toothbrush  may  indeed  harbour  organisms  with  the  potential  to 
cause  bacteraemia. 
197 Figure  7.6  PFGE  analysis  of  S.  oralis  I  from  blood  culture,  mouth,  teeth  and 
toothbrush  swabs* 
123456 
Lane  -1  DNA  molecular  weight  marker  (48.5  kb  Lambda  ladder) 
Lane  2  S.  oralis  i  from  blood  20.12.97 
Lane  3  S.  oralis  I  from  mouth  22.12.97 
Lane  4  S.  oralis  I  from  toothbrush  9.03.98 
Lane  5  S.  oralis  I  from  teeth  9.03.98 
Lane  6  S.  oralis  I  from  mouth  9.03.98 
*:  All  isolates  obtained  from  the  patient  described  in  Section  7.3.2  (Case  2) 
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The  results  of  this  part  of  the  study  indicated  that  S.  oralis  was  the  predominant 
species  of  viridans  streptococcus  in  the  oral  cavity  of  this  group  of  paediatric  patients 
with  cancer.  This  finding  was  consistent  with  the  predominance  of  this  species  in 
blood  culture.  Phenotypic  and  genotypic  analyses  of  viridans  streptococci  from  oral 
specimens  and  blood  cultures  from  two  selected  patients,  indicated  that  viridans 
streptococci  originating  in  the  mouth  may  cause  bloodstream  infection  in  neutropenic 
patients.  Both  mucositis  and  gingivitis  were  shown  to  be  likely  portals  of  entry. 
From  analyses  of  the  organisms  from  Casel,  it  was  possible  to  demonstrate  that 
isolates  of  both  Strep.  oralis  I  and  Staph.  epidermidis  from  the  oral  cavity  were 
phenotypically  and  genotypically  indistinguishable  from  isolates  from  blood  culture, 
indicating  that  organisms  responsible  for  polymicrobial  bacteraemia  can  originate  in 
the  mouth.  In  contrast,  analyses  of  viridans  streptococci  from  Case  3  demonstrated 
that  in  this  non-neutropenic  patient,  with  no  symptoms  of  mucositis,  the  mouth  was 
unlikely  to  be  the  source  of  viridans  streptococci  which  were  isolated  from  multiple 
blood  cultures. 
All  isolates  of  viridans  streptococci  from  the  present  study  with  identical  PFGE-types 
also  possessed  identical  biochemical  identification  profiles  and  antibiograms. 
However  the  reverse  association  does  not  necessarily  follow.  Case  3  demonstrated 
that  viridans  streptococci  with  identical  antibiograms  possessed  different  biochemical 
identification  profiles  and  that  isolates  with  identical  biochemical  identification  profiles 
had  different  PFGE-types.  It  can  therefore  be  concluded  that  only  genotypic 
methods  such  as  PFGE  can  provide  definitive  proof  of  the  relatedness  of  isolates. 
199 Finally,  phenotypic  followed  by  genotypic  analyses  demonstrated  that  viridans 
streptococci  colonizing  the  teeth  and  oral  mucosae  may  also  colonize  toothbrushes, 
which  may  in  turn  become  potential  vectors  of  infection. 
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8.1  Species  of  viridans  streptococci  causing  bacteraemia 
Viridans  streptococci  belonging  to  the  mitis  group  were  responsible  for  the  majority 
of  episodes  of  bacteraemia  in  this  study  -a  finding  which  is  in  agreement  with  earlier 
investigations  (Cohen  et  al.,  1983;  Henslee  et  al.,  1984;  Sotiropoulos  et  al.,  1989; 
Classen  et  al.,  1990;  Villablanca  et  al.,  1990;  Guiot  et  al.,  1990;  Kern,  Kurrle  & 
Schmeiser,  1990;  McWhinney  et  al.,  1991;  Burden  et  al.,  1991;  Elting,  Bodey  & 
Keefe,  1992;  Awada  et  al.,  1992;  McWhinney  et  al.,  1993;  Steiner  et  al.,  1993; 
Donnelly  et  al.,  1993;  Broun  et  al.,  1994;  Bochud  et  al.,  1994).  From  the  present 
study,  only  one  isolate  from  outwith  this  group  was  cultured  from  blood  -  one  strain 
of  S.  salivarius. 
The  predominant  species  from  the  mitis  group,  identified  using  the  Rapid  ID  32  Strep 
system,  was  S.  oralis  (63%),  while  S.  mitis  represented  25%  of  total  isolates.  In 
contrast,  studies  carried  out  during  the  1980s  and  early  `90s  described  S.  mitis  or  S. 
sanguis  as  the  predominant  organism  in  this  clinical  setting  (Cohen  et  al.,  1983; 
Henslee  et  al.,  1984;  Sotiropoulos  et  al.,  1989;  Classen  et  al.,  1990;  Villablanca  et 
al.,  1990;  Guiot  et  al.,  1990;  Kern,  Kurrie  &  Schmeiser,  1990;  McWhinney  et  al., 
1991;  Burden  et  al.,  1991;  Elting,  Bodey  &  Keefe,  1992;  Awada  et  al.,  1992;  Steiner 
et  al.,  1993;  Donnelly  et  al.,  1993;  Broun  et  al.,  1994;  Bochud  et  al.,  1994).  There 
were  only  5  isolates  of  S.  sanguis  (7%  of  total  isolates  of  viridans  streptococci)  from 
the  present  study. 
Earlier  investigations  used  a  variety  of  methods  for  identification  of  viridans 
streptococci,  but,  by  far,  that  most  commonly  employed  was  API  20  Strep 
(BioMerieux).  The  taxonomy  of  the  viridans  streptococci  was  less  well  defined  at 
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databases  prior  to  version  5.1  (1995)  did  not  even  include  S.  oralis.  This  species 
was  first  proposed  by  Bridge  and  Sneath  in  1982  and  an  amended  description  was 
proposed  by  Kilian,  Mikkelsen  &  Henrichsen  in  1989.  However,  it  was  rarely 
reported  from  clinical  specimens  before  publication  of  the  identification  scheme  of 
Beighton,  Hardie  &  Whiley  in  1991  and  its  introduction  into  the  API  profile  registers 
some  years  later.  As  a  consequence,  some  isolates  identified  by  earlier  commercial 
systems  as  S.  mitis  or  S.  Banguis  would  probably  be  more  accurately  identified  today 
as  S.  oralis. 
Even  now,  the  current  API  20  Strep  system  does  not  include  certain  critical  tests 
which  have  been  incorporated  into  the  more  recently  introduced  Rapid  ID  32  Strep 
system  which  also  possesses  a  more  extensive  identification  database.  As  a  result 
of  this,  S.  gordonii,  S.  parasanguis,  S.  vestibularis  and  S.  downei/sobrinus  can  be 
identified  using  the  latter  system  but  not  the  former. 
Comparison  of  the  identification  results  of  the  present  study,  using  the  Rapid  ID  32 
Strep  system  with  those  for  the  same  organisms  identified  routinely  in  the  diagnostic 
microbiology  laboratory  using  the  API  20  Strep  system  from  1994  to  2000,  revealed 
a  significant  difference  in  proportions  of  individual  species.  Identification  results 
using  the  older  system,  demonstrated  a  predominance  of  strains  of  S.  mitis  (72%)  - 
in  accord  with  several  earlier  studies. 
As  mentioned  previously,  in  1991  Beighton  and  co-workers  published  an 
identification  scheme  for  viridans  streptococci.  They  used  a  collection  of  strains 
representative  of  a  wide  range  of  viridans  streptococcal  species  whose  taxonomic 
position  had  been  established  by  DNA-DNA  hybridization  or  by  analysis  of  SDS- 
PAGE  cell-protein  profiles  (Whitey,  1987). 
204 This  identification  scheme  determined  the  ability  of  isolates  to  produce  acid  from 
nine  carbohydrates,  to  hydrolyse  aesculin  and  arginine  and  to  hydrolyse  10 
fluorogenic  (4-methylumbelliferone-linked)  glycosidase  substrates  (Beighton,  Hardie 
&  Whiley,  1991).  Two  years  later,  the  publication  of  McWhinney  and  co-workers 
included  the  identification  of  47  isolates  of  viridans  streptococci  from  blood  cultures 
from  neutropenic  patients,  using  this  method  (McWhinney  et  al.,  1993).  S.  oralis  was 
the  predominant  species  (n=39  (83%  of  total  isolates)),  followed  by  S.  mitis  (n=5 
(11  %))  and  S.  parasanguis  (n=1  (2%)).  Two  isolates  could  not  be  identified  further 
than  `Streptococcus  spp'.  The  following  year,  a  further  report  using  the  identification 
method  of  Beighton  et  al.,  described  a  predominance  of  S.  oralis  (Beighton,  Carr  & 
Oppenheim,  1994).  This  study  identified  23  isolates  of  viridans  streptococci  from 
blood  cultures  of  neutropenic  patients  with  cancer.  These  streptococci  consisted  of 
14  isolates  of  S.  oralis  (61  %  of  total  isolates),  5  of  S.  mitis  (22%)  and  2  of  S. 
salivarius.  Two  isolates  could  not  be  identified  definitively. 
The  predominance  of  S.  oralis  in  the  present  study  is  in  accord  with  both  of  the 
above  studies.  In  particular,  the  proportions  of  isolates  of  S.  oralis  and  S.  mitis  from 
the  latter  study  are  very  similar  to  those  of  the  present  work,  in  which  S.  oralis 
represented  63%  of  total  isolates  and  S  mitis  represented  25%. 
There  are  few  studies,  published  after  the  commencement  of  the  present  work, 
which  describe  the  species  of  viridans  streptococci  associated  with  bacteraemia  in 
neutropenic  patients,  and  of  those  which  exist,  some  do  not  state  the  precise  method 
of  identification.  One  study  which  utilized  the  Rapid  ID  32  Strep  system,  that  of 
Reinert  and  colleagues  (2001),  investigated  both  a  -haemolytic  and  P  -haemolytic 
streptococci  isolated  from  blood  culture,  and  demonstrated  that  S.  oralis  strains 
represented  26.3%  of  total  isolates  of  streptococci,  while  S.  mitis  represented  9%. 
(Other  predominant  species,  identified  by  other  methods,  were  S.  pneumoniae 
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Wisplinghoff  and  co-workers  (1999)  identified  37  isolates  of  S.  mitis,  19  of  S.  oralis 
and  2  of  S.  salivarius  from  blood  culture  of  neutropenic  patients.  The  study  of 
Richard  and  colleagues  of  1995  identified  15  strains  of  S.  mitis,  8  of  S.  oralis  and  2 
of  S.  sanguis.  However  the  particular  method  of  identification  used  was  not 
mentioned.  In  1995,  Donnelly  and  co-workers  described  bacteraemia  caused  by  S. 
oralis  in  BMT  patients  and  by  S.  mitis  in  non-BMT  patients  with  malignancy  using 
`API  Strep'  for  identification.  The  trend  from  the  results  of  these  studies  using 
modern  identification  techniques  and  classification  schemes,  and  those  of  the 
present  work  suggest  that  the  species  most  commonly  associated  with  sepsis  in  the 
immunocompromised  population,  are  S.  oralis  and  S.  mitis. 
Since  the  commencement  of  this  study,  the  Rapid  ID  32  Strep  system  has  been 
adopted  more  widely  and  experience  of  its  usefulness  is  accumulating. 
Nevertheless,  this  system  should  not  be  considered  to  be  the  definitive  answer  to 
identification  of  viridans  streptococci.  It  cannot  identify  the  more  recently  described 
species  of  viridans  streptococci,  such  as  S.  crista  (Handley  et  al.,  1991),  S.  peroris 
and  S.  infantis  (Kawamura  et  al.,  1998)  and  some  authors  have  reported  problems  in 
differentiating  between  certain  strains  of  S.  mitis  and  S.  oralis  (Kikuchi  et  al,  1995; 
Jensen,  Konradsen  &  Bruun,  1999).  These  problems  were  encountered  in  the 
present  study,  and  as  described  earlier,  7  of  the  isolates  of  viridans  streptococci  from 
blood  cultures  (9%  of  total)  were  sent  to  the  Streptococcal  Reference  Laboratory, 
PHLS  Central  Public  Health  Laboratory,  London,  for  further  tests  and  identification. 
8.2  Polymicrobial  bacteraemia 
During  six  episodes  of  bacteraemia,  multiple  strains  or  species  of  streptococci 
associated  with  the  oral  cavity  were  concomitantly  isolated  from  blood  culture.  Few 
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et  al.,  1991;  Valteau  et  al.,  1991;  Awada  et  al.,  1992;  Arns  da  Cunha  et  al.,  1998; 
Graber  et  al.,  2001).  However  it  seems  reasonable  that  if  chemotherapy-induced 
mucositis  provides  a  portal  of  entry,  more  than  one  species  of  viridans  streptococcus 
from  the  mouth  or  gastrointestinal  tract  could  concomitantly  access  the  blood  stream. 
A  further  episode  of  polymicrobial  bacteraemia  involved  S.  mitis,  2  different  strains  of 
S.  oralis,  Haemophilus  parainfluenzae  and  Moraxella  catarrhalis  -  all  organisms 
associated  with  the  oropharynx. 
Several  other  investigators  have  reported  polymicrobial  bacteraemia  caused  by 
viridans  streptococci  plus  organisms  of  other  genera  (Pizzo,  Ladisch  &  Witebsky, 
1978;  Groot-Loonen  et  al.,  1987;  Kern,  Kurrle  &  Schmeiser,  1990;  Burden  et  al., 
1991;  Awada  et  a!.,  1992;  Donnelly  et  al.,  1993;  Bochud  et  al.,  1994;  Engelhard  et 
al.,  1995;  Spanik  et  al.,  1997;  Arns  da.  Cunha  et  al.,  1998).  Coagulase-negative 
staphylococci  were  the  most  common  co-infecting  bacteria  (Groot-Loonen  et  al., 
1987;  Burden  et  al.,  1991;  Donnelly  et  al.,  1993;  Bochud  et  a!.,  1994;  Spanik  et  al., 
1997),  in  accord  with  the  findings  of  the  present  study,  which  featured  three  episodes 
of  such  polymicrobial  bacteraemia.  Historically  it  has  become  accepted  that 
coagulase-negative  staphylococcal  bacteraemia  is  most  commonly  associated  with 
line-related  colonization  in  immunocompromised  patients.  However,  the  oral  cavity 
of  children  with  cancer  may  also  be  colonized  by  these  organisms  (Jackson  et  al., 
2000)  and,  as  part  of  the  present  study,  it  has  been  shown  that  viridans  streptococci 
with  coagulase-negative  staphylococci  originating  in  the  mouth  may  cause 
polymicrobial  bacteraemia  (Kennedy  et  al.,  2000). 
There  were  two  episodes  of  bacteraemia  caused  by  viridans  streptococci  with 
Enterococcus  spp,  a  finding  rarely  reported  in  earlier  papers  (Kern,  Kurrle  & 
Schmeiser,  1990).  In  both  cases,  the  patients  suffered  from  oral  compromise  and 
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authors  have  described  concomitant  infection  by  viridans  streptococci  with 
Enterobacteria  (Groot-Loonen  et  al.,  1987;  Kern,  Kurrle  &  Schmeiser,  1990;  Burden 
et  al,  1991;  Awada  et  al.,  1992;  Engelhard  et  al.,  1995;  Spanik  et  al.,  1997),  as  was 
also  observed  in  the  present  study  (1  episode:  S.  oralis  and  Enterobacter  cloacae). 
Coliforms  are  most  commonly  associated  with  the  gastrointestinal  tract,  but  may  also 
be  isolated  from  the  mouths  of  cancer  patients  (Sixou,  de  Medeiros-Batista  & 
Bonnaure-Mallet,  1996;  Meurman  et  al.,  1997). 
Concomitant  isolation  of  viridans  streptococci  with  Candida  spp  from  blood  culture 
has  rarely  been  described  (Kern,  Kurrle  &  Schmeiser,  1990;  Awada  et  al.,  1992).  In 
the  present  study  C.  albicans  plus  S.  mitis  caused  one  episode  of  bloodstream 
infection  and  C.  lusitaniae  plus  S.  mitis,  another.  Candida  spp.  commonly  colonize 
the  oral  cavity  of  immunocompromised  patients,  causing  opportunistic  infection 
(Wray  &  Bagg,  1997).  It  is  quite  possible  that  damaged  oral  mucosal  membranes 
may  provide  a  portal  of  entry  for  such  organisms  into  the  bloodstream.  In  addition, 
candidaemia  and  infection  by  yeasts  of  other  genera  may  also  be  associated  with  the 
use  of  central  venous  catheters  (Stratov  et  al.,  1998;  Krcmery,  Kunova  &  Trupl, 
1998).  The  bloodstream  infection,  described  in  the  present  study,  involving  the 
environmental  yeast,  Rhodotorula  rubra  with  S.  oralis,  in  a  patient  with  no  evidence 
of  mucosal  damage  to  the  oral  cavity  or  gastrointestinal  tract  was  more  likely  to  have 
been  associated  with  such  a  device. 
The  present  study  found  no  relationship  between  polymicrobial  bacteraemia  and 
severity  of  infection  in  immunocompromised  patients  with  cancer,  in  common  with 
the  findings  of  Burden  and  co-workers  (1991)  who  reported  that  55%  of  episodes  of 
viridans  streptococcal  bacteraemia  involved  additional  organisms.  The  study  of  Kern 
and  colleagues  (1990)  revealed  that  the  death  rate  was  slightly  higher  in  patients 
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streptococci  alone  (5/15  versus  7/40),  however  the  difference  was  not  statistically 
significant.  The  report  of  Pizzo  and  co-workers,  published  considerably  earlier 
(1978),  revealed  that,  of  a  total  of  twelve  patients  with  polymicrobial  bacteraemia,  all 
eight  with  Gram-negative  organisms,  isolated  concomitantly  with  viridans 
streptococci,  died.  All  eight  showed  evidence  of  Gram-negative  sepsis  at  post 
mortem.  Of  the  fifteen  patients  from  whom  viridans  streptococcus  was  the  sole 
isolate  from  blood  culture,  three  died,  and  in  none  of  these  could  death  be  directly 
related  to  viridans  streptococcal  sepsis. 
8.3  Origins  of  viridans  streptococci  and  portals  of  entry 
As  referred  to  previously,  the  presence  of  oropharyngeal  mucositis,  was  observed  in 
the  majority  of  earlier  studies  of  viridans  streptococcal  bacteraemia  in  neutropenic 
patients  (Pizzo,  Ladisch  &  Witebsky,  1978;  Hoecker  et  a!.,  1978;  Cohen  et  a!.,  1983; 
Groot-Loonen  et  al.,  1987;  Sotiropoulos  et  al.,  1989;  Classen  et  al.,  1990;  Kern, 
Kurrle  &  Schmeiser,  1990;  Burden  et  al.,  1991;  Elting,  Bodey  &  Keefe,  1992; 
Donnelly  et  al.,  1993;  Bochud  et  al.,  1994;  Donnelly  et  al.,  1995;  Engelhard  et  al., 
1995;  Gonzalez-Barca  et  al.,  1996),  and  was  demonstrated  to  be  a  statistically 
significant  risk  factor  in  three  case  control  studies  (Kern,  Kurrle  &  Schmeiser,  1990; 
Elting,  Bodey  &  Keefe,  1992;  Bochud  et  al.,  1994).  More  recently,  a  case  control 
study  has  identified  severe  oral  mucositis  as  a  factor  significantly  associated  with  the 
development  of  complications  related  to  viridans  streptococcal  bacteraemia  (Marron 
et  al.,  2000). 
From  the  earliest  reports  of  viridans  streptococcal  bacteraemia,  it  was  accepted  by 
many  investigators,  that  the  mouth  was  a  likely  source  of  these  bacteria.  However, 
in  1994,  when  the  present  study  was  commenced,  there  was  still  no  definitive  proof 
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bacteraemia  were  actually  identical  to  those  isolated  from  the  oral  cavity. 
As  discussed  earlier,  one  of  the  aims  of  the  present  study  was  to  address  this  issue 
by  performing  phenotypic  followed  by  genotypic  analyses  of  viridans  streptococci 
from  both  sites.  In  preparation  for  this  part  of  the  present  study,  the  range  of  species 
of  viridans  streptococci  resident  in  the  oral  cavities  of  paediatric  immuno- 
compromised  patients  was  determined.  As  detailed  in  Chapter  7,  S.  oralis  was  the 
predominant  species  (71  %)  in  the  mouth,  followed  by  S.  mitis  (12%).  S.  parasanguis 
represented  10%  of  total  isolates,  with  the  remaining  species,  S.  sanguis,  S.  gordonii 
and  S.  salivarius  each  representing  <  5%. 
The  work  of  Lucas  and  colleagues  (1997),  which  utilized  an  oral  rinse  technique  to 
investigate  viridans  streptococci  from  the  mouths  of  20  paediatric  BMT  patients 
demonstrated  that  1  week  post  transplantation,  S.  oralis  was  the  predominant 
species  of  viridans  streptococcus.  As  part  of  their  analysis,  these  investigators 
grouped  S.  oralis  and  S.  mitis  together,  and  termed  them  the  `S.  oralis  group'.  They 
reported  that  13  of  the  20  children  were  colonized  with  species  belonging  to  this 
group  alone.  From  the  mouths  of  two  children,  S.  salivarius  was  isolated  in  addition 
to  species  of  the  `S.  oralis  group'.  From  two,  S.  gordonii  was  the  additional  species 
and  from  one,  S.  gordonii  plus  S.  parasanguis.  From  two  children  no  oral  viridans 
streptococci  were  detected.  Although  the  present  study  used  a  different  method  of 
assessing  oral  colonization  by  swabbing  the  mouth,  the  predominance  of  viridans 
streptococcal  species  of  the  `S.  oralis'  group  is  in  agreement  with  the  work  of  Lucas 
and  colleagues.  It  has  been  shown  by  others  that  the  oral  flora  of  paediatric  patients 
with  cancer  becomes  less  complex  and  that  dominant  organisms  arise  (Sixou  et  al., 
1998). 
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predominance  of  S.  oralis  in  the  oral  cavity  of  the  patients  of  the  present  study  also 
corresponded  to  its  predominance  in  blood  cultures  (71  %  of  total  isolates  versus 
63%  respectively). 
As  described  in  Chapter  7,  three  patients  were  selected,  and  phenotypic,  followed  by 
genotypic  investigations  were  performed  to  determine  whether  the  oral  cavity  was  a 
potential  source  of  viridans  streptococci  causing  bacteraemia  in  these  individuals. 
The  demonstration  that  from  two  patients  (cases  1&  2),  isolates  from  the  respective 
mouth  swabs  and  blood  cultures  were  indistinguishable  by  biochemical  identification 
profile,  antibiogram  and  also  by  PFGE-type  fulfilled  the  aim  of  this  part  of  the  study. 
Of  interest,  shortly  after  the  commencement  of  this  work,  another  group  published  an 
article,  using  a  different  molecular  typing  technique  which  provided  the  first  definitive 
evidence  that  the  mouth  was  a  potential  source  (Richard  et  al.,  1995).  Ribotyping 
demonstrated  that  in  all  seven  described  cases  of  viridans  streptococcal 
bacteraemia,  the  strain  from  blood  culture  had  an  identical  ribotype  to  that  recovered 
from  the  mouth  of  the  respective  patient  and  that  similar  ribotypes  were  never  shared 
by  strains  from  different  patients.  All  seven  patients  in  the  study  of  Richard  and  co- 
workers  suffered  from  oral  mucositis. 
As  discussed  in  Section  8.2,  viridans  streptococci  plus  bacteria  of  different  genera 
may  cause  polymicrobial  bacteraemia  in  neutropenic  patients.  The  present  study 
demonstrated  that  Staph.  epidermidis  and  Strep.  oralis  from  mouth  swab  and  blood 
culture  of  a  BMT  patient  (case  1)  with  severe  mucositis  were  identical  by  biochemical 
identification  profile,  antibiogram  and  PFGE-type.  Previously,  it  had  been 
demonstrated  by  others  that  Staph.  epidermidis  isolated  from  the  throat  of  a 
neutropenic,  bacteraemic  patient  had  an  identical  PFGE  profile  to  that  isolated  from 
blood  culture  (Lina  et  al.,  1994).  However  the  work  reported  in  this  thesis  is  the  first 
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gain  access  to  the  blood  stream  concomitantly  (Kennedy  et  al.,  2000). 
Classical  chemotherapy-induced  oral  mucositis  was  associated  with  just  less  than 
half  (48%)  of  the  total  episodes  of  viridans  streptococcal  bacteraemia  described  in 
the  present  study.  The  simple  scoring  system  used  in  the  ward  indicated  that  the 
majority  of  patients  who  experienced  the  more  severe  symptoms  associated  with 
viridans  streptococcal  bacteraemia  did  have  some  degree  of  mucositis.  However, 
for  the  group  of  4  patients  (5  episodes)  with  both  septic  shock  and  ARDS,  severity  of 
oral  mucositis  varied.  In  2  of  these  episodes,  mucositis  was  described  as  mild,  in 
one,  as  moderate  and  in  2  as  severe.  Moreover,  four  other  patients  who  developed 
viridans  streptococcal  bacteraemia  and  who  suffered  from  severe  mucositis  did  not 
develop  septic  shock  or  any  degree  of  respiratory  distress.  Therefore,  severity  of 
mucositis  may  not  necessarily  correlate  with  severity  of  clinical  symptoms  associated 
with  viridans  streptococcal  bacteraemia.  Nevertheless,  it  must  be  appreciated  that 
the  scoring  system  used  was  not  particularly  sophisticated  and  that  interpretation 
was  probably  subject  to  some  degree  of  inter-observer  variation. 
Historically,  most  investigators  have  focused  on  mucositis  as  providing  a  portal  of 
entry  for  viridans  streptococci  into  the  bloodstream.  Accordingly,  various  scoring 
systems  have  been  devised  to  monitor  this  feature  (World  Health  Organization, 
1979;  Weisdorf  et  al.,  1989;  Donnelly  et  al.,  1992,  Sonis  et  al.,  1999).  However, 
other  forms  of  oral  compromise  should  also  be  considered  in  this  context.  As  part  of 
the  present  study,  all  oral  complications  were  recorded,  including  mucositis, 
gingivitis,  pharyngitis,  caries,  loose  teeth,  bleeding  lips,  oral  candidiasis  and  herpetic 
lesions,  increasing  the  total  number  of  cases  with  oral  symptoms  to  65%. 
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cancer  is  high  (Fayle  &  Curzon,  1991)  and  far  exceeds  that  of  adults  (Sonis  &  Sonis, 
1979).  The  higher  mitotic  index  of  mucosal  cells  of  children  renders  these  cells 
particularly  sensitive  to  the  effects  of  chemotherapy.  As  a  consequence,  they  are 
lost  faster  and  are  replaced  more  slowly  than  those  of  the  adult  oral  cavity 
(Campbell,  Evans  &  MacTavish,  1995).  The  child's  mouth  is  a  particularly  dynamic 
environment  with  loss  of  deciduous  teeth  and  eruption  of  permanent  teeth  with 
associated  gingival  trauma. 
In  1998,  Lucas  and  colleagues  demonstrated  that  plaque  and  gingival  inflammation 
scores  increased  significantly  in  the  mouths  of  paediatric  patients  during  the  intense 
period  of  immunosuppression  following  BMT.  They  suggested  that  inflamed  gingival 
tissues  may  conceivably  provide  a  portal  of  entry  for  oral  organisms  into  the 
bloodstream.  The  findings  of  the  present  work  suggested  that  gingivitis,  in  the 
absence  of  mucositis,  could  provide  such  a  portal.  Phenotypic  followed  by  genotypic 
analyses  of  viridans  streptococci  isolated  from  the  oral  cavity  and  blood  culture  of  a 
child  with  AML  (Case  2)  with  gingivitis  but  no  evidence  of  mucositis  showed 
indistinguishable  typing  patterns. 
Extension  of  this  part  of  the  study  revealed  another  potential  source  of  infection  by 
viridans  streptococci.  Two  months  later,  when  not  neutropenic,  the  same  child  was 
issued  with  a  TePE  Special  Select  soft  toothbrush  (Molar  Ltd.,  Mayfield,  U.  K.  )  to 
control  plaque  levels  without  damaging  delicate  oral  structures.  After  two  weeks  of 
use,  the  toothbrush  was  colonized  with  oral  bacteria  and  an  isolate  of  S.  oralis  from 
the  brush  was  shown  to  be  identical  by  biochemical  identification  profile,  antibiogram 
and  PFGE-type  to  one  cultured  from  swabs  of  the  buccal  mucosa  and  teeth.  As 
described  in  the  Section  7.4,  the  strain  of  S.  oralis  isolated  from  this  patient's  blood 
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identical. 
Earlier  investigators  had  demonstrated  that  toothbrushes  may  become  colonized 
readily  by  oral  bacteria  (Svanberg,  1978;  Glass  &  Lare,  1986;  Kozai,  lwai  &  Miura, 
1989),  and  it  has  been  shown  that  even  simple  toothbrushing  may  produce  viridans 
streptococcal  bacteraemia  (Donley  &  Donley,  1988,  Roberts  et  al.,  1997).  However 
until  now,  genotypic  analyses  to  compare  toothbrush  with  blood  culture  isolates  have 
not  been  performed. 
These  novel  results  demonstrated  that  strains  of  viridans  streptococci  can  persist  in 
the  oral  cavity  and  suggest  that  a  heavily  colonized  toothbrush  may  be  a  potential 
vector  of  infection  in  neutropenic  patients  with  oral  compromise.  Special  soft 
toothbrushes  are  now  recommended  as  more  effective  tools  for  mouth  care  for 
paediatric  cancer  patients  (Gibson,  Horsford  &  Nelson,  1997;  Corbett,  1997),  than 
the  disposable  foam  toothettes,  which  were  commonly  used  in  the  past.  Children 
with  painful  mouths  are  perhaps  unlikely  to  use  aggressive  techniques  of 
toothbrushing.  However,  the  results  of  this  study  demonstrate  the  importance  of 
replacing  such  brushes  regularly  to  prevent  excessive  accumulation  of  oral  bacteria. 
Damaged  gastrointestinal  mucosa  should  also  be  considered  as  a  portal  of  entry  for 
viridans  streptococci.  In  the  present  study,  when  the  total  number  of  cases  with 
some  form  of  oral  complication  plus  those  with  chemotherapy-related  diarrhoea 
and/or  rectal  mucositis  were  considered  together,  a  total  of  58  cases  (84%),  could  be 
included  as  a  group  with  possible  bacterial  translocation  from  the  oral  cavity  or 
gastrointestinal  tract  into  the  bloodstream. 
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manifestations  of  gastrointestinal  toxicity  in  adults  treated  for  cancer.  They  found 
that  treatment  of  chemotherapy-induced  gastritis  with  antacids  or  with  H2  antagonists 
was  associated  with  a  sevenfold  increase  in  risk  of  viridans  streptococcal 
bacteraemia.  They  proposed  that  overgrowth  of  viridans  streptococci  was  facilitated 
by  the  use  of  antacids  and  that  gastrointestinal  tract  ulceration  would  allow  access  to 
the  bloodstream. 
It  should  still  be  appreciated  that,  in  some  instances,  the  mouth  or  gastrointestinal 
tract  may  not  be  the  source  of  viridans  streptococci.  As  demonstrated  by  case  (3)  of 
the  present  study,  viridans  streptococci  cultured  from  line  blood  on  two  occasions, 
were  not  genotypically  identical  to  any  strain  of  viridans  streptococcus  isolated  from 
the  patient's  oral  cavity.  In  this  particular  case,  the  patient  was  not  neutropenic  and 
was  afebrile.  The  source  of  viridans  streptococci  may  have  been  the  Hickman  line. 
8.4  The  changing  pattern  of  viridans  streptococcal  bacteraemia 
8.4.1  Introduction 
It  was  outwith  the  remit  of  this  study  to  determine  the  reason  for  the  increase  in 
cases  of  viridans  streptococcal  bacteraemia  at  RHSC  during  the  early  1990s  - 
reaching  a  maximum  of  18  (representing  22%  of  total  episodes  of  culture-proven 
bloodstream  infection  and  5.9%  of  all  febrile  episodes)  in  1994.  Intensification  of 
chemotherapy  protocols,  as  reported  by  others  (Sotiropoulos  et  al.,  1989;  Kern, 
Kurrle  &  Schmeiser,  1990)  may  have  been  a  contributory  factor.  With  the  success  of 
such  chemotherapeutic  approaches  in  the  treatment  of  certain  malignancies,  oral 
and  gastro-intestinal  mucositis  became  viewed  as  undesirable  but  inevitable  side 
effects. 
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in  the  previous  year  at  RHSC  (15  versus  18),  the  associated  morbidity  and  mortality 
were  unacceptable  (Sections  5.12  and  5.13).  Mouth  care  protocols  were  being 
followed  satisfactorily,  and  a  preliminary  diagnosis  of  streptococcal  bacteraemia  from 
Gram  staining  of  any  positive  blood  cultures  prompted  the  rapid  addition  of 
vancomycin  to  first  line  empirical  therapy.  However,  at  this  time,  in  spite  of  such 
efforts,  viridans  streptococcal  bacteraemia  had  become  a  potentially  life-threatening 
infection. 
Then,  from  late  summer  of  1996,  in  conjunction  with  a  further  decrease  in  the 
number  of  cases  of  viridans  streptococcal  bacteraemia,  serious  complications 
associated  with  this  infection  also  declined.  By  the  end  of  this  study,  in  the  year 
2000,  there  occurred  only  5  episodes  of  viridans  streptococcal  bacteraemia. 
However,  with  the  continued  use  of  intensive  chemotherapeutic  protocols,  potentially 
providing  a  mucosal  portal  of  entry  for  viridans  streptococci  into  the  bloodstream  of 
neutropenic  patients,  how  could  the  statistically  significant  decrease  in  cases  from 
1994  to  2000  be  explained? 
A  decrease  in  incidence  of  viridans  streptococcal  bacteraemia  was  observed  in 
EORTC  trial  IX  (Cometta  et  al.,  1995)  compared  to  trial  VIII  (EORTC  International 
Antimicrobial  Therapy  Cooperative  Group,  1993),  however  the  precise  reasons  for 
this  decrease  were  not  proposed.  During  trial  VIII  the  combination  of  ceftriaxone 
plus  amikacin  was  compared  with  standard  ceftazidime  plus  amikacin  as  empirical 
therapy  and  during  trial  IX  the  comparator  regimen  was  piperacillin/tazobactam  plus 
amikacin. 
It  is  difficult  to  make  firm  conclusions  regarding  changing  trends  in  incidence  of 
microbial  infection  and  influential  factors,  when  relatively  small  sample  sizes  are 
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obviously  no  way  of  assessing  definitively  what  the  outcome  would  have  been 
otherwise.  However,  in  the  following  sections,  the  findings  of  this  study  will  be 
discussed  and  evaluated,  and  possible  reasons  for  and  contributory  factors  to  the 
decrease  in  viridans  streptococcal  bacteraemia  will  be  proposed. 
8.4.2  The'influence  of  underlying  malignancy,  cytotoxic  chemotherapy  and 
empirical  antibiotics 
Cases  of  viridans  streptococcal  bacteraemia  were  more  likely  to  be  associated  with  a 
primary  diagnosis  of  acute  leukaemia  than  that  of  other  malignancies  (80%  versus 
20%  in  the  present  study),  as  described  previously  by  others  (Cohen  et  al.,  1983; 
Groot-Loonen  et  al.,  1987;  Weisman  et  al.,  1990;  Burden  et  al.,  1991;  Elting,  Bodey 
&  Keefe,  1992;  Bochud  et  al.,  1994;  Richard  et  al.,  1995;  Wisplinghoff  et  al.,  1999). 
Patients  with  acute  leukaemia  generally  receive  more  intensive  chemotherapy  than 
those  with  solid  tumours,  therefore  the  former  group  would  be  expected  to 
experience,  to  a  greater  extent,  toxic  side  effects  such  as  oral  and/or  gastrointestinal 
mucositis  and  profound  neutropenia.  This  in  turn,  may  more  readily  predispose  them 
to  viridans  streptococcal  bacteraemia.  A  logical  conclusion  therefore  is  that  the 
therapy  for  the  malignancy,  more  than  the  malignancy  itself  may  be  a  predisposing 
factor. 
More  boys  than  girls  (32  versus  22)  developed  viridans  streptococcal  bacteraemia. 
This  finding  may  be  related  to  the  fact  that  males  are  affected  more  often  by  cancer 
than  are  females.  Twenty-nine  paediatric  patients  with  ALL  developed  viridans 
streptococcal  bacteraemia  compared  to  14  with  AML.  However,  as  mentioned 
earlier,  AML  comprises  around  15-20%  of  all  cases  of  childhood  acute  leukaemia, 
therefore  children  with  this  disease  are  at  greater  risk  than  those  with  ALL  of 
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than  that  for  ALL,  producing  profound  neutropenia  with  more  severe  mucosal 
toxicity,  thus  potentially  increasing  the  predisposition  to  infection  by  oral  organisms 
such  as  viridans  streptococci.  In  particular,  the  frequency  of  viridans  streptococcal 
bacteraemia  was  found  to  be  associated  with  increasing  dose  of  cytosine 
arabinoside  (Section  5.11).  Chemotherapy  regimens  containing  high  doses  of  this 
agent,  such  as  CLASP,  or  `intermediate-high'  doses,  such  as  MidAC  and  FLAG  are 
used  in  the  treatment  of  AML.  As  detailed  in  the  results  section,  32%  of  total 
courses  of  CLASP  administered  in  the  unit  were  associated  with  the  development  of 
viridans  streptococcal  bacteraemia.  Twenty-three  percent  of  courses  of  MidAC  and 
similarly,  23%  of  courses  of  FLAG  preceded  viridans  streptococcal  bacteraemia, 
compared  with  an  association  with  less  than  5%  of  all  courses  of  DATES  (which 
contains  a  lower  dose  of  cytosine  arabinoside). 
Earlier  studies  demonstrated  the  relationship  between  high  or  intermediate  high- 
dose  cytosine  arabinoside  and  the  incidence  of  viridans  streptococcal  bacteraemia 
(Sotiropoulos  et  al.,  1989;  Kern,  Kurrie  &  Schmeiser,  1990;  Weisman  et  al.,  1990; 
Bochud  et  al.,  1994;  Richard  et  al.,  1995).  In  1989,  Sotiropoulos  and  co-workers 
described  14  episodes  of  viridans  streptococcal  bacteraemia  which  occurred  after 
therapy  with  either  continuous  or  high-dose  cytosine  arabinoside.  Prior  to  the 
introduction  of  these  intensive  chemotherapeutic  protocols,  only  one  case  of  viridans 
streptococcal  bacteraemia  had  occurred  in  the  previous  8  years.  Several  case 
control  studies  confirmed  a  statistically  significant  association  between  therapy  with 
high  doses  of  cytosine  arabinoside  and  the  incidence  of  viridans  streptococcal 
bacteraemia  (Kern,  Kurrle  &  Schmeiser;  Weisman  et  al.,  1990,  Bochud  et  al.,  1994; 
Richard  et  al.,  1995).  In  a  5-year  prospective  study  of  the  incidence  of  viridans 
streptococcal  bacteraemia  in  bone  marrow  transplantation  recipients  (Engelhard  et 
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the  conditioning  regimen  (p  <  0.01). 
However,  an  important  new  aspect  of  this  association  emerged  as  a  result  of  the 
present  work.  Detailed  analyses  of  the  relationship  between  administration  of  the 
CLASP  regimen  and  incidence  of  viridans  streptococcal  bacteraemia,  described  in 
Section  6.7.2,  revealed  an  asymmetrical  distribution  of  cases  (Figure  6.3),  with  the 
association  between  these  two  factors  much  stronger  during  the  first  2  years  than 
during  the  last  four.  As  mentioned  previously,  the  only  significant  change  in 
management  of  haematology/  oncology  patients  receiving  the  CLASP  regimen  (or 
any  other  form  of  chemotherapy),  between  these  two  time  intervals  was  the  change 
of  empirical  antibiotic  therapy  for  episodes  of  febrile  neutropenia,  from  the 
combination  of  ceftazidime  plus  amikacin  to  piperacillin/tazobactam  plus  amikacin. 
Cotrimoxazole  prophylaxis  was  a  constant  factor  for  the  majority  of  cases  throughout 
the  period  of  this  study,  with  rates  of  resistance  to  this  agent  virtually  identical  prior  to 
the  change  and  following  it  (73%  versus  74%). 
All  patients  who  had  been  treated  with  the  CLASP  regimen  had  received  empirical 
antibiotics  for  previous  episodes  of  febrile  neutropenia.  It  is  possible  that  the  use  of 
an  antibiotic  with  poor  activity  against  viridans  streptococci,  such  as  ceftazidime, 
may  have  selected  for  resistant  strains  which  could  readily  colonize  their  oral  cavities 
and  gastrointestinal  tracts.  It  has  previously  been  discussed  that  in  certain 
circumstances  bacterial  loading  can  occur,  and  that  dominant  organisms  may 
become  established  in  the  mouths  of  patients  with  cancer  (Sixou  et  al.,  1998).  This 
phenomenon  may  have  occurred  in  the  patients  of  the  present  study,  with  resistant 
strains  of  S.  oralis  predominating. 
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tazobactam  for  empirical  therapy,  bacterial  loading  effects  may  be  less  likely  to 
occur.  Piperacillin/tazobactam  is  more  active  against  viridans  streptococci  and 
would  therefore  not  tend  to  select  for  overgrowth  of  these  organisms.  In  the  study  of 
Bradley  and  colleagues  (1999),  which  also  compared  ceftazidime  with 
piperacillin/tazobactam  as  empirical  therapy  in  febrile  neutropenia,  clinical  cases  of 
infection  with  glycopeptide-resistant  enterococci  were  observed  only  when  carriage 
rates  were  high  and  only  during  the  ceftazidime  phase  of  the  study. 
A  further  factor  which  may  have  influenced  anti-bacterial  activity  by  piperacillin/ 
tazobactam  or  ceftazidime  is  synergy  with  amikacin.  The  combination  of  piperacillin/ 
tazobactam  plus  the  aminoglycoside  antibiotic,  gentamicin,  has  been  shown  to  be 
synergistic  in  vitro  against  streptococci  (Gould  &  Milne,  1997).  Synergy  has  also 
been  reported  between  the  extended-spectrum  cephalosporin,  cefriaxone  and  the 
aminoglycoside,  netilmicin  in  a  rat  model  of  streptococcal  endocarditis  (Francioli  & 
Glauser,  1993).  Although  piperacillin/tazobactam  itself  demonstrated  far  superior  in 
vitro  activity  against  viridans  streptococci  to  that  of  ceftazidime,  it  would  have  been 
interesting  to  determine  whether  differential  synergy  existed  between  the 
aminoglycoside/ß  -lactam  combinations  of  the  present  study. 
The  recent  study  of  Marron  and  colleagues  (2001)  described  the  prevalence  of 
resistance  to  cephalosporins  among  viridans  streptococci  causing  bacteraemia  in 
neutropenic  patients  with  cancer.  They  found  that  previous  administration  of  aß- 
lactam  antibiotic  (predominantly  ceftazidime)  was  the  only  factor  significantly 
associated  with  bacteraemia  due  to  cephalosporin-resistant  strains.  The  present 
study  revealed  that  higher  geometric  mean  MICs  of  cephalosporins  were  associated 
with  isolates  of  viridans  streptococci  from  blood  cultures  while  empirical  therapy  was 
ceftazidime  plus  amikacin  rather  than  piperacillin/tazobactam  plus  amikacin.  As  the 
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received  prior  courses  of  ceftazidime  during  phase  1,  this  finding  concurs  with  that  of 
Marron  and  co-workers.  The  present  study  also  demonstrated  that  susceptibility  to 
other  0  -lactam  antibiotics  may  be  affected  by  prior  empirical  therapy  with  ceftazidime 
and  also  revealed  that  viridans  streptococci  isolated  from  blood  cultures  of  patients 
after  the  change  in  empirical  therapy  had  lower  geometric  mean  MICs  for  all  ß- 
lactam  antibiotics  tested.  Smith  (1999)  also  described  a  reduction  in  resistance  to 
antibiotics,  associated  with  a  change  in  prescription  from  third-generation 
cephalosporins  to  piperacillin/tazobactam.  Over  a  four-year  period,  the  overall 
bacterial  resistance  pattern  in  a  U.  S.  hospital  changed  significantly,  with  reduction  in 
antimicrobial  resistance  in  Enterobacteriaceae,  Enterococcus  spp.  and  methicillin- 
resistant  Staphylococcus  aureus. 
In  summary,  the  findings  of  the  present  study  indicated  that  viridans  streptococcal 
bacteraemia  occurred  more  often  following  chemotherapy  with  regimens  containing 
high-dose  cytosine  arabinoside,  such  as  CLASP.  However  the  frequency  of  viridans 
streptococcal  bacteraemia  following  this  form  of  chemotherapy  was  significantly 
reduced  when  empirical  therapy  for  episodes  of  febrile  neutropenia  was  changed 
from  ceftazidime  plus  amikacin  to  piperacillin/tazobactam  plus  amikacin,  suggesting 
that  multiple  inter-related  factors  may  contribute  to  the  development  of  this  infection. 
Chemotherapy-induced  mucositis  produces  a  portal  of  entry,  but  bacteraemia  may 
be  more  likely  to  occur  in  the  presence  of  high  oral  bacterial  loads  of  resistant 
organisms.  Although  there  were  fewer  episodes  of  viridans  streptococcal 
bacteraemia  in  1995  than  in  1994,  this  decrease  was  not  statistically  significant,  and 
while  it  is  obviously  impossible  to  determine  the  pattern  of  infection  which  would 
have  followed  in  the  absence  of  the  change  in  empirical  antibiotic  therapy,  the 
findings  of  this  thesis  suggest  that  the  substitution  of  ceftazidime  with 
piperacillin/tazobactam  was  influential  in  the  consistent  decline  in  viridans 
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discussing  the  increase  in  Gram-positive  bacteraemia  amongst  immuno- 
compromised  patients,  commented  that  "Cyclical  variation  over  several  decades  has 
been  recognized  in  the  type  of  offending  pathogens  and  may  be  related  to  the 
selective  pressure  of  antibiotics  with  a  modified  spectrum  of  action,  such  as  the 
cephalosporins"  (Viscoli,  Van  der  Auwera  &  Meunier,  1988). 
8.5  Spectrum  of  symptoms  associated  with  viridans  streptococcal 
bacteraemia 
8.5.1  Introduction 
The  results  of  this  study  demonstrated  that  a  variety  of  symptoms  may  accompany 
viridans  streptococcal  bacteraemia  in  immunocompromised  paediatric  patients.  In 
the  majority  of  episodes  (70%  of  total),  patients  responded  readily  to  antimicrobial 
therapy  with  no  further  complications.  Varying  degrees  of  respiratory  compromise 
were  associated  with  the  remaining  21  episodes.  In  eight  (12%  of  total),  this  feature 
became  so  severe  that  ITU  support  with  mechanical  ventilation  was  required.  Septic 
shock  accompanied  ARDS  in  5  of  these  severe  cases. 
As  mentioned  earlier,  one  aim  of  the  present  work  was  to  identify  why  there  existed 
such  a  spectrum  of  symptoms  in  patients  suffering  from  viridans  streptococcal 
bacteraemia.  Previous  authors  had  described  a  severe  form  of  viridans 
streptococcal  bacteraemia  sometimes  referred  to  as  "viridans  streptococcal  shock 
syndrome"  (Cohen  et  al.,  1983;  Henslee  et  al.,  1984;  Sotiropoulos  et  al.,  1989; 
Weisman  et  al.,  1990;  Classen  et  al.,  1990;  Villablanca  et  al.,  1990;  Elting,  Bodey  & 
Keefe,  1992;  Martino  et  al.,  1995).  However,  in  contrast  to  the  present  study,  most 
had  identified  S.  mitis  as  the  causative  organism  in  the  severe  form  of  sepsis  (Elting, 
Bodey  &  Keefe,  1992;  Bochud  et  al.,  1994;  Carratala  et  al.,  1995;  Engel,  Kern  & 
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a  predominance  of  S.  oralis,  which  may  be  related  to  the  advances  in  identification 
and  taxonomy  of  viridans  streptococci.  However  the  distribution  of  species  of 
viridans  streptococci  in  the  oral  cavity  varies  with  age  (as  discussed  in  Section  1.3.1) 
and  therefore  species  from  blood  culture  may  also  vary  from  one  study  group  to 
another.  The  present  study  demonstrated  that  the  identification  of  S.  oralis  per  se 
did  not  necessarily  predict  severity  of  infection. 
8.5.2  Complications  associated  with  viridans  streptococcal  bacteraemia:  the 
influence  of  chemotherapeutic  agents,  empirical  antibiotics  and 
concomitant  infections 
In  addition  to  its  association  with  the  actual  incidence  of  viridans  streptococcal 
bacteraemia  (Sotiropoulos  et  al.,  1989;  Kern,  Kurrie  &  Schmeiser,  1990;  Weisman  et 
al.,  1990;  Bochud  et  al.,  1994;  Richard  et  al.,  1995),  the  use  of  chemotherapy 
regimens  containing  high-doses  of  cytosine  arabinoside  is  also  the  most  commonly 
quoted  risk  factor  for  development  of  the  severe  form  of  this  infection  (Sotiropoulos 
et  al.,  1989;  Kern,  Kurrie  &  Schmeiser,  1990;  Bochud  et  al.,  1994).  Twelve  of  the  21 
episodes  (57%)  of  the  present  study  with  respiratory  complications  occurred 
following  therapy  with  either  high-  or  `intermediate-high'  dose  cytosine  arabinoside, 
with  3  of  these  progressing  to  ARDS  and  septic  shock  and  two  to  ARDS  alone. 
However,  it  must  be  acknowledged  that  not  all  patients  treated  with  high  or 
intermediate-high  dose  cytosine  arabinoside  developed  viridans  streptococcal 
bacteraemia  and  not  all  who  did,  developed  respiratory  complications  or  shock. 
During  the  first  two  years  of  the  study,  both  a  higher  frequency  of  viridans 
streptococcal  bacteraemia  and  increased  severity  of  associated  symptoms  were 
found  amongst  patients  who  received  the  CLASP  regimen  when  compared  with 
those  receiving  this  regimen  during  the  later  4  years.  Five  of  these  cases,  from  1995 
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developing  septic  shock),  compared  with  one  case  from  1997  -  2000  with  mild 
respiratory  symptoms  only  (patient  No.  44). 
It  has  been  shown  that  even  organisms  with  low  pathogenic  potential,  such  as 
coagulase-negative  staphylococci  can  induce  the  release  of  cytokines  and  produce 
shock  if  inoculated  experimentally  in  large  doses  (Wakabayashi  et  al.,  1991).  The 
combination  of  large  numbers  of  viridans  streptococci  and  their  persistence  in  the 
bloodstream  due,  in  part,  to  resistance  to  first  line  empirical  therapy  in  the  early 
years  of  the  present  work,  may  have  provided  these  organisms  with  a  distinct 
pathogenic  advantage. 
Preparations  of  cell  walls  from  viridans  streptococci  have  been  shown  to  induce  the 
production  of  TNF-a  and  IL-6  from  human  monocytes  (Heumann  et  al.,  1994). 
Lipoteichoic  acids  derived  from  viridans  streptococci  may  also  induce  the  production 
of  proinflammatory  cytokines  (Bhakdi  et  al.,  1991).  The  study  of  Soto  and  co- 
workers  (1998)  demonstrated  that  cell  free  extracts  of  viridans  streptococci  could 
induce  TNF-a,  TNF-ß  and  IL-8  from  human  peripheral  blood  mononuclear  cells  in 
vitro.  In  certain  clinical  settings,  infecting  viridans  streptococci  may  also  be  able  to 
elicit  the  release  of  proinflammatory  cytokines  in  vivo,  as  suggested  by  the  work  of 
Engel  and  colleagues  (1996),  which  demonstrated  that  TNF-a  and  IL-6  could  be 
detected  from  serum  of  patients  with  "lethal  viridans  streptococcal  sepsis".  If  the 
bacterial  load  is  high,  sufficient  levels  of  cytokines  may  be  produced  to  result  in  the 
development  of  septic  shock.  Septic  shock  did  not  accompany  any  episodes  of 
viridans  streptococcal  bacteraemia  in  the  present  study,  after  empirical  therapy  was 
changed  to  piperacillin/tazobactam. 
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ARDS  in  the  patients  of  this  study.  The  definition  of  the  American-European 
Concensus  Conference  on  ARDS  requires  two  positive  criteria  -  bilateral  infiltrates 
on  chest  radiograph  and  arterial  hypoxaemia,  and  one  negative  criterion  -  absence 
of  clinical  evidence  of  cardiogenic  pulmonary  oedema  (Bernard  et  al.,  1994). 
Historically  ARDS  was  considered  to  be  a  neutrophil  mediated  disease.  When 
associated  with  septic  shock,  it  was  postulated  that  within  the  lung,  cytokine  induced 
changes  led  to  profound  hypoxaemia  and  respiratory  failure.  TNF-a,  IL-8  and  C5a 
all  contributed  to  neutrophil  chemotaxis,  whilst  the  upregulation  of  endothelial  cell 
adhesion  molecules  and  neutrophil  integrins  facilitated  the  passage  of  fluid  and 
leucocytes  from  the  circulation  into  the  lung  interstitium  and  alveolar  spaces 
(Sriskandan  &  Cohen,  1995). 
However,  ARDS  also  occurs  in  neutropenic  patients  (Braude  et  al.,  1985;  Ognibene 
et  al.,  1986;  Sivan  et  al.,  1990)  as  in  the  present  study,  therefore  there  must  also 
exist  neutrophil  independent  mechanisms  capable  of  producing  this  condition.  A 
further  complicating  factor  is  that  although  sepsis  is  a  major  factor  associated  with 
the  development  of  ARDS,  other  events  such  as  aspiration,  severe  trauma  and 
pneumonia  can  also  predispose  to  this  condition  (Bagshaw  &  Gajraj,  1999;  Ware  & 
Matthay,  2000).  It  has  also  been  reported  that  the  risk  of  developing  ARDS 
increases  when  more  than  one  factor  is  present  (Kollef  &  Schuster,  1995). 
A  variety  of  chemotherapeutic  agents  such  as  bleomycin,  busuiphan,  carmustine, 
cyclophosphamide  and  cytosine  arabinoside  are  known  to  induce  pulmonary 
dysfunction  (Haupt,  Hutchins  &  Moore,  1981;  Andersson  et  al.,  1985;  Tjon  A  Tham  et 
al.,  1987;  Seibert  &  Lewis,  1992).  Therefore,  any  one  of  these  agents  could 
potentially  contribute  to  the  development  of  ARDS  in  cancer  patients.  However, 
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of  viridans  streptococcal  bacteraemia? 
The  work  of  Guiot  and  colleagues  (1990),  demonstrated  that  prophylaxis  with 
penicillin  reduced  not  only  the  incidence  of  viridans  streptococcal  bacteraemia  in 
patients  treated  with  this  agent,  but  also  that  of  respiratory  complications.  This 
observation  may,  in  part,  relate  to  that  of  the  present  study,  where  a  change  to 
empirical  therapy  with  superior  activity  against  viridans  streptococci  was  temporally 
associated  with  a  decrease  in  incidence  of  viridans  streptococcal  bacteraemia  and 
pulmonary  complications  following  cytotoxic  therapy  with  high-dose  cytosine 
arabinoside.  One  explanation  for  these  findings  is  that  additional  stress,  such  as 
viridans  streptococcal  bacteraemia  is  more  likely  to  contribute  to  the  development  of 
respiratory  distress  in  patients  treated  with  agents  with  pulmonary  toxicity.  An 
extension  of  this  hypothesis  is  that,  the  higher  the  bacterial  load  and  the  longer  these 
organisms  are  allowed  to  persist  in  the  bloodstream,  the  greater  the  additional  stress 
and  the  more  severe  the  clinical  symptoms. 
Five  of  the  seven  cases  with  ARDS  in  the  present  study  also  featured  septic  shock, 
therefore  sepsis-driven  induction  of  cytokines  may  have  influenced  the  development 
of  pulmonary  complications.  However,  in  all  of  these  cases,  multiple  predisposing 
factors  for  respiratory  compromise  were  present.  Three  had  recently  received 
therapy  with  high-doses  of  cytosine  arabinoside.  In  one  of  these  three,  pulmonary 
CMV  infection  was  diagnosed  and  in  another,  P.  carinii  infection.  Another  patient 
with  ARDS  and  septic  shock  had  a  history  of  recurrent  chest  infections  and  had 
received  chemotherapy  some  time  earlier  for  a  different  malignancy.  Finally,  the 
development  of  ARDS  in  the  baby  with  viridans  streptococcal  bacteraemia  and 
septic  shock  on  two  occasions  may  also  have  been  associated  with  pulmonary 
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for  AML. 
A  variety  of  viruses  may  contribute  to  the  development  of  severe  respiratory 
complications  in  immunocompromised  patients.  On  chest  X-ray,  viral  pneumonitis  or 
that  produced  by  P.  carinii  may  resemble  the  early  ARDS-type  pattern  (Sivan  et  al., 
1990).  Very  few  earlier  reports  of  viridans  streptococcal  bacteraemia,  included 
details  of  concomitant  infection  by  these  agents  (Groot-Loonen  et  al.,  1987)  or 
mentioned  their  exclusion  as  contributory  to  respiratory  complications  (Tjon  A  Tham, 
1987;  Dybedal  &  Lamvik,  1989).  Today,  immunofluorescence  and  molecular 
techniques,  such  as  PCR  have  lead  to  improved  diagnosis  of  respiratory  pathogens. 
The  findings  of  this  study  in  which  5  of  the  21  episodes  (i.  e.  24%)  with  respiratory 
complications  featured  concomitant  infection  with  viruses  or  P.  carinii  demonstrate 
that  these  organisms  may  play  a  significant  role. 
One  of  the  two  patients  with  viridans  streptococcal  bacteraemia  who  developed 
ARDS  in  the  absence  of  septic  shock  had  received  therapy  with  high-dose  cytosine 
arabinoside  and  had  no  other  predisposing  factors.  In  the  other,  pulmonary 
infiltration  by  lymphoma  was  strongly  suspected.  Diffuse  bilateral  infiltrates  on 
radiography  may  also  result  from  lung  infiltration  by  certain  malignancies  such  as 
lymphoma  (Seibert  &  Lewis,  1992).  Histological  confirmation  could  not  be  obtained 
because  of  the  very  poor  clinical  condition  of  the  child.  Infection  by  Picorna  virus 
(diagnosed  by  viral  PCR)  in  this  compromised  patient  may  also  have  contributed  to 
respiratory  complications. 
The  development  of  and  range  of  severity  of  features  accompanying  viridans 
streptococcal  bacteraemia,  appear  to  depend  on  several  highly  interrelated  elements 
which  may  co-exist  in  the  immunocompromised  host.  An  awareness  of  the  complex 
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of  these  patients. 
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9.1  Antibiotic  therapy 
Viridans  streptococci  have  now  become  a  rare  cause  of  bacteraemia  in 
immunocompromised  patients  at  RHSC.  Empirical  antibiotic  therapy  for  episodes  of 
febrile  neutropenia  is  still  amikacin  plus  piperacillin/tazobactam,  a  combination  which 
remains  active  against  a  wide  variety  of  bacteria  responsible  for  infection  in  this 
patient  group. 
As  detailed  in  Chapter  6,  since  the  change  in  empirical  therapy  for  episodes  of  febrile 
neutropenia,  MICs  of  all  0  -lactam  antibiotics  against  isolates  of  viridans  streptococci 
are  generally  lower.  However  if  resistance  to  piperacillin/tazobactam  were  to 
develop,  which  new  antimicrobial  treatment  options  would  be  considered? 
From  the  in  vitro  results  of  this  study,  one  would  expect  that  meropenem  would  be  a 
useful  option,  because  of  its  extremely  low  MIC  values  against  all  isolates  of  viridans 
streptococci.  Other  authors  have  also  reported  the  excellent  in  vitro  activity  of 
carbapenem  antibiotics  against  these  organisms  (Potgieter  et  al.,  1992;  McWhinney 
et  al.,  1993;  Alcaide  et  al.,  1995;  Teng  et  al.,  1998;  Marron  et  al.,  2001).  However  it 
is  unlikely  that  meropenem  would  become  part  of  first  line  empirical  therapy  at 
RHSC.  Its  role  at  present  is  that  of  a  reserve  agent  -  for  treatment  of  infection  by 
coliforms  which  produce  extended  spectrum  ß  -lactamases. 
Cefpirome  may  be  another  option.  This  fourth  generation  cephalosporin  antibiotic 
demonstrated  considerable  in  vitro  activity  against  viridans  streptococci  and  has 
been  used  by  others  in  the  setting  of  febrile  neutropenia  (Paredes  &  South,  1997). 
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currently  being  undertaken  by  the  author  for  future  reference. 
The  present  study  demonstrated  the  effective  in  vitro  activity  of  vancomycin  against 
viridans  streptococci.  However,  because  of  its  nephrotoxic  potential  (Kibbler  et  al., 
1989;  EORTC,  1991)  and  the  possibility  that  its  widespread  use  may  lead  to  the 
selection  of  glycopeptide-resistant  Enterococcus  spp.  or  S.  aureus  it  is  unlikely  that 
this  antibiotic  would  be  considered  as  part  of  first  line  empirical  therapy  at  RHSC. 
Rather,  it  will  remain  a  reserve  agent  for  treatment  of  microbiologically  documented 
infection  by  certain  Gram-positive  bacteria. 
The  newer  antibiotics  tested  in  this  study,  quinupristin/dalfopristin  and  linezolid  both 
displayed  excellent  in  vitro  activity  against  viridans  streptococci  with  no  cross 
resistance  with  the  other  antimicrobial  agents  tested.  Several  recent  reports  describe 
the  considerable  in  vitro  activity  of  these  new  agents  against  Gram-positive  bacteria 
(Schouton  &  Hoogkamp-Korstanje,  1997;  Barry,  Fuchs  &  Brown,  1998;  Wise  et  al., 
1998;  Johnson,  Warner  &  Livermore,  2000;  Fines  &  Leclerq,  2000;  Henwood  et  al., 
2000;  Cercenado,  Garcia-Garrote  &  Bouza,  2001;  Gemmell  et  at.,  2001;  Kennedy  et 
a1.,  2001;  Tubau  et  al.,  2001).  The  few  publications  which  include  susceptibility 
testing  against  viridans  streptococci  confirm  the  findings  of  the  work  described  in  this 
thesis  (Schouton  &  Hoogkamp-Korstanje,  1997;  Barry,  Fuchs  &  Brown,  1998; 
Johnson,  Warner  &  Livermore,  2000;  Cercenado,  Garcia-Garrote  &  Bouza,  2001). 
At  present  only  quinupristin/dalfopristin  is  licensed  for  treatment  of  infection  in 
paediatrics. 
It  is  impossible  to  predict  whether  these  agents  will  ultimately  be  required  for 
treatment  of  infection  caused  by  Gram-positive  bacteria  other  than  strains  of 
Enterococcus  spp  or  S.  aureus  which  are  resistant  to  multiple  antibiotics.  However  it 
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with  excellent  activity  against  Gram-positive  bacteria  have  become  available. 
9.2  Antibiotic  prophylaxis 
Antibacterial  prophylaxis  is  used  less  commonly  in  paediatric  patients  with  malignant 
disease  than  in  their  adult  counterparts.  As  mentioned  earlier,  the  only  form  of 
antibiotic  prophylaxis  used  routinely  at  RHSC,  for  high-risk  groups,  is  cotrimoxazole, 
as  prophylaxis  against  P.  carinii  pneumonia.  As  discussed  previously,  its  use  has 
been  reported  by  others  as  a  risk  factor  for  the  development  of  viridans  streptococcal 
bacteraemia  (Elting,  Bodey  &  Keefe,  1992).  Although  the  results  of  the  present 
study  suggest  that  the  prophylactic  administration  of  cotrimoxazole  may  be 
associated  with  high  rates  of  resistance  to  this  agent  amongst  viridans  streptococci 
isolated  from  blood  culture,  its  use  will  continue,  as  the  benefits  significantly 
outweigh  the  disadvantages.  As  this  study  demonstrated,  both  the  incidence  and 
severity  of  symptoms  associated  with  viridans  streptococcal  bacteraemia  decreased 
throughout  the  period  of  this  study,  in  spite  of  the  continuing  use  of  cotrimoxazole. 
Quinolones  are  not  generally  used  for  prophylaxis  or  treatment  of  infection  in 
paediatric  patients  because  of  the  arthropathogenic  potential  of  these  agents  in 
juvenile  animals  (Schluter,  1987).  Prophylaxis  using  these  agents  has  been  reported 
as  a  risk  factor  for  viridans  streptococcal  bacteraemia  in  adult  patients  (Kern,  Kurrie 
&  Schmeiser,  1990;  Classen  et  al.,  1990). 
The  results  of  this  study  demonstrated  considerable  rates  of  high-level  resistance  to 
penicillin  in  spite  of  the  fact  that  penicillin  is  neither  used  for  therapy  or  prophylaxis  of 
infection  in  this  patient  population.  Such  resistance  rates  may  be  related,  in  part,  to 
the  use  of  other  ß  -lactam  agents  as  empirical  therapy.  In  addition,  it  has  been 
shown  that  even  healthy  children  harbour  more  penicillin  resistant-viridans 
232 streptococci  than  adults  with  cancer  (Guiot,  Corel  &  Vosen,  1994).  Again,  in  contrast 
to  the  situation  with  adult  cancer  patients  (Spanik  et  al.,  1997),  penicillin  is  unlikely  to 
be  used  as  antibacterial  prophylaxis  for  paediatric  patients  with  cancer  at  RHSC. 
9.3  Pre-emptive  antibiotic  therapy 
Future  research  in  the  field  of  viridans  streptococcal  infection  in 
immunocompromised  patients  should  attempt  to  determine  why  some  patients 
develop  several  episodes  of  viridans  streptococcal  infection.  The  present  study 
demonstrated  that  five  patients  developed  2  episodes  of  viridans  streptococcal 
bacteraemia,  two  patients  developed  3  and  two  developed  four.  As  early  as  1978, 
Pizzo  and  colleagues  reported  three  discrete  episodes  of  viridans  streptococcal 
bacteraemia  in  one  patient  with  cancer.  Similar  findings  have  been  described  by 
others  (Sotiropolous  et  al.,  1989;  Weisman  et  al.,  1990;  Gamis  et  al.,  2000).  Recent 
investigation  has  demonstrated  that  multiple  episodes  in  the  one  patient  may  be  due 
to  either  the  same  isolate  or  different  isolates  (Wisplinghoff  et  al.,  1999).  Pre- 
emptive  antibiotic  therapy  for  such  patients  may  be  appropriate. 
9.4  Dental  and  oral  assessment 
Several  studies  have  focused  on  the  oral  health  of  children  with  malignancy,  and 
have  demonstrated  that  considerable  dental  and  mucosal  disease  often  exists  at 
diagnosis,  as  well  as  during  anti-cancer  therapy  (Berkowitz  et  at.,  1987;  Fayle  & 
Curzon,  1991;  Clarkson  &  Eden,  1998;  Lucas,  Roberts  &  Beighton,  1998).  In  view  of 
the  subsequent  very  high  incidence  of  complications  as  a  result  of  oral  compromise 
in  such  patients,  it  is  clear  that  preventative  approaches  are  important.  However, 
these  should  ideally  be  tailored  to  the  individual  patient  and  his/her  treatment 
schedules,  as  elective  dental  procedures  and  manipulation  of  the  oral  tissues  should 
not  be  undertaken  when  the  patient  is  receiving  chemotherapy  or  is 
233 myelosuppressed.  A  thorough  oral  examination  is  important  in  the  overall  pre- 
chemotherapy  evaluation.  Existing  and  potential  dental  and  oral  disease  should  be 
identified  and,  if  possible,  eradicated  and  a  plan  devised  for  continuing  management 
during,  and  following  therapy. 
9.5  Mouth  care  protocols 
In  the  past,  mouth  care  protocols  for  patients  receiving  cytotoxic  chemotherapy 
tended  to  be  ritualistic  with  the  same  regimen  being  used  for  patients  with  different 
levels  of  oral  compromise  or  risks  of  infection.  However,  today,  in  many  centres, 
procedures  are  being  reviewed  to  suit  individual  patients  or  patient  groups  (Gibson, 
Horsford  &  Nelson,  1997).  The  mouth  care  protocol  (Appendix  II)  used  throughout 
the  period  of  this  study  remained  essentially  unchanged,  therefore  were  unlikely  to 
have  significantly  influenced  the  decrease  in  incidence  of  viridans  streptococcal 
bacteraemia.  However,  the  demonstration,  by  PFGE,  that  the  predominant  strain  of 
S.  oralis  which  colonized  the  oral  mucosa,  gingivae  and  teeth  of  one  patient,  and 
which  had  caused  one  episode  of  bacteraemia,  could  also  readily  colonize  his 
toothbrush,  indicated  that  tools  for  mouth  care  could  potentially  become  vectors  of 
infection.  Therefore,  although  soft  toothbrushes  may  now  be  regarded  as  the  most 
efficient  (non-specialist)  tool  for  removing  plaque  and  debris  from  the  teeth  and 
mouth  (Campbell,  Evans  &  MacTavish,  1995;  Gibson,  Horsford  &  Nelson,  1997), 
they  should  be  replaced  regularly  to  prevent  excessive  accumulation  of  oral  bacteria 
on  their  bristles. 
9.6  Recent  developments 
The  prevention  and  management  of  oral  mucositis  remains  unsatisfactory.  However, 
some  promising  results  have  been  produced  using  sucralfate,  a  complex  of 
sucrosuiphate  and  aluminium  hydroxide.  In  a  recent  double-blind  randomized  trial  in 
234 patients  undergoing  autologous  or  allogeneic  bone  marrow  transplantation,  the 
prophylactic  administration  of  this  agent  was  found  to  be  associated  with  a  lower 
frequency  of  severe  mucositis  and  also  of  diarrhoea  (Castagna  et  al.,  2001).  In 
contrast,  in  earlier  studies,  sucralfate  did  not  ameliorate  radiation-induced  mucositis 
(Makkonen  et  al.,  1994;  Franzen  et  al.,  1995).  Other  recent  studies  have  attempted 
to  evaluate  the  efficacy  of  growth  factors  (G-CSF  and  GM-CSF),  used  locally  as  a 
mouth  wash  (Sprinzl  et  al.,  2001;  Hejna  et  al.,  2001).  However  these  studies  were 
small,  with  conflicting  results.  Methods  of  detecting  and  monitoring  mucosal  barrier 
injury  are  now  being  developed  and  these  will  be  useful  in  assessing  new 
therapeutic  agents  (Blijievens,  Donnelly  &  De  Pauw,  2000). 
9.7  Concluding  comments  and  a  `wider  perspective' 
During  the  time  interval  of  this  study,  the  prevalence  of  viridans  streptococcal 
bacteraemia  in  paediatric  cancer  patients  attending  RHSC  has  decreased,  as  has 
the  severity  of  symptoms  associated  with  this  infection.  The  intervention  of  a  change 
in  empirical  antibiotic  therapy  in  the  present  study  may  have  played  a  part.  Of 
interest,  similar  decreases  in  viridans  streptococcal  bacteraemia  have  occurred  in 
other  haematology/oncology  centres  in  the  U.  K.  and  abroad.  Perhaps  the  growing 
trend  towards  the  use  of  carbapenems  or  piperacillin/tazobactam  rather  than 
ceftazidime  for  empirical  therapy  of  febrile  neutropenia,  may  be  a  factor  in  the 
general  decline  in  cases  of  this  infection.  While  the  role  of  antibiotic  prophylaxis  in 
selection  of  resistant  strains  has  been  studied  extensively,  more  investigations  into 
the  part  played  by  previous  courses  of  empirical  antibiotics  are  required. 
Studies  to  investigate  possible  virulence  factors  of  viridans  streptococci  continue 
(Tarelli  et  al.,  1998;  Byers  et  al.,  1999;  Whatmore  et  al.,  2000).  While  subtle 
mechanisms,  such  as  mannosidae  and  sialidase  activities  may  contribute  to 
235 proliferation  amongst  members  of  the  mitis  group,  there  is  no  evidence  of  production 
of  conventional  bacterial  exotoxins  by  these  organisms. 
The  pathogenesis  of  viridans  streptococcal  bacteraemia  in  paediatric  immuno- 
compromised  patients  is  an  excellent  example  of  the  interplay  of  the  effects  of 
cytotoxic  chemotherapy,  the  prior  use  of  antibacterial  agents  and  a  disturbance  in 
microbial  homeostasis.  Thankfully,  management  of  this  particular  infection  is  less  of 
a  challenge  today.  However  as  further  advances  in  the  management  of  malignant 
disease  result  in  an  ever-increasing  number  of  immunocompromised  patients,  new 
challenges  will  arise. 
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CHEMOTHERAPY  REGIMENS 
The  following  is  not  a  comprehensive  list  of  the  many  chemotherapy  protocols  used 
at  RHSC.  Rather,  it  provides  information  on  the  treatment  regimens  relevant  to  the 
present  study. 
Treatment  of  AML  (from  MRC  protocol  -  AML  12) 
Induction  Chemotherapy 
Each  induction  schedule  comprises  two  courses  of  chemotherapy  -  either  ADE  or 
MAE.  Remission  status  is  determined  after  each  course.  If  remission  is  not 
confirmed  after  the  second  course,  the  patient  is  off  protocol  for  standard  MRC  AML 
therapy  and  may  be  entered  into  the  current  MRC  refractory/relapse  trial  or  can 
receive  alternative  therapy. 
ADE  schedule 
Course  1  ADE  10+3+5 
Cytarabine  100  mg/m2  12-hourly  by  i.  v.  push  on  days  1-10  inclusive. 
Daunorubicin  50  mg/m2  daily  by  6  hour  i.  v.  infusion  on  days  1,3  and  5. 
Etoposide  100  mg/m2  daily  by  4  hour  i.  v.  infusion  on  days  1-5  inclusive. 
Course  2  ADE  8+3+5 
Cytarabine  100  mg/m2  12-hourly  by  i.  v.  push  on  days  1-8  inclusive. 
Daunorubicin  50  mg/m2  daily  by  6  hour  i.  v.  infusion  on  days  1,3  and  5. 
Etoposide  100  mg/m2  daily  by  4  hour  i.  v.  infusion  on  days  1-5  inclusive. 
MAE  schedule 
Course  1  MAE  3+10+5 
Mitozantrone  12  mg/m2  daily  by  6  hour  i.  v.  infusion  on  days  1,3  and  5. 
Cytarabine  100  mg/m2  12-hourly  by  i.  v.  push  on  days  1-10  inclusive. 
Etoposide  100  mg/m2  daily  by  4  hour  i.  v.  infusion  on  days  1-5  inclusive. 
279 Course2  MAE  3+8+5 
Mitozantrone  12  mg/m2  daily  by  6  hour  i.  v.  infusion  on  days  1,3  and  5. 
Cytarabine  100  mg/m2  12-hourly  by  i.  v.  push  on  days  1-8  inclusive. 
Etoposide  100  mg/m2  daily  by  4  hour  i.  v.  infusion  on  days  1-5  inclusive. 
In  children  less  than  1  year  old,  the  above  doses  are  reduced  by  25%. 
Consolidation  chemotherapy 
Course  3  MACE 
Amsacrine  100  mg/m2  daily  by  1  hour  i.  v.  infusion  (in  5%  dextrose)  on  days  1-5 
inclusive. 
Cytarabine  200  mg/m2  daily  by  continuous  i.  v.  infusion  on  days  1-5  inclusive 
Etoposide  100  mg/m2  daily  by  4  hour  i.  v.  infusion  on  days  1-5  inclusive. 
In  children  less  than  1  year  old,  the  above  doses  are  reduced  by  25%. 
Additional  consolidation  chemotherapy  is  dependent  on  randomisation  and  the 
availability  of  a  matched  sibling  donor.  Courses  may  include  the  following: 
MidAC 
Mitozantrone  10  mg/m2  by  6  hour  i.  v.  infusion  on  days  1-5  inclusive. 
Cytarabine  1.0  g/m2  12-hourly  by  2  hour  i.  v.  infusion  on  days  1-3  inclusive. 
CLASP 
Cytarabine  3  g/m2  12-hourly  by  3  hour  i.  v.  infusion  on  days  1,2,8  and  9. 
Asparaginase  6000  units/m2  S.  C.  on  days  2  and  9,  three  hours  after 
Completion  of  4th  and  8th  doses  of  cytarabine. 
280 MRC  Chemotherapy  Protocols  for  the  Treatment  of  ALL 
(UKALL  XI,  UKALL  97) 
Standard  Remission  Induction  Chemotherapy 
(Days  1-  28) 
(a)  Allopurinol  100  mg/m2  orally  thrice  daily  should  commence  24  hours 
before  cytotoxic  therapy  is  started  and  continue  for  14  days. 
(b)  Prednisolone  40  mg/m2  oral  daily  in  three  divided  doses  from  the  beginning 
of  Week  1  to  the  end  of  week  4. 
(c)  Vincristine  1.5  mg/m2  (maximum  single  dose  2  mg)  i.  v.  weekly  for  five 
weeks,  starting  on  day  1  of  the  first  week. 
(d)  L-asparaginase  6000  units/m2  S.  C.  three  times  a  week,  for  9  doses. 
(First  dose  on  Day  4  of  Week  1) 
(e)  IT.  Methotrexate  On  days  1  and  8  (Dose  related  to  CSF  volume) 
Consolidation  Therapy 
The  `DATES'  regimen 
`DATES'  chemotherapy  (two  courses  per  patient)  was  used  as  intensification  therapy 
for  ALL  patients  at  RHSC  until  the  end  of  1999. 
Prednisolone  40  mg/m2  oral  daily  for  one  week 
Vincristine  1.5  mg/m2  i.  V.  (maximum  2  mg)  as  a  single  dose  on  day  1 
Daunorubicin  45  mg/m2  im.  as  an  infusion  over  6  hours  on  both  days  1  and  2. 
Etoposide  100  mg/m2  i.  v.  by  4  hour  infusion  on  days  1-5  inclusive. 
Cytarabine  100  mg/m2  i.  v.  , 
12  hourly,  by  bolus  injection  on  days  1-5  inclusive. 
Thioguanine  80  mg/m2  orally,  daily  on  days  1-5  inclusive. 
i.  t.  Methotrexate  On  day  1  (dose  by  age) 
281 Third  intensification  block 
(a)  Dexamethasone 
(b) Vincristine 
(c)  L-Asparaginase 
(d)  I.  T.  Methotrexate 
(e)  Cyclophosphamide 
(f)  Cytarabine 
(g)  Thioguanine 
10  mg/m2/day  oral  for  10  days  and  then  tailed  over  4 
days. 
1.5  mg/m2  i.  v.  (maximum  of  2  mg)  on  day  1  of  weeks 
35,36,37  and  38 
6,000  u/m2  S.  C.  days  4,6  (week  35) 
days  1,3,5  (week  36) 
days  1,3,5  (week  37) 
day  1  (week  38) 
On  day  1  of  week  35  and  39. 
600  mg/m2  i.  v.  day  1  week  39  and  41. 
75  mg/m2  i.  v.  or  s.  c.  daily  on  days  1-4  of  weeks  39, 
40,41,42. 
60  mg/m2  daily  weeks  39-42  inclusive 
Extract  from  MRC  ALL  Regimen  B  (ALL  97  -  modified  1999) 
-Used  at  RHSC  from  the  beginning  of  2000. 
Consolidation 
Cyclophosphamide  1,000  mg/m2  i.  V.  over  20-30  minutes  on  days  1&  15. 
Cytarabine  75  mg/m2/day  by  i.  v.  push  or  subcutaneously.  Sixteen  doses 
in  four  pulses  of  4  days  each.  Days  2-5,9-12,16-19  and  23- 
26. 
Mercaptopurine  60  mg/m2/day  p.  o.  at  least  one  hour  after  evening  meals  on 
days  1-28. 
I.  T.  Methotrexate  once  a  week  for  4  doses  on  days  1,8,15,  and  22.  (Dose  by 
age.  ) 
282 Extract  from  MRC  ALL  Relapse  Protocol 
Consolidation  Phase 
Days  1-15 
Vincristine  1.5  mg/m2  i.  v.  (maximum  2  mg)  on  Dayl. 
Etoposide  150  mg/m2  by  4  hour  i.  v.  infusion.  Days  1,4,8,11. 
Cytarabine  300  mg/m2  by  1  hour  i.  v.  infusion.  Days  1,4,8,11. 
I.  T.  Methotrexate  Dayl  (Dose:  age  dependent) 
Days  15-28 
Dexamethasone  10  mg/m2  Days  15-28  orally. 
Tail  over  48  hours. 
Asparaginase  10,000  i.  u.  /m2  i.  m.  /s.  c.  Days  15,18,22,25. 
Epirubicin  50  mg/m2  i.  v.  Days  15  and  22. 
Vincristine  1.5  mg/m2  i.  v.  Days  15  and  22. 
Days  29-42 
I.  T.  Methotrexate  Days  29  and  36  (dose  :  age  dependent). 
Thioguanine  60  mg/m2  orally  daily.  Days  29-42  inclusive. 
Cytarabine  75  mg/m2  s.  c.  /i.  m.  /i.  v.  Days  29,30,31,32. 
Days  36,37,38,39. 
Cyclophosphamide  1  g/m2  i.  v.  given  at  the  start  of  week  5,  i.  e.  day  29. 
-  infused  over  1  hour. 
Extract  from  the  FLAG  Regimen 
Consolidation  regimen 
Fludarabine  25  mg/m2  daily  by  4  hour  i.  v.  infusion  for  4  days,  (4  hours  prior  to  each 
daily  infusion  of  cytarabine). 
Cytarabine  2  g/m2  daily  by  4  hour  i.  v.  infusion  for  4  days,  (beginning  4  hours  after 
the  start  of  the  infusion  of  fludarabine  phosphate). 
G-CSF  0.5  miu/kg  daily  by  i.  v.  /s.  c.  injection  beginning  24  hours  prior  to  the 
first  administration  of  fludarabine  until  count  recovery. 
283 Extracts  from  UKCSSG  NHL  Protocols 
COPADM  2  (Protocol  903) 
Vincristine  2  mg/m2  i.  V.  (maximum  2  mg)  Daysland  6. 
Methotrexate  (H.  D)  8  g/m2  i.  v.  Day  1. 
Folinic  acid  Days  2-4. 
I.  T.  Methotrexate  8-15  mg  (by  age).  Days  1,3,5. 
IT.  Hydrocortisone  8-15  mg  (by  age).  Days  1,3,5. 
I.  T.  Cytarabine  16-30  mg  (by  age).  Days  1,3,5. 
Cyclophosphamide  1  g/m2/day  i.  v.  (in  2  injections)  Days  2-4. 
Mesna  infusion  500  mg/m2/day  i.  v.  Days  2-4. 
+  100  mg/m2  bolus  i.  v.  Day  2. 
Doxorubicin  60  mg/m2  i.  v.  Day  2. 
Prednisolone  60  mg/m2/day  p.  o.  Days  1-5. 
CYT/ETOP  (Protocol  903) 
Cytarabine  (over  12  hours)  50  mg/m2  i.  v.  Days  1-5  (from  20.00  -  08.00  hours). 
Cytarabine  (over  3  hours)  3  g/m2  i.  v.  Days  1-4  (from  08.00  -  11.00  hours). 
Etoposide  (over  2  hours)  200  mg/m2  i.  v.  Days  1-4  (from  14.00  -  16.00  hours). 
CYM 
Methotrexate  3000  mg/m2  in  500mIs/m2  dextrose  as  i.  v  infusion  over  3  hours 
on  day  1. 
Folinic  acid  15  mg/m2  orally  every  6  hours  for  a  total  of  12  doses  -  starting 
at  24  hours  from  the  start  of  the  methotrexate  infusion 
Cytarabine  100mg/m2  in  1000  mIs/m2  dextrose  saline  as  infusion  over  24 
hours  -  days  2-6. 
i.  t.  Methotrexate  8-  15  mg  by  i.  t.  injection  day  2  (dose  varies  with  age) 
i.  t.  Cytarabine  15  -  30  mg  by  i.  t.  injection  on  day  7  (dose  varies  with  age) 
i.  t.  Hydocortisone  8-  15  mg  by  i.  t.  injection  on  day  2  and  7  (dose  varies  with 
age) 
284 Extract  from  MRC  Trial  for  Therapy  of  Osteosarcoma  (MRC  BO  06) 
Conventional  therapy  arm 
Regimen  1-  cisplatin  (CDDP)  +  doxorubicin  (DOX) 
This  therapy  comprises  2  pre-operative  cycles  of  CDDP  +  DOX  at  3-weekly  intervals 
followed  by  surgery  scheduled  for  week  6.  Two  weeks  after  surgery  a  further  4 
cycles  of  CDDP  +  DOX  are  given  at  3-weekly  intervals. 
The  following  comprises  one  treatment  cycle: 
Doxorubicin  25  mg/m2/day  Days  1-3  -  i.  v.  4  hour  infusion. 
Cisplatin  100  mg/m2  Day  1.24  hour  infusion. 
Extract  from  OPEC/OJEC  protocol  for  therapy  of  neuroblastoma 
OJEC 
0  hours  Vincristine  1.5  mg/m2  (maximum  dose  2  mg)  i.  v.  bolus 
Cyclophosphamide  600  mg/m2  i.  v.  bolus 
Etoposide  200  mg/m2  in  500  mI/m2  0.9%  sodium  chloride  infused  i.  v. 
over  4  hours 
4  hours  Carboplatin  500  mg/m2  in  total  volume  of  100  mI/m2  of  5%  glucose 
infused  i.  v.  over  1  hour. 
Extract  from  UKCCSG  Malignant  Mesenchymal  Tumour  Study  for  metastatic 
disease  (1998) 
Week  6-  High  dose  cyclophosphamide  (course  1  (Day  0)) 
Pre-hydration  -according  to  protocol 
Cyclophosphamide  2  g/m2  on  days  1,2  and  3  of  the  monotherapy  sequence 
as  a1  hour  infusion  with  Mesna  uroprotection 
Mini-BEAM  Salvage  Chemotherapy  for  Relapsed  Large  Cell  Anaplastic 
Lymphoma 
BCNU  60  mg  /m2  Day  1. 
Etoposide  75  mg/m2  Days  2-5. 
Cytarabine  100mg  /m2  q12  h  Days  2-5. 
Melphalan  30  mg/m2  Day  6. 
285 APPENDIX  II 
MOUTH  CARE  PROTOCOL 
The  following  is  a  copy  of  the  protocol  issued  to  patients/parents  during  the  study  period. 
MOUTH  CARE  FOR  YOUR  CHILD 
Following  chemotherapy  or  radiotherapy  your  child  may  be  at  risk  of  developing  a  sore  mouth,  as  the  fast  growing  cells  in  his/her  mouth  are  broken  down. 
The  following  may  develop  -  Thrush  (a  fungal  infection) 
-  Ulcers 
-  Cold  sores  (a  viral  infection  called  Herpes) 
-  Bleeding  gums 
It  is  important  that  good  dental  hygiene  continues  throughout  your  child's  treatment.  A  dental 
hygienist  will  usually  visit  the  ward  once  a  week  to  discuss  mouth  care  with  you.  Normal  teeth  brushing  and  mouth  care  should  be  continued  unless  you  are  instructed  to  do  otherwise  by  a  doctor  or  nurse. 
When  your  child  has  a  low  blood  count  he/she  will  be  started  on  a  special  mouth  care 
regimen  (see  below).  A  low  white  cell  count  will  mean  that  your  child  may  be  more  likely  to 
develop  mouth  infections  and  a  low  platelet  count  may  cause  the  gums  to  bleed. 
..................................................................................................................................................... 
The  following  mouth  care  should  be  carried  out  by  your  child  4  times  a  day,  that  is,  after 
meals  and  before  going  to  bed  at  night. 
1.  Brush  teeth  with  a  pink  sponge  and  a  pea-sized  amount  of  Corsodyl  dental  gel.  The 
sponges  will  be  supplied  and  they  must  be  discarded  after  use. 
2.  Rinse  the  mouth  with  Corsodyl  mouth  wash.  Swirl  the  mouth  wash  around  the 
mouth.  There  are  two  flavours  of  mouth  wash: 
-  Original  flavour  (pink) 
-  Mint  flavour  (clear) 
Corsodyl  helps  prevent  bacterial  infections. 
3.  WAIT  20  MINUTES  before  using  Nystatin  if  this  has  been  prescribed.  This  yellow 
medicine  is  swirled  around  the  mouth  and  swallowed.  Nystatin  helps  prevent  fungal 
infections.  This  is  also  available  in  pastille  form.  Your  child  may  prefer  an  orange 
flavoured  gel  called  Daktarin  which  also  helps  prevent  fungal  infections.  Ask  a  nurse 
if  you  think  your  child  would  prefer  this. 
4.  If  possible  wait  a  further  20-30  minutes  before  giving  your  child  anything  to  eat  or 
drink. 
.....................................................................................................................................................  r 
Sometimes  your  child  may  be  prescribed  medications  called  fluconazole  or  itraconazole. 
These  also  help  prevent  fungal  infections  and  Nystatin  or  Daktarin  may  not  be  required. 
Watch  for  sore  areas  or  white  patches  in  your  child's  mouth  and  inform  a  doctor  or 
nurse  if  any  should  develop. 
If  your  child  does  get  a  sore  mouth,  Diff  lam  mouth  wash  may  be  useful.  This  numbs 
the  mouth  to  help  relieve  pain  and  discomfort.  It  may  be  useful  to  use  it  15-20 
minutes  before  meals.  Pain  killers  will  also  be  given  if  your  child  does  develop  a  sore 
mouth. 
Occasionally  chemotherapy  can  distort  the  taste.  This  can  mean  a  reduced  sensitivity  to 
taste,  an  unusual  or  unpleasant  taste  or  absence  of  taste.  These  problems  should 
resolve  once  the  treatment  has  stopped. 
Produced  by  Senior  Staff  Nurse  Debbie  McClure,  Yorkhill  NHS  Trust. 
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